<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1257450</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2023.1257450</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Phytochemicals targeting glycolysis in colorectal cancer therapy: effects and mechanisms of action</article-title>
<alt-title alt-title-type="left-running-head">Zhan et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2023.1257450">10.3389/fphar.2023.1257450</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhan</surname>
<given-names>Lu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2257365/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Su</surname>
<given-names>Fangting</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Li</surname>
<given-names>Qiang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wen</surname>
<given-names>Yueqiang</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wei</surname>
<given-names>Feng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1931880/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Zhelin</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Xiaoyan</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yin</surname>
<given-names>Xiang</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Jian</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cai</surname>
<given-names>Yilin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gong</surname>
<given-names>Yuxia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chen</surname>
<given-names>Yu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ma</surname>
<given-names>Xiao</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zeng</surname>
<given-names>Jinhao</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1522963/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Oncology</institution>, <institution>Hospital of Chengdu University of Traditional Chinese Medicine</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>School of Basic Medicine</institution>, <institution>Chengdu University of Traditional Chinese Medicine</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Guang&#x2019;an Hospital of Traditional Chinese Medicine</institution>, <addr-line>Guang&#x2019;an</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>State Key Laboratory of Southwestern Chinese Medicine Resources</institution>, <institution>School of Pharmacy</institution>, <institution>Chengdu University of Traditional Chinese Medicine</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Department of Gastroenterology</institution>, <institution>Hospital of Chengdu University of Traditional Chinese Medicine</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province</institution>, <institution>Hospital of Chengdu University of Traditional Chinese Medicine</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/112301/overview">Pranav Kumar Prabhakar</ext-link>, Lovely Professional University, India</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/882825/overview">Jinjun Wu</ext-link>, Guangzhou University of Chinese Medicine, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2386006/overview">Ali AbdelWahab</ext-link>, Cairo University, Egypt</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Yu Chen, <email>735405661@qq.com</email>; Xiao Ma, <email>tobymaxiao@cdutcm.edu.cn</email>; Jinhao Zeng, <email>zengjinhao@cdutcm.edu.cn</email>
</corresp>
<fn fn-type="equal" id="fn001">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>08</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1257450</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>07</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>08</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Zhan, Su, Li, Wen, Wei, He, Chen, Yin, Wang, Cai, Gong, Chen, Ma and Zeng.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Zhan, Su, Li, Wen, Wei, He, Chen, Yin, Wang, Cai, Gong, Chen, Ma and Zeng</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Colorectal cancer (CRC) is the third most common malignant tumor in the world, and it is prone to recurrence and metastasis during treatment. Aerobic glycolysis is one of the main characteristics of tumor cell metabolism in CRC. Tumor cells rely on glycolysis to rapidly consume glucose and to obtain more lactate and intermediate macromolecular products so as to maintain growth and proliferation. The regulation of the CRC glycolysis pathway is closely associated with several signal transduction pathways and transcription factors including phosphatidylinositol 3-kinases/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR), adenosine 5&#x2032;-monophosphate (AMP)-activated protein kinase (AMPK), hypoxia-inducible factor-1 (HIF-1), myc, and p53. Targeting the glycolytic pathway has become one of the key research aspects in CRC therapy. Many phytochemicals were shown to exert anti-CRC activity by targeting the glycolytic pathway. Here, we review the effects and mechanisms of phytochemicals on CRC glycolytic pathways, providing a new method of drug development.</p>
</abstract>
<kwd-group>
<kwd>colorectal cancer</kwd>
<kwd>warburg effect</kwd>
<kwd>glycolysis</kwd>
<kwd>phytochemicals</kwd>
<kwd>molecular pathways</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Pharmacology of Anti-Cancer Drugs</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Colorectal cancer (CRC) ranks third among the globally most prevalent cancers, in terms of incidence and mortality (<xref ref-type="bibr" rid="B152">Sheng et al., 2020</xref>). The morbidity and mortality of CRC are consistently increasing, which poses a serious threat to the general population&#x2019;s health (<xref ref-type="bibr" rid="B73">Jian et al., 2020</xref>). After initial CRC diagnosis, 20% of the patients develop metastatic disease, and an additional 25% of the patients with initially localized disease will subsequently develop metastasis (<xref ref-type="bibr" rid="B10">Biller and Schrag, 2021</xref>). At present, surgical resection and chemo-radiotherapy are the most common treatment options for CRC patients (<xref ref-type="bibr" rid="B108">Liang et al., 2019</xref>). Surgery is the only curative treatment of CRC, however, even after radical surgery, a high recurrence rate remains (<xref ref-type="bibr" rid="B171">van der Stok et al., 2017</xref>). Further, there is considerable resistance to CRC to chemotherapy (<xref ref-type="bibr" rid="B170">Van der Jeught et al., 2018</xref>). Therefore, the current treatment of CRC is in urgent need of novel and more effective avenues.</p>
<p>The Warburg effect of cancer cells dictates that even under aerobic conditions, cancer cells require glycolysis for energy, which is a hallmark of tumor metabolism (<xref ref-type="bibr" rid="B143">Salimian Rizi et al., 2015</xref>). Normal cells generate energy primarily through mitochondrial oxidative phosphorylation, and glycolysis is increased only under hypoxia (<xref ref-type="bibr" rid="B96">Leung et al., 2015</xref>). The glucose uptake by cancer cells is markedly higher than that of normal cells, and most of the pyruvate produced is converted to lactic acid through lactate dehydrogenase (LDH). Compared with 36 ATP molecules produced by oxidative metabolism, glycolysis yields only 2 ATP plus 2 lactic acid molecules from 1 molecule of glucose (<xref ref-type="bibr" rid="B49">Gatenby and Gillies, 2004</xref>). Although the efficiency of ATP production through glycolysis is lower, the ATP generation rate through glycolysis is nearly 100-fold faster, compared to oxidative phosphorylation (<xref ref-type="bibr" rid="B232">Zhou et al., 2012</xref>). Further, rapid aerobic glycolysis produces many intermediates that are conducive to the growth of tumor cells, and these intermediates maintain the proliferation, invasion, and metastasis of tumor cells (<xref ref-type="bibr" rid="B115">Lunt and Vander Heiden, 2011</xref>). The metabolic pathway of the Warburg effect has become the focus of tumor treatment in recent years, and its related targeted pathways will be used as an important approach for researching treatment options for colorectal malignancies.</p>
<p>Phytochemicals are an important source of medicines, and plant drugs still play an important role in the treatment of diseases in developing countries (<xref ref-type="bibr" rid="B161">Tamene and Endale, 2019</xref>). Despite the rapid development of synthetic drugs, natural compounds remain one of the main sources of drugs (<xref ref-type="bibr" rid="B84">Kazantseva et al., 2022</xref>). Approximately 25% of anti-cancer drugs are derived from phytochemicals and contain one or more plant-active ingredients (<xref ref-type="bibr" rid="B89">Kopaskova et al., 2011</xref>). At present, many anticancer drugs are derived from phytochemicals, such as vinblastine, paclitaxel, and camptothecin (<xref ref-type="bibr" rid="B178">Wang H. et al., 2018</xref>). With the wide application of phytochemicals in cancer treatment and synthetic drug development becoming more difficult, research on anticancer drugs is focused on the development and utilization of phytochemicals and their active substances (<xref ref-type="bibr" rid="B167">Tong et al., 2019</xref>), and phytochemicals targeting tumor metabolism have been extensively studied. Moreover, the synergistic effects of phytochemical drugs and anticancer drugs have been attracting attention, as a combination of the two drugs can inhibit the recurrence and metastasis of cancer and reduce the resistance of tumor cells to chemotherapy (<xref ref-type="bibr" rid="B95">Lee et al., 2021</xref>). Therefore, it is vital to accelerate the development and utilization of phytochemical drugs for cancer treatment.</p>
<p>Here, we review research on phytochemicals and their active components acting on the glycolysis pathway of CRC cells, and we discuss the molecular mechanisms of phytochemicals targeting the glycolysis pathway to treat CRC. This review will provide a clue for further research on the treatment of CRC targeting the glycolysis pathway.</p>
</sec>
<sec id="s2">
<title>2 Aerobic glycolysis in CRC</title>
<p>Substantial evidence suggests that metabolic enzymes and transporters associated with the glycolytic pathway are highly expressed in CRC, and these changes may be related to the regulation of several signaling pathways and transcription factors (As shown in <xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Glycolysis in colorectal cancer cells and the related regulatory pathways. Abbreviation: GLUTs, Glucose transporters; HKs, Hexokinases; PFK1, Phosphofructokinase-1; PK, Pyruvate kinase; LDH, Lactate dehydrogenase; PDK, Pyruvate dehydrogenase kinase; PDH, Pyruvate dehydrogenase; AMPK, Adenosine 5&#x2032;-monophosphate-activated protein kinase; TSC1/2, Tuberous sclerosis complex1/2; AKT, Protein kinase B; mTOR, Mammalian target of rapamycin; HIF-1, Hypoxia-inducible factor-1; PI3K, Phosphatidylinositol 3-kinases; PTEN, Phosphatase and tensin homolog; USP13, Ubiquitin-specific peptidase 13; RPS7, ribosomal protein S7; TCA, Tricarboxylic acid; PPP, Pentose phosphate pathway; HSP90, Heat shock protein 90; MCTs, Monocarboxylic acid transporters; MEG3, lncRNA maternally expressed gene 3; SOD2, Superoxide dismutase 2.</p>
</caption>
<graphic xlink:href="fphar-14-1257450-g001.tif"/>
</fig>
<sec id="s2-1">
<title>2.1 Upregulation of the glycolytic pathways in CRC</title>
<p>The glycolytic metabolism of CRC cells is closely associated with particular transporters and key enzymes of the glycolytic pathway. Glucose metabolism in cells is mediated by glucose transporters (GLUTs), which occur in the cell membrane. There are 14 subtypes of the GLUT gene (<xref ref-type="bibr" rid="B5">Ancey et al., 2018</xref>), of which GLUT1, as one of the most intensively studied membrane transporters, is a key speed-limiting factor of glucose metabolism (<xref ref-type="bibr" rid="B165">Thorens and Mueckler, 2010</xref>). This transporter is highly expressed in various cancer tissues, including CRC (<xref ref-type="bibr" rid="B208">Younes et al., 1995</xref>; <xref ref-type="bibr" rid="B8">Baer et al., 1997</xref>; <xref ref-type="bibr" rid="B128">Mori et al., 2007</xref>; <xref ref-type="bibr" rid="B43">Feng et al., 2017</xref>), and it has been confirmed to be related to the progress and metastasis of CRC (<xref ref-type="bibr" rid="B209">Younes et al., 1996</xref>; <xref ref-type="bibr" rid="B54">Haber et al., 1998</xref>). Hexokinase (HK) is a catalytic enzyme that converts glucose into glucose-6-phosphate and is the first rate-limiting enzyme in the glycolysis pathway. There are four types of HK isoenzymes, among which HK2 is abnormally highly expressed in the metabolic pathway of tumor cells, and its expression is closely associated with CRC proliferation and metastasis (<xref ref-type="bibr" rid="B153">Shinohara et al., 1994</xref>; <xref ref-type="bibr" rid="B191">Wilson, 2003</xref>; <xref ref-type="bibr" rid="B83">Katagiri et al., 2017</xref>; <xref ref-type="bibr" rid="B65">Huang et al., 2021</xref>). Phosphofructokinase-1, as a catalytic enzyme for the synthesis of 1,6-fructose-diphosphate from fructose-6-phosphate, is one of the key rate-limiting enzymes in the glycolytic pathway. Genes encoding phosphofructokinase-1 activity are highly expressed in CRC (<xref ref-type="bibr" rid="B64">Houddane et al., 2017</xref>). The key regulatory enzyme of the pyruvate kinase (PK) glycolysis pathway is responsible for the dephosphorylation of phosphoenolpyruvate to pyruvate and ATP. There are four PK isoenzymes, of which PKM2 is highly expressed in many malignant tumors, including colorectal tumors (<xref ref-type="bibr" rid="B192">Wong et al., 2014</xref>; <xref ref-type="bibr" rid="B28">Cui and Shi, 2015</xref>; <xref ref-type="bibr" rid="B57">Han et al., 2016</xref>). PKM2 maintains the high glycolysis rate of tumor cells and regulates the proliferation of tumor cells (<xref ref-type="bibr" rid="B210">Yu et al., 2015</xref>). In the process of tumor glycolysis, most pyruvate is converted into lactic acid by LDH (<xref ref-type="bibr" rid="B104">Li et al., 2020b</xref>). LDHA is highly expressed in colorectal and other malignant tumors and is closely related to tumor proliferation and metastasis (<xref ref-type="bibr" rid="B179">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="B197">Xian et al., 2015</xref>; <xref ref-type="bibr" rid="B29">Cui et al., 2017</xref>; <xref ref-type="bibr" rid="B223">Zhao et al., 2017</xref>).</p>
<p>Monocarboxylic acid transporters (MCTs) are lactic acid transporters located on the cell membrane, which are responsible for transporting intracellular lactic acid to the exterior of the cell to maintain the pH in tumor cells; further, they are highly expressed in primary CRC and are associated with CRC metastasis and prognosis (<xref ref-type="bibr" rid="B120">Martins et al., 2016</xref>). Pyruvate can be converted to acetyl coenzyme A (CoA) under the action of the pyruvate dehydrogenase complex, and enter mitochondria for metabolism through the oxidative phosphorylation pathway (<xref ref-type="bibr" rid="B145">Saunier et al., 2016</xref>). Pyruvate dehydrogenase complex acts as the gatekeeper of the oxidative phosphorylation pathway, and the respective enzymes are inhibited in CRC to maintain the high glycolysis rate of CRC and its proliferation and invasion (<xref ref-type="bibr" rid="B55">Hamabe et al., 2014</xref>; <xref ref-type="bibr" rid="B61">Ho and Coomber, 2015</xref>). Therefore, targeting pyruvate dehydrogenase complex may be a new direction for CRC treatment. The above glycolytic metabolic pathways are abnormally expressed in CRC cells and have exacerbating effects on the occurrence and development of CRC.</p>
</sec>
<sec id="s2-2">
<title>2.2 Regulatory mechanisms of glycolytic pathways in CRC</title>
<p>Enzymes and transporters related to the CRC glycolysis pathway are abnormally expressed by different molecular regulatory mechanisms, thus leading to the occurrence and development of CRC.</p>
<sec id="s2-2-1">
<title>2.2.1 PI3K/AKT/mTOR</title>
<p>PI3K/AKT/mTOR signaling pathway is a cellular signal transduction pathway, which affects cell growth, proliferation, angiogenesis, and other processes (<xref ref-type="bibr" rid="B27">Coutte et al., 2012</xref>; <xref ref-type="bibr" rid="B59">He et al., 2022</xref>; <xref ref-type="bibr" rid="B236">Hu et al., 2023</xref>). Activation of the PI3K/AKT signal pathway plays an important role in maintaining the glucose metabolism of cells, as it can increase glucose intake by increasing the expression of GLUT and upregulate the expression of glycolysis-related enzymes to promote cell glycolysis (<xref ref-type="bibr" rid="B18">Chang et al., 2015</xref>; <xref ref-type="bibr" rid="B136">Prabakaran et al., 2018</xref>). AKT is frequently overexpressed in most CRC, whereas phosphatase and tensin homolog (PTEN) expression is lost (<xref ref-type="bibr" rid="B141">Robey and Hay, 2009</xref>). As a tumor suppressor gene, PTEN negatively regulates the PI3K/AKT/mTOR pathway (<xref ref-type="bibr" rid="B62">Hollander et al., 2011</xref>), and deletion of PTEN can specifically increase the protein level of HIF-1&#x3b1; through PI3K signaling (<xref ref-type="bibr" rid="B74">Jiang et al., 2001</xref>), mTOR is closely related to cell growth and mTOR expression is regulated by a variety of factors, including the energy regulator AMPK. mTOR can also regulate the expression of HIF-1&#x3b1; by sensing the intracellular level of hypoxia (<xref ref-type="bibr" rid="B119">Martin and Hall, 2005</xref>).</p>
<p>Kallikrein-related peptidase, forkhead box class O6, and S100 calcium-binding protein A2 are highly expressed in CRC and play an activating role in glycolysis by activating PI3K/AKT/mTOR pathway and up-regulating GLUT1 expression (<xref ref-type="bibr" rid="B100">Li et al., 2019</xref>; <xref ref-type="bibr" rid="B97">Li C. et al., 2020</xref>; <xref ref-type="bibr" rid="B188">Wei et al., 2020</xref>). MicroRNAs are non-coding RNA molecules that play a central part in cell differentiation, proliferation, and survival (<xref ref-type="bibr" rid="B142">Rupaimoole and Slack, 2017</xref>). MiR-135b is highly expressed in CRC cells, which can activate PI3K pathway and promote glycolysis of CRC cells by down-regulating the expression of ubiquitin-specific peptidase 13 and reducing the stability of PETN (<xref ref-type="bibr" rid="B198">Xiang et al., 2015</xref>).</p>
</sec>
<sec id="s2-2-2">
<title>2.2.2 AMPK</title>
<p>AMPK is a conservative Ser/Thr protein kinase, which regulates cell metabolism and maintains the dynamic balance of cell metabolism, thus it is referred to as a regulator of energy homeostasis (<xref ref-type="bibr" rid="B42">Faubert et al., 2013</xref>; <xref ref-type="bibr" rid="B130">Narayanankutty, 2019</xref>). AMPK is activated by sensing the increase of AMP and ATP (<xref ref-type="bibr" rid="B166">Tokunaga et al., 2019</xref>). Once activated, AMPK will immediately block the energy consumption process of cells, and turn to increase the ATP decomposition process (<xref ref-type="bibr" rid="B186">Wang and Guan, 2009</xref>). AMPK is an important kinase of cell metabolism and has been widely studied in many metabolic diseases (<xref ref-type="bibr" rid="B169">Towler and Hardie, 2007</xref>).</p>
<p>Superoxide dismutase 2 (SOD2) is a key antioxidant enzyme that is highly expressed in CRC. The reduction of SOD2 can significantly downregulate AMPK phosphorylation and the expression of MCT4 and L-lactate and ultimately inhibit the migration and glycolytic metabolism of CRC cells (<xref ref-type="bibr" rid="B228">Zhou C. et al., 2020</xref>). Pim1 is an oncogene promoting the growth and metastasis of CRC, which is highly expressed in CRC cells, and it has been found that pim1 can upregulate the expression of HK2 and LDHA in CRC cells, which may be related to the activation of the AMPK pathway under glucose deprivation (<xref ref-type="bibr" rid="B219">Zhang et al., 2018</xref>).</p>
</sec>
<sec id="s2-2-3">
<title>2.2.3 HIF-1</title>
<p>Compared with normal cells, the oxygen consumption of tumor cells is markedly increased to maintain cancer cells rapid proliferation, thus leading to relative hypoxia in the local microenvironment (<xref ref-type="bibr" rid="B50">Georges et al., 2018</xref>). HIF plays a critical role in driving tumor growth, invasion, and metastasis and is found to be highly expressed in most solid tumors (<xref ref-type="bibr" rid="B91">Kumar and Gabrilovich, 2014</xref>; <xref ref-type="bibr" rid="B76">Jiang et al., 2020</xref>). HIF - 1 has been demonstrated to participate in regulating key transcription factors of EMT and indirectly promotes EMT by Notch, TGF-&#x3b2;, Wnt, and Hedgehog signal pathways, thereby promoting tumor invasive metastasis (<xref ref-type="bibr" rid="B139">Rankin and Giaccia, 2016</xref>). HIF-1 can also induce the expression of the epidermal growth factor receptor (EGFR), transforming growth factor-&#x3b2;, insulin-like growth factor 2 to promote tumor angiogenesis (<xref ref-type="bibr" rid="B12">Bui et al., 2022</xref>). HIF has been confirmed to be involved in the glycolytic pathway of tumor cells, and it can directly upregulate the expression of glycolysis-related transporters and key enzymes such as GLUT, PFK, LDH, HK, etc. (<xref ref-type="bibr" rid="B156">Song et al., 2016</xref>). At the same time, HIF can also be activated by PI3K/AKT (<xref ref-type="bibr" rid="B206">Yeh et al., 2018</xref>), YAP/TAZ (<xref ref-type="bibr" rid="B154">Simula et al., 2022</xref>), hippo/YAP1 (<xref ref-type="bibr" rid="B160">Sun et al., 2020</xref>) and other signaling pathways to further promote the glycolytic process of tumor cells.</p>
<p>
<italic>miR-103a-3p</italic> is an oncogene that is highly expressed in CRC tissues and cell lines and promotes the glycolysis pathway and proliferation, invasion, and migration of CRC cells by up-regulating the transcription of HK2, LDHA, and PKM1 through the Hippo/YAP1/HIF1&#x3b1; axis (<xref ref-type="bibr" rid="B160">Sun et al., 2020</xref>). The ribosomal protein S7 gene (RPS7), as a tumor suppressor gene plays a role in inhibiting glycolysis of CRC cells by inhibiting the expression of HIF-1&#x3b1;, GLUT4, and LDHB (<xref ref-type="bibr" rid="B220">Zhang et al., 2016</xref>).</p>
</sec>
<sec id="s2-2-4">
<title>2.2.4 Myc</title>
<p>Myc is highly overexpressed in human cancers, thus providing energy for tumor growth and proliferation and the synthesis of substrates required for the respective metabolism pathways (<xref ref-type="bibr" rid="B30">Dang et al., 2006</xref>; <xref ref-type="bibr" rid="B125">Miller et al., 2012</xref>). c-myc can directly upregulate the expression of LDHA and promote the conversion of pyruvate to lactic acid, and it can upregulate the expression of enzymes related to glycolytic pathways, such as HK2 and phosphoinositide-dependent protein kinase 1, and promote the glycolytic metabolism of cells (<xref ref-type="bibr" rid="B30">Dang et al., 2006</xref>; <xref ref-type="bibr" rid="B125">Miller et al., 2012</xref>). Myc is inhibited by HIF-1&#x3b1;, however, the two show synergistic effects in regulating the expression of glycolysis-related enzymes including HK2 and PDK1 (<xref ref-type="bibr" rid="B207">Yeung et al., 2008</xref>).</p>
<p>Long non-coding RNAs (lncRNAs) are commonly involved in tumor metabolic rewiring and immune cell infiltration and functioning (<xref ref-type="bibr" rid="B221">Zhang Y. et al., 2021</xref>). The lncRNA maternally expressed gene 3 (MEG3) reduces glycolytic levels in CRC cells by degrading the expression of c-myc, including down-regulating the expressions of glycolysis-related enzymes such as LDHA, PKM2, and HK2 (<xref ref-type="bibr" rid="B235">Zuo et al., 2020</xref>). Thus, MEG3 expression is inhibited in CRC cells (<xref ref-type="bibr" rid="B235">Zuo et al., 2020</xref>). Glycolysis-associated lncRNA of colorectal cancer (lncRNA GLCC1) interacts with heat shock protein90 (HSP90) to stabilize c-myc transcription and thus target c-myc-mediated LDHA expression (<xref ref-type="bibr" rid="B162">Tang et al., 2019</xref>).</p>
</sec>
</sec>
</sec>
<sec id="s3">
<title>3 Targeting glycolysis in colorectal cancer therapy</title>
<p>Increasing evidence suggests that metabolic reprogramming is closely related to the occurrence and development of most tumors, including CRC (<xref ref-type="bibr" rid="B131">Nenkov et al., 2021</xref>). Cancer cells show a significant increase in aerobic glycolysis in their metabolism, making them potentially more susceptible to inhibition of glycolytic pathways than normal cells. Numerous studies on CRC metabolic pathways attempted to identify new therapeutic directions, including the glycolysis pathway, and the drug-targeting glycolysis pathway is an attractive strategy for CRC therapy.</p>
<p>lncRNAs play an important role in the epigenetic regulation of cancer progression by regulating cell function and development (<xref ref-type="bibr" rid="B226">Zheng et al., 2021</xref>). Some lncRNAs are highly expressed in CRC, and they exert anti-tumor effects by regulating the glycolytic pathway (<xref ref-type="bibr" rid="B187">Wang Y. et al., 2019</xref>; <xref ref-type="bibr" rid="B111">Liu et al., 2020</xref>; <xref ref-type="bibr" rid="B98">Li C. et al., 2021</xref>). Chemotherapeutic resistance is a major challenge in CRC treatment, and reprogramming of glucose metabolism is also associated with chemical drug resistance, and high glycolysis levels found in human CRC drug-resistant models (<xref ref-type="bibr" rid="B185">Wang T. et al., 2018</xref>). Targeted inhibition of the glycolytic pathway can increase the sensitivity of CRC cells to chemotherapy drugs (<xref ref-type="bibr" rid="B15">Cao et al., 2018</xref>; <xref ref-type="bibr" rid="B4">An and Ha, 2022</xref>). 5-FU is an important drug in first-line chemotherapy for CRC. In CRC cells resistant to 5-FU, glucose uptake and lactic acid production increase, and glycolysis-related enzymes and GLUT1 and MCT1/4 are significantly upregulated, which may be related to the activation of PI3K/AKT and the Wnt/&#x3b2;-catenin signaling pathway by upregulation of HIF-1&#x3b1; (<xref ref-type="bibr" rid="B34">Dong et al., 2022</xref>). The onset of CRC is closely associated with intestinal environment disorders caused by lifestyle and dietary habits, thus probiotics show promising prospects in the treatment of CRC (<xref ref-type="bibr" rid="B37">Donovan et al., 2017</xref>; <xref ref-type="bibr" rid="B39">Eslami et al., 2020</xref>). Butyrate, a short-chain fatty acid produced by bacterial fermentation of dietary fibers in the colon, was the first probiotic identified as a histone deacetylase inhibitor, which may be related to the inhibition of the Warburg effect in CRC (<xref ref-type="bibr" rid="B56">Hamer et al., 2008</xref>; <xref ref-type="bibr" rid="B36">Donohoe et al., 2012</xref>; <xref ref-type="bibr" rid="B39">Eslami et al., 2020</xref>).</p>
<p>In conclusion, the glycolytic pathway can affect the occurrence and development of CRC through various processes. Therefore, studying the mechanism of CRC and reprogramming glucose metabolism in tumor cells may provide a new research strategy for CRC treatment (<xref ref-type="bibr" rid="B172">Vasaikar et al., 2019</xref>).</p>
</sec>
<sec sec-type="methods" id="s4">
<title>4 Methods</title>
<p>We conducted a comprehensive literature search using the Web of Science, PubMed, Embase, SpringerLink, ScienceDirect, and EBSCO databases from the beginning of the database to 30 September 2022 and collated and analyzed the literature for this review. The literature search was conducted by two authors independently and separately to minimize potential oversights. This review evaluates and summarizes all previous scientific studies on the effects of phytochemicals on CRC glycolysis pathways. In PubMed, we used MeSH search terms such as &#x201c;colorectal neoplasm,&#x201d; &#x201c;colorectal cancer,&#x201d; &#x201c;glycolysis,&#x201d; &#x201c;Embden Meyerhof pathway,&#x201d; &#x201c;Warburg effect,&#x201d; &#x201c;phytochemicals&#x201d; and &#x201c;natural product.&#x201d; We excluded non-experimental articles and repeated articles in the search process.</p>
<p>Through screening and summarizing plant chemicals targeting the CRC glycolytic pathway, we found that numerous <italic>in vitro</italic> and <italic>in vivo</italic> studies confirmed that plant chemicals can target the CRC glycolytic pathway and exert anti-cancer effects (As shown in <xref ref-type="fig" rid="F2">Figures 2</xref>, <xref ref-type="fig" rid="F3">3</xref>; <xref ref-type="table" rid="T1">Table 1</xref>). Here, the targets affecting the glycolytic pathway are divided into 1) phytochemicals directly targeting the CRC glycolysis pathway; 2) phytochemicals targeting PI3K/AKT/mTOR to affect glycolysis in CRC; 3) phytochemicals targeting AMPK to affect glycolysis in CRC; 4) phytochemicals targeting HIF-1 to affect glycolysis in CRC; 5) phytochemicals targeting c-myc to affect glycolysis in CRC; 6) phytochemicals targeting other pathways that affect CRC glycolysis.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Phytochemicals targeting glycolysis in colorectal cancer. Abbreviation: HKs, Hexokinases; PFK1, Phosphofructokinase-1; PK, Pyruvate kinase; LDH, Lactate dehydrogenase; MCTs, Monocarboxylic acid transporters; PDH, Pyruvate dehydrogenase; TCA, Tricarboxylic acid; IL-6, Interleukin 6; SIRT3, Sirtuin-3; JAK2/STAT3, Janus kinase 2/signal transducer and activator of transcription 3; PI3K, Phosphatidylinositol 3-kinases; AKT, Protein kinase B; HIF-1, Hypoxia-inducible factor-1; AMPK, Adenosine 5&#x2032;-monophosphate-activated protein kinase; hnRNPA1, Heterogeneous nuclear ribonucleoprotein A1; PTBP1, polypyrimidine tract-binding protein 1; PTEN, Phosphatase and tensin homolog.</p>
</caption>
<graphic xlink:href="fphar-14-1257450-g002.tif"/>
</fig>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Structural formulae of the phytochemicals.</p>
</caption>
<graphic xlink:href="fphar-14-1257450-g003.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Phytochemicals targeting glycolysis for colorectal cancer therapy.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th rowspan="2" align="center">Signal pathways and transcription factors in glycolysis</th>
<th rowspan="2" align="center">Compound</th>
<th rowspan="2" align="center">Source</th>
<th colspan="2" align="center">Experimental model</th>
<th rowspan="2" align="center">Efficacy</th>
<th rowspan="2" align="center">Mechanism</th>
<th rowspan="2" align="center">Experimental dosage</th>
<th rowspan="2" align="center">References</th>
</tr>
<tr>
<th align="left">
<italic>In vitro</italic>
</th>
<th align="left">
<italic>In vivo</italic>
</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="2" align="center">GLUT1</td>
<td align="center">Anthocyanin (Flavonoids)</td>
<td align="left">
<italic>grape, mulberry, and raspberry</italic>
</td>
<td align="left">MC38</td>
<td align="left">&#x2014;</td>
<td align="left">Disturbtion of glucose transport; inhibition of energy metabolism</td>
<td align="left">&#x2193;GLUT1</td>
<td align="left">500,1000, 2000&#xa0;&#xb5;M (24&#xa0;h)</td>
<td align="left">
<xref ref-type="bibr" rid="B79">Jing et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Silybin (Flavonoids)</td>
<td align="left">
<italic>Silybum marianum</italic> (L.) <italic>Gaertner</italic>
</td>
<td align="left">LoVo</td>
<td align="left">&#x2014;</td>
<td align="left">Downregulation of the glucose uptake</td>
<td align="left">&#x2193;GLUT1</td>
<td align="left">5, 10, 50&#xa0;&#xb5;M (24/48/72&#xa0;h)</td>
<td align="left">
<xref ref-type="bibr" rid="B16">Catanzaro et al. (2018)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">PKM2</td>
<td align="center">Scutellarin (Flavonoids)</td>
<td align="left">
<italic>Erigeron breviscapus</italic> (Vant.) Hand.-Mazz.</td>
<td align="left">SW480 HT29</td>
<td align="left">OR-SW480 cells mouse model</td>
<td align="left">Induction of apoptosis; reduction of ATP product; inhibition of glycolysis</td>
<td align="left">&#x2193;PKM2</td>
<td align="left">2&#xa0;&#xb5;M 10&#xa0;&#x338d;/kg</td>
<td align="left">
<xref ref-type="bibr" rid="B159">Sun et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Kaempferol (Flavonoids)</td>
<td align="left">
<italic>Acacia nilotica</italic> (L.) Delile<italic>, Aloe vera</italic> (L.) Burm.f.<italic>, Crocus sativus</italic> L<italic>.</italic>
</td>
<td align="left">HCT116 DLD1</td>
<td align="left">&#x2014;</td>
<td align="left">Inhibition of glycolysis and ATP product; induction of apoptosis</td>
<td align="left">&#x2191;miR-339-5p; &#x2193;hnRNPA1; &#x2193;PTBP1; &#x2193;PKM2</td>
<td align="left">0, 50, 100&#xa0;&#xb5;M (48&#xa0;h)</td>
<td align="left">
<xref ref-type="bibr" rid="B193">Wu et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">MCT4</td>
<td align="center">Epigallocatechin-3-gallate (Polyphenols)</td>
<td align="left">
<italic>green tea</italic>
</td>
<td align="left">HCT116; HT29</td>
<td align="left">&#x2014;</td>
<td align="left">Inhibition of the proliferation, migration and metastasis; Inhibition of glycolysis</td>
<td align="left">&#x2193;PFK; &#x2193;MCT4</td>
<td align="left">25, 50, 100&#xa0;&#xb5;M</td>
<td align="left">
<xref ref-type="bibr" rid="B21">Chen et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">PDH</td>
<td rowspan="2" align="center">Hemistepsin A (Sesquiterpene lactone)</td>
<td rowspan="2" align="left">
<italic>Hemistepta lyrata</italic>
</td>
<td rowspan="2" align="left">DLD1 CT26</td>
<td rowspan="2" align="left">CT26 cells xenograft tumors</td>
<td rowspan="2" align="left">Inhibition of cell growth; inhibition of glycolysis; induction of apoptosis</td>
<td rowspan="2" align="left">&#x2193;PDK1; &#x2193;PDHA1</td>
<td align="left">0,5,7.5.10&#xa0;&#xb5;M(4&#xa0;h)</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B77">Jin et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">1&#xa0;mg/kg, 10&#xa0;mg/kg</td>
</tr>
<tr>
<td rowspan="14" align="center">PI3K/AKT/mTOR</td>
<td align="center">Thymoquinone (Quinones)</td>
<td align="left">
<italic>Nigella sativa</italic>
</td>
<td align="left">HCT116; SW480</td>
<td align="left">&#x2014;</td>
<td align="left">Inhibition of proliferation and migration; induction of apoptosis; inhibition of glycolysis and ATP product</td>
<td align="left">&#x2193;PI3K; &#x2193;AKT; &#x2193;HK2</td>
<td align="left">21.71&#xa0;&#xb5;M, 20.53&#xa0;&#xb5;M</td>
<td align="left">
<xref ref-type="bibr" rid="B82">Karim et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Daphnetin (Coumarins)</td>
<td align="left">
<italic>Daphne Korean Nakai</italic>
</td>
<td align="left">SW480 HT29</td>
<td align="left">&#x2014;</td>
<td align="left">Inhibition of proliferation and migration; induction of apoptosis; inhibition of glycolysis</td>
<td align="left">&#x2193;PI3K; &#x2193;AKT; &#x2193;HK2; &#x2193;GLUT1</td>
<td align="left">0, 25, 50&#xa0;&#xb5;M (24&#xa0;h)</td>
<td align="left">
<xref ref-type="bibr" rid="B60">He et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Andrographolide (Diterpenoids)</td>
<td align="left">
<italic>Andrographis paniculata</italic>
</td>
<td align="left">HCT116</td>
<td align="left">&#x2014;</td>
<td align="left">inhibition of glycolysis and ATP product</td>
<td align="left">&#x2193;HK2; &#x2193;PFK1; &#x2193;GLUT1; &#x2193;PI3K; &#x2193;AKT; &#x2193;mTOR</td>
<td align="left">20&#xa0;&#xb5;M</td>
<td align="left">
<xref ref-type="bibr" rid="B105">Li et al. (2020c)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Wogonin (Flavonoids)</td>
<td rowspan="2" align="left">
<italic>Scutellaria baicalensis</italic>
</td>
<td rowspan="2" align="left">HCT116</td>
<td rowspan="2" align="left">HCT116 cells xenograft mice</td>
<td rowspan="2" align="left">inhibition of glycolysis and ATP product; Inhibition of tumor growth</td>
<td rowspan="2" align="left">&#x2193;PI3K/AKT; &#x2193;HIF-1&#x3b1;; &#x2193;HK2; &#x2193;PDHK1; &#x2193;LDHA; &#x2193;GLUT1</td>
<td rowspan="2" align="left">20, 40, 60, 80, 100&#xa0;&#xb5;M(24&#xa0;h) 30, 60&#xa0;mg/kg; 0, 10, 20, 40&#xa0;&#xb5;M</td>
<td align="left">
<xref ref-type="bibr" rid="B177">Wang et al. (2014)</xref>
</td>
</tr>
<tr>
<td align="left">
<xref ref-type="bibr" rid="B225">Zhao et al. (2018)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Atractylenolide I (Sesquiterpene lactones)</td>
<td rowspan="2" align="left">
<italic>Atractylodis macrocephalus</italic>
</td>
<td rowspan="2" align="left">HCT116 Colo205</td>
<td rowspan="2" align="left">HCT116 xenograft nude mice</td>
<td rowspan="2" align="left">Disruption of glucose metabolism; induction of apoptosis; inhibition of invasion and glycolysis; Inhibition of tumor growth</td>
<td rowspan="2" align="left">&#x2193;AKT/mTOR&#x2192;&#x2193;GLUT1; &#x2193;LDH; &#x2193;HK2; &#x2193;PKM2; &#x2193;JAK2/STAT3 &#x2192; &#x2193;HK2</td>
<td align="left">0, 80, 150, 200&#xa0;&#x3bc;M (24&#xa0;h)</td>
<td align="left">
<xref ref-type="bibr" rid="B181">Wang et al. (2020b)</xref>
</td>
</tr>
<tr>
<td align="left">25, 75&#xa0;mg/kg; 0, 100, 200&#xa0;&#xb5;M (24&#xa0;h) 50&#xa0;mg/kg</td>
<td align="left">
<xref ref-type="bibr" rid="B107">Li et al. (2020d)</xref>
</td>
</tr>
<tr>
<td align="center">Xanthatin (Sesquiterpene lactones)</td>
<td align="left">
<italic>Xanthium strumarium</italic> L<italic>.</italic>
</td>
<td align="left">HT-29 HCT-116</td>
<td align="left">&#x2014;</td>
<td align="left">inhibition of glycolysis and ATP product</td>
<td align="left">&#x2193;mTOR&#x2192;&#x2193;GLUT1; &#x2193;HK1; &#x2193;MCT4</td>
<td align="left">0, 20, 30, 40&#xa0;&#xb5;M (24&#xa0;h)</td>
<td align="left">
<xref ref-type="bibr" rid="B99">Li et al. (2022a)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Halofuginone (Alkaloids)</td>
<td rowspan="2" align="left">
<italic>Dichroa febrifuga</italic>
</td>
<td rowspan="2" align="left">SW480 HCT116</td>
<td rowspan="2" align="left">HCT116 xenograft nude mice</td>
<td rowspan="2" align="left">induction of apoptosis; inhibition of glycolysis; Inhibition of tumor growth</td>
<td rowspan="2" align="left">&#x2193;AKT/mTORC1&#x2192;&#x2193;P70S6K; &#x2191;4EBP1&#x2192;&#x2193; HK2; &#x2193;GLUT1</td>
<td align="left">0, 5, 10, 20&#xa0;nM</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B19">Chen et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">0.1&#xa0;mg/kg</td>
</tr>
<tr>
<td rowspan="2" align="center">Beta-caryophyllene (Sesquiterpenes)</td>
<td rowspan="2" align="left">
<italic>Syzygium aromaticum</italic>
</td>
<td rowspan="2" align="left">CT26</td>
<td rowspan="2" align="left">diabetic Balb/c mice</td>
<td rowspan="2" align="left">Inhibition of proliferation and glycolysis; induction of apoptosis</td>
<td rowspan="2" align="left">&#x2193;p-AKT; &#x2193;p-mTOR; &#x2193;c-myc; &#x2193;PDK1; &#x2193;LDHA</td>
<td align="left">50&#xa0;&#xb5;M</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B231">Zhou et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">200&#xa0;mg/kg</td>
</tr>
<tr>
<td rowspan="2" align="center">Xanthohumol (Polyphenol)</td>
<td rowspan="2" align="left">
<italic>Humulus lupulus</italic> L.</td>
<td align="left">HCT116</td>
<td rowspan="2" align="left">HT29 and HCT116 cells xenotransplantation mice</td>
<td rowspan="2" align="left">Inhibition of proliferation and glycolysis; induction of apoptosis; Inhibition of tumor growth</td>
<td rowspan="2" align="left">&#x2193;EGFR/AKT&#x2192;&#x2193;ERK1/2&#x2192;&#x2193;HK2</td>
<td align="left">0,2,4,8&#xa0;&#xb5;M</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B112">Liu et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">SW620 HT29</td>
<td align="left">10&#xa0;mg/kg</td>
</tr>
<tr>
<td rowspan="9" align="center">AMPK</td>
<td align="center">Isoliquiritigenin (Flavonoids)</td>
<td align="left">
<italic>Glycyrrhiza uralensis, Mongolian glycyrrhiza, Glycyrrhiza glabra</italic>
</td>
<td align="left">HCT116</td>
<td align="left">&#x2014;</td>
<td align="left">Inhibition of proliferation, glycolysis and ATP product; induction of apoptosis</td>
<td align="left">&#x2191;AMPK&#x2192;&#x2193;AKT/mTOR&#x2192;&#x2193;ENO1; &#x2193;ALDOA; &#x2193;LDHA; &#x2193;MCT4; &#x2193;c-myc; &#x2193;HIF-1&#x3b1;</td>
<td align="left">12.5, 25, 50, 100&#xa0;&#xb5;M</td>
<td align="left">
<xref ref-type="bibr" rid="B176">Wang et al. (2020a)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Caulerpin (Alkaloids)</td>
<td rowspan="2" align="left">
<italic>Caulerpa racemosa, C. serrulata</italic>
</td>
<td align="left">LoVo</td>
<td rowspan="2" align="left">SW480 xenograft nude mice</td>
<td rowspan="2" align="left">Disturbtion of glycolysis Delay the tumor growth</td>
<td rowspan="2" align="left">&#x2191;AMPK&#x2192;&#x2193;mTORC1; &#x2193;GLUT1</td>
<td rowspan="2" align="left">5,10,20&#xa0;&#xb5;M 30&#xa0;mg/kg</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B211">Yu et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">SW480</td>
</tr>
<tr>
<td rowspan="3" align="center">Resveratrol (Polyphenols)</td>
<td rowspan="3" align="left">
<italic>pomegranates, berries, peanuts,</italic> and <italic>red wine</italic>
</td>
<td rowspan="3" align="left">Caco2 HCT116 CT26 HT29</td>
<td rowspan="3" align="left">CT26 tumor bearing mice</td>
<td rowspan="3" align="left">inhibition of glycolysis; Inhibition of tumor growth</td>
<td rowspan="3" align="left">&#x2191;Ca2&#x2b;/CamKKB/AMPK&#x2192;&#x2191;PDH; &#x2193;HIF-1&#x3b1;</td>
<td rowspan="3" align="left">10&#xa0;&#xb5;M (48&#xa0;h); 50&#xa0;&#x3bc;M; 50&#xa0;&#xb5;M</td>
<td align="left">
<xref ref-type="bibr" rid="B144">Saunier et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">
<xref ref-type="bibr" rid="B80">Jung et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">
<xref ref-type="bibr" rid="B81">Jung et al. (2013)</xref>
</td>
</tr>
<tr>
<td align="center">Oridonin (Diterpenoid)</td>
<td align="left">
<italic>Rabdosia rubescens</italic>
</td>
<td align="left">SW480</td>
<td align="left">SW480 xenograft tumors</td>
<td align="left">Inhibition of proliferation and glycolysis; Inhibition of tumor growth</td>
<td align="left">&#x2193;AMPK; &#x2193;GLUT1; &#x2193;MCT1</td>
<td align="left">5,10,15,20.25&#xa0;&#xb5;M</td>
<td align="left">
<xref ref-type="bibr" rid="B205">Yao et al. (2017)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">DT-13 (Saponins)</td>
<td rowspan="2" align="left">
<italic>Liriope muscari</italic> (Decne.) Bailey</td>
<td rowspan="2" align="left">HT29 HCT116 HCT15 COLO205</td>
<td rowspan="2" align="left">HCT-15 orthotopic nude mice</td>
<td rowspan="2" align="left">Inhibition of proliferation and glycolysis; Inhibition of tumor growth</td>
<td rowspan="2" align="left">&#x2191;AMPK&#x2192;&#x2193;mTOR&#x2192;&#x2193;GLUT1; &#x2193;HK2; &#x2193;PFKM; &#x2193;LDHA</td>
<td align="left">2.5, 5, 10&#xa0;&#x3bc;M (72&#xa0;h)</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B190">Wei et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">0.625, 1.25, 2.5&#xa0;mg/kg</td>
</tr>
<tr>
<td rowspan="5" align="center">HIF-1</td>
<td align="center">Worenine (Alkaloids)</td>
<td align="left">
<italic>Coptis chinensis</italic>
</td>
<td align="left">HCT116 SW620</td>
<td align="left">&#x2014;</td>
<td align="left">inhibition of glycolysis</td>
<td align="left">&#x2193;HIF-1&#x3b1;&#x2192;&#x2193;GLUT3; &#x2193;HK2; &#x2193;PFK-L; &#x2193;PKM2; &#x2193;LDHA; &#x2193;PKM</td>
<td align="left">50,10,20&#xa0;&#x3bc;M (24&#xa0;h)</td>
<td align="left">
<xref ref-type="bibr" rid="B72">Ji et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Berberine (Alkaloids)</td>
<td align="left">
<italic>Rhizoma coptidis</italic>
</td>
<td align="left">HCT116 KM12C</td>
<td align="left">&#x2014;</td>
<td align="left">inhibition of glycolysis</td>
<td align="left">&#x2193;mTOR; &#x2193;HIF-1&#x3b1;&#x2192;&#x2193;GLUT1; &#x2193;LDHA; &#x2193;HK2</td>
<td align="left">0,6.25,12.5, 25,50,100&#xa0;&#xb5;M</td>
<td align="left">
<xref ref-type="bibr" rid="B118">Mao et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="center">Matrine (Alkaloids)</td>
<td align="left">
<italic>Sophora flavescens</italic>
</td>
<td align="left">HCT116 SW620</td>
<td align="left">&#x2014;</td>
<td align="left">inhibition of glycolysis</td>
<td align="left">&#x2193;HIF-1&#x3b1;&#x2192;&#x2193;GLUT1; &#x2193;HK2; &#x2193;LDHA</td>
<td align="left">0,2,4,6,8&#xa0;&#xb5;M</td>
<td align="left">
<xref ref-type="bibr" rid="B63">Hong et al. (2019)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Quercetin (Flavonoids)</td>
<td rowspan="2" align="left">
<italic>apples, cabbage, cauliflower, and berries</italic>
</td>
<td rowspan="2" align="left">HCT116</td>
<td rowspan="2" align="left">F344 rats</td>
<td rowspan="2" align="left">induction of apoptosis; inhibition of glycolysis; upregulation of the mitochondrial fatty acid degradation</td>
<td rowspan="2" align="left">&#x2193;AMPK&#x2192;&#x2193;HIF-1&#x3b1;&#x2192;&#x2193;VEGF; &#x2193;GLUT1 &#x2193;F-1,6-BP; &#x2193;GAPDH; &#x2193;ENO1; &#x2193;PK &#x2191;3-hydroxy-3-methylglutaryl-CoA synthase 2; &#x2191;acetyl-CoA acyltransferase 1; &#x2191;acyl-CoA dehydrogenase short-chain</td>
<td rowspan="2" align="left">100 &#xb5;M; 10&#xa0;g/kg</td>
<td align="left">
<xref ref-type="bibr" rid="B87">Kim et al. (2012)</xref>
</td>
</tr>
<tr>
<td align="left">
<xref ref-type="bibr" rid="B33">Dihal et al. (2008)</xref>.</td>
</tr>
<tr>
<td rowspan="9" align="center">c-myc</td>
<td align="center">Diosgenin (Saponins)</td>
<td align="left">
<italic>legumes, fenugreek, yams</italic>
</td>
<td align="left">SW1116 RKO</td>
<td align="left">SW1116 cells xenograft mice</td>
<td align="left">Inhibition of proliferation, invasion and metastasis; induction of apoptosis; inhibition of glycolysis; Inhibition of tumor growth</td>
<td align="left">&#x2193;cAMP/PKA/CREB&#x2192;&#x2193;GLUT3; &#x2193;GLUT2; &#x2193;PC</td>
<td align="left">20 &#xb5;M</td>
<td align="left">
<xref ref-type="bibr" rid="B101">Li et al. (2021b)</xref>
</td>
</tr>
<tr>
<td align="center">Dioscin (Saponins)</td>
<td align="left">
<italic>Dioscoreae rhizome, Paridis rhizome</italic>
</td>
<td align="left">HT29 HCT116 SW480 SW620</td>
<td align="left">HCT116 and HT29 xenograft mice; HT29 and SW620 xenograft mice</td>
<td align="left">Inhibition of proliferation and glycolysis; Inhibition of tumor growth</td>
<td align="left">&#x2193;c-myc; &#x2193;Skp2; &#x2193;Cdh1&#x2192;&#x2193;HK2</td>
<td align="left">0, 1, 2, 5&#xa0;&#x3bc;M, 5&#xa0;mg/kg; 0,1,2,4&#xa0;&#x3bc;M, 10&#xa0;mg/kg</td>
<td align="left">
<xref ref-type="bibr" rid="B230">Zhou et al. (2020b)</xref>, <xref ref-type="bibr" rid="B195">Wu et al. (2020)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Astragalus saponins (Saponins)</td>
<td rowspan="2" align="left">
<italic>Astragalus membranaceus</italic>
</td>
<td rowspan="2" align="left">SW620</td>
<td rowspan="2" align="left">DSS-induced colitis mouse model</td>
<td rowspan="2" align="left">induction of apoptosis; Inhibition of proliferation and glycolysis</td>
<td rowspan="2" align="left">&#x2193;c-myc&#x2192;&#x2193;HK2; &#x2193;LDHA</td>
<td align="left">50&#xa0;&#x3bc;g/mL (0, 12, 24 and 48&#xa0;h)</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B53">Guo et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">0.1&#xa0;mg/g</td>
</tr>
<tr>
<td rowspan="2" align="center">Morin (Flavonoids)</td>
<td rowspan="2" align="left">
<italic>mulberry figs, fustic</italic>
</td>
<td rowspan="2" align="left">SW480</td>
<td rowspan="2" align="left">DMH induce colon cancer model</td>
<td rowspan="2" align="left">Reduce the incidence of tumors; inhibition of glycolysis and ATP production; induction of apoptosis</td>
<td rowspan="2" align="left">&#x2193;&#x3b2;-cateinin/c-myc; &#x2193;GLUT1; &#x2193;HK2; &#x2193;PKM2; &#x2193;LDHA</td>
<td align="left">50&#xa0;&#x3bc;g/kg</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B151">Sharma et al. (2017),</xref> <xref ref-type="bibr" rid="B155">Sithara et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">150, 200, and 250&#xa0;&#x3bc;M (48&#xa0;h)</td>
</tr>
<tr>
<td rowspan="2" align="center">Esculetin (Coumarins)</td>
<td rowspan="2" align="left">
<italic>Fraxinus rhynchophylla</italic> Hance</td>
<td rowspan="2" align="left">&#x2014;</td>
<td rowspan="2" align="left">DMH induce colon cancer model</td>
<td rowspan="2" align="left">Reduce the incidence of tumors; downregulate the expression of proto-oncogenes; affect tumor metabolism</td>
<td align="left">&#x2193;&#x3b2;-cateinin/c-myc</td>
<td rowspan="2" align="left">50&#xa0;&#x3bc;g/kg</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B151">Sharma et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2193;GLUT1; &#x2193;HK2; &#x2193;PKM2; &#x2193;LDHA</td>
</tr>
<tr>
<td align="center">Apigenin (Flavonoids)</td>
<td align="left">
<italic>parsley, celery, chamomile</italic>
</td>
<td align="left">HCT116 HT29 DLD1</td>
<td align="left">&#x2014;</td>
<td align="left">inhibition of the cell survival and colony formation; inhibition of glycolysis</td>
<td align="left">&#x2193;&#x3b2;-catenin/c-myc/polypyrimidine tract binding protein 1; &#x2193;PKM2</td>
<td align="left">0, 20, 40&#xa0;&#xb5;M</td>
<td align="left">
<xref ref-type="bibr" rid="B148">Shan et al. (2017)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">p53</td>
<td rowspan="2" align="center">Oroxylin A (Flavonoids)</td>
<td rowspan="2" align="left">
<italic>Scutellaria baicalensis Georgi.</italic>
</td>
<td rowspan="2" align="left">HCT116</td>
<td rowspan="2" align="left">HCT116 xenograft mice</td>
<td rowspan="2" align="left">inhibition of glycolysis; Inhibition of tumor growth</td>
<td rowspan="2" align="left">&#x2191;p53; &#x2191;TIGAR; &#x2191;SIRT3 &#x2193;PGM; &#x2193;GLUT4; &#x2193;MDM2</td>
<td align="left">200&#xa0;&#x3bc;M (48&#xa0;h)</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B224">Zhao et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">100&#xa0;mg/kg</td>
</tr>
<tr>
<td align="center">SIRT3/Cypd</td>
<td align="center">Ganoderma acid D (Triterpenoids)</td>
<td align="left">
<italic>Ganoderma lucidum</italic>
</td>
<td align="left">HT29 SW620</td>
<td align="left">&#x2014;</td>
<td align="left">inhibition of glycolysis</td>
<td align="left">&#x2193;CypD&#x2192;&#x2191;SIRT3</td>
<td align="left">0,50,100,200&#xa0;&#x3bc;mol/L</td>
<td align="left">
<xref ref-type="bibr" rid="B113">Liu et al. (2018)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">IL/STAT3</td>
<td align="center">Rosmarinic acid (Phenylpropanoids)</td>
<td align="left">
<italic>Rosmarinus officinalis</italic> L. (Lamiaceae)</td>
<td align="left">HCT8 HCT116</td>
<td align="left">&#x2014;</td>
<td align="left">inhibition of glycolysis</td>
<td align="left">&#x2193;miR-155-5p&#x2192;&#x2193;IL-6/STAT3&#x2192;&#x2193;LDH; &#x2193;HIF-1&#x3b1;</td>
<td align="left">075,150&#xa0;&#x3bc;mol/L (24&#xa0;h)</td>
<td align="left">
<xref ref-type="bibr" rid="B200">Xu et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="center">6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (Alkaloids)</td>
<td align="left">
<italic>Mucuna pruriens</italic>
</td>
<td align="left">&#x2014;</td>
<td align="left">DMH induce CRC rats</td>
<td align="left">inhibition of glycolysis</td>
<td align="left">&#x2193;IL-6&#x2192;&#x2193;JAK2/STAT3&#x2192;&#x2193;LDH</td>
<td align="left">25&#xa0;mg/kg</td>
<td align="left">
<xref ref-type="bibr" rid="B126">Mishra et al. (2018)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s5">
<title>5 Phytochemicals targeting signal pathways and transcription factors in the CRC glycolysis pathway</title>
<sec id="s5-1">
<title>5.1 Phytochemicals directly targeting CRC glycolysis pathway</title>
<sec id="s5-1-1">
<title>5.1.1 Anthocyanin</title>
<p>Anthocyanin (ANC) is a flavonoid that is common in plants (<xref ref-type="bibr" rid="B122">McGhie and Walton, 2007</xref>). And after glycosylation, ANC glycosides can be rapidly absorbed by the human body (<xref ref-type="bibr" rid="B121">McGhie et al., 2003</xref>). Cyanidin-3-glucoside, a member of the anthocyanin family, is found in purple or red vegetables and fruits (<xref ref-type="bibr" rid="B149">Shan et al., 2021</xref>). A comparative study using cyanidin-3-glucoside and its anthocyanidin aglycone showed that cyanidin-3-glucoside significantly inhibited the expression of GLUT1 in MC38 (mouse colon cancer cells), and it can disturb glucose transport, inhibit energy metabolism, and cause mitochondrial damage and apoptosis in CRC cells (<xref ref-type="bibr" rid="B79">Jing et al., 2020</xref>).</p>
</sec>
<sec id="s5-1-2">
<title>5.1.2 Silybin</title>
<p>Silybin is the major component of silymarin, a flavonolignan mixture extracted from the fruits of <italic>Silybum marianum</italic> (L.) Gaertner displays antioxidant, anti-inflammatory, immunomodulatory and hepatoprotective properties (<xref ref-type="bibr" rid="B17">Chambers et al., 2017</xref>). Compared with doxorubicin-sensitive LoVo cells (LoVo WT), doxorubicin-resistant LoVo cells (LoVo DOX) show higher mRNA and protein expression levels of glycolysis-related enzymes, such as GLUT1 and MCT4 (<xref ref-type="bibr" rid="B16">Catanzaro et al., 2018</xref>). Further, it also shows a tendency for metabolic transfer from the oxidative phosphorylation pathway to the glycolysis pathway. After treatment of cells with silybin 10&#x2013;50&#xa0;&#x3bc;M, glucose uptake and GLUT1 expression is downregulated in sensitive and drug-resistant LoVo cells in silybin 10&#xa0;&#x3bc;M, and silybin 50&#xa0;&#x3bc;M resulted effective only in resistant cells (<xref ref-type="bibr" rid="B16">Catanzaro et al., 2018</xref>).</p>
</sec>
<sec id="s5-1-3">
<title>5.1.3 Scutellarin</title>
<p>Scutellarin is a flavonoid drug derived from the plant <italic>Erigeron breviscapus</italic> (Vant.) Hand.-Mazz. (<xref ref-type="bibr" rid="B22">Chen et al., 2006</xref>; <xref ref-type="bibr" rid="B35">Dong and Qu, 2022</xref>). <italic>Erigeron breviscapus</italic> (Vant.) Hand.-Mazz. is a Chinese herbal medicine that was first recorded in South Yunnan Materia Medica with multiple pharmacological effects and clinical applications, such as detoxification, inflammation reduction and pain relief (<xref ref-type="bibr" rid="B22">Chen et al., 2006</xref>; <xref ref-type="bibr" rid="B35">Dong and Qu, 2022</xref>). Studies have found that Oxaliplatin-resistant CRC cells (OR-SW480 and OR-HT29) exhibit higher glycolysis rate and high mRNA and protein expression of PKM2, while scutellarin can inhibit the glucose metabolism rate and ATP production of cells by decreasing the PKM2 expression of OR-SW480 and OR-HT29 cells, leading to mitochondrial dysfunction and finally inducing cell apoptosis (<xref ref-type="bibr" rid="B159">Sun et al., 2021</xref>). This previous study established an <italic>in vivo</italic> model using OR-SW480 cells injected into 4-week-old female immunodeficient nude BALB/c mice, showing that 10&#xa0;mg/kg scutellarin reversed the drug resistance of oxaliplatin in the OR-SW480 mouse model, increased apoptosis induced by oxaliplatin, and significantly reduced protein expression of PKM2 and ATP production in the tumor (<xref ref-type="bibr" rid="B159">Sun et al., 2021</xref>).</p>
</sec>
<sec id="s5-1-4">
<title>5.1.4 Kaempferol</title>
<p>Kaempferol is a flavonoid compound that occurs in many plants such as <italic>Acacia nilotica</italic> (L.) Delile, <italic>Aloe vera</italic> (L.) Burm.f., and <italic>Crocus sativus</italic> L, and has been shown to be cardioprotective, anti-inflammatory, antidiabetic, antioxidant, antitumor, and have anticancer activities (<xref ref-type="bibr" rid="B32">Devi et al., 2015</xref>; <xref ref-type="bibr" rid="B67">Imran et al., 2019</xref>). Studies have shown that kaempferol can exert anticancer effects by inducing apoptosis of cancer cells, causing cell cycle arrest and autophagy (<xref ref-type="bibr" rid="B194">Wu et al., 2018</xref>). Studies have shown that after Kaempferol treatment, the cell cycle of HCT116 and DLD1 cells is delayed, and apoptosis is upregulated (<xref ref-type="bibr" rid="B193">Wu et al., 2021</xref>). In addition, glucose consumption, lactic acid production, and ATP level exhibit a downward trend. Kaempferol can also upregulate the expression of miR-339-5p in HCT116 and DLD1 cells, reducing the expression of hnRNPA1 and PTBP1, leading to the downregulation of PKM2 expression, thereby inhibiting glycolysis of CRC (<xref ref-type="bibr" rid="B193">Wu et al., 2021</xref>).</p>
</sec>
<sec id="s5-1-5">
<title>5.1.5 Epigallocatechin-3-gallate</title>
<p>Green tea, which originated in China, is one of the most popular drinks in the world and was used in traditional Chinese medicine to treat many illnesses (<xref ref-type="bibr" rid="B3">Akbarialiabad et al., 2021</xref>). Epigallocatechin-3-gallate (EGCG) is mainly sourced from green tea (<xref ref-type="bibr" rid="B129">Nagle et al., 2006</xref>). EGCG inhibits the proliferation, migration, and metastasis of HCT116 and HT29 cells (<xref ref-type="bibr" rid="B21">Chen et al., 2022</xref>). In addition, in cancer-associated fibroblasts (CAFs) co-cultured with HCT116 and HT29 cells, 50&#xa0;&#x3bc;M EGCG significantly decreased lactate production, PFK, and MCT4 expression (<xref ref-type="bibr" rid="B21">Chen et al., 2022</xref>). After further silencing the expression of MCT4, it was found that the above inhibitory effect of EGCG was reversed. Therefore, it is speculated that EGCG may inhibit the glycolysis of CAFs through MCT4.</p>
</sec>
<sec id="s5-1-6">
<title>5.1.6 Hemistepsin A</title>
<p>
<italic>Hemisteptia lyrata</italic> is a kind of Chinese herb, its leaves and flowers are used for the treatment of sore throat and treatment of tumor (<xref ref-type="bibr" rid="B69">Jang et al., 1999</xref>). Hemistepsin A (HsA) is a sesquiterpene lactone isolated from <italic>Hemistepta lyrata</italic> Bunge, which exerts various pharmacological effects including anti-hepatotoxic, anti-inflammatory, and anti-cancer activities (<xref ref-type="bibr" rid="B133">Park et al., 2020</xref>). Treatment of various CRC cell lines with HsA showed that HsA had significant cytotoxicity, and significantly inhibited cell growth, but had no significant effect on normal cells (<xref ref-type="bibr" rid="B77">Jin et al., 2020</xref>). Further, after treatment with HsA, the extracellular acidification rate (ECAR) of DLD1 and CT26 cells decreased in a dose-dependent manner. Further study of its internal mechanism found that HsA inhibited the activity of PDK1 by interfering with the interaction between PDK1 protein and lipoamide binding domains of PDH-E2 (L1 and L2), reduced the phosphorylation of PDHA1, and thus inhibited the formation of lactic acid. <italic>In vivo</italic>, experiments showed that HsA (1, 10&#xa0;mg/kg/day) treated for 10d inhibited the growth of BALB/c mice bearing CT26 cells in a dose-dependent manner, upregulated the expression of apoptosis-related genes, and reduced the phosphorylation of PDHA1, which was consistent with the results of <italic>in vitro</italic> experiments (<xref ref-type="bibr" rid="B77">Jin et al., 2020</xref>).</p>
</sec>
</sec>
<sec id="s5-2">
<title>5.2 Phytochemicals targeting PI3K/AKT/mTOR to affect glycolysis in CRC</title>
<sec id="s5-2-1">
<title>5.2.1 Thymoquinone</title>
<p>
<italic>Nigella sativa</italic> is a flowering plant that belongs to the Ranunculaceae family, native to south and southwest Asia, and is used to treat a variety of ailments such as diarrhea, asthma, headaches, cough, eczema, and more (<xref ref-type="bibr" rid="B26">Ciesielska-Figlon et al., 2023</xref>). Thymoquinone is a bioactive constituent derived from the seeds of <italic>N. sativa</italic> and has shown significant anticancer activity in various tumors (<xref ref-type="bibr" rid="B135">Phua et al., 2021</xref>). Thymoquinone significantly inhibits the proliferation, invasion, and metastasis of HCT116 and SW480 cells, induces cell apoptosis, and downregulates the lactic acid production, glucose uptake, and ATP levels of tumor cells (<xref ref-type="bibr" rid="B82">Karim et al., 2022</xref>). Furthermore, it exerts anti-CRC effects by inhibiting HK2 expression under the PI3K/AKT pathway, thus affecting the glycolysis pathway of CRC cells (<xref ref-type="bibr" rid="B82">Karim et al., 2022</xref>).</p>
</sec>
<sec id="s5-2-2">
<title>5.2.2 Daphnetin</title>
<p>Daphnetin, a coumarin derivative, was first isolated from <italic>Daphne Korean Nakai</italic>, and it exerts various pharmacological activities such as anticoagulation, anti-inflammatory, heart protection, and anti-cancer effects (<xref ref-type="bibr" rid="B58">Hang et al., 2022</xref>; <xref ref-type="bibr" rid="B71">Javed et al., 2022</xref>). After daphnetin treatment for 24&#xa0;h, the proliferation and migration of SW480 and HT29 cells are inhibited, apoptosis is increased, glucose uptake and lactic acid production are inhibited, and the protein expression levels of HK2 and GLUT1 are downregulated (<xref ref-type="bibr" rid="B60">He et al., 2018</xref>). In addition, the phosphorylated expression of PI3K and AKT is significantly downregulated in SW480 cells treated with daphnetin, LY294002 (a PI3K/AKT inhibitor) could enhance the inhibitory effect of daphnetin on the glycolysis pathway in SW480 cells. Thus daphnetin may exert anti-cancer effects by targeting the PI3K/AKT pathway to affect glycolysis in CRC cells (<xref ref-type="bibr" rid="B60">He et al., 2018</xref>).</p>
</sec>
<sec id="s5-2-3">
<title>5.2.3 Andrographolide</title>
<p>
<italic>Andrographis paniculata</italic> belongs to the genus Andrographis, widely distributed in Asian countries such as India, China, and Malaysia, and has been often used to treat inflammatory diseases (<xref ref-type="bibr" rid="B106">Li et al., 2022c</xref>). Andrographolide is the principal active ingredient of <italic>Andrographis paniculate</italic> extract, which has shown great potential in the treatment of a variety of inflammatory diseases as well as tumors (<xref ref-type="bibr" rid="B217">Zhang H. et al., 2021</xref>; <xref ref-type="bibr" rid="B137">Qu et al., 2022</xref>). Andrographolide not only inhibits glucose uptake and lactic acid production in HCT116 cells, decreases ATP levels, and inhibits the expression of glycolysis proteins and enzymes, such as PFK1, HK2, and GLUT1, but also inhibits the phosphorylation of the PI3K/AKT/mTOR pathway (<xref ref-type="bibr" rid="B105">Li et al., 2020c</xref>). Further, IGF-1 (a PI3K activator) can reverse the downregulated expression of PI3K, p-AKT, and p-mTOR by andrographolide, and andrographolide shows similar inhibitory effects on HCT116 as LY294002 (a PI3K inhibitor). Therefore, andrographolide may inhibit CRC by targeting PI3K/AKT signal pathway. Interestingly, andrographolide may also improve the radio sensitivity of HCT116 cells through the PI3K/AKT pathway (<xref ref-type="bibr" rid="B105">Li et al., 2020c</xref>).</p>
</sec>
<sec id="s5-2-4">
<title>5.2.4 Wogonin</title>
<p>
<italic>Scutellaria Baicalensis</italic>, belonging to the Lamiaceae family, is a commonly used Chinese herb for clearing heat and detoxification (<xref ref-type="bibr" rid="B203">Yang et al., 2022</xref>). Wogonin is a flavonoid from <italic>Scutellaria baicalensis</italic>, which has anti-tumor, anti-inflammatory, antiviral, and other pharmacological effects (<xref ref-type="bibr" rid="B9">Banik et al., 2022</xref>). Wogonin at 20, 40, 60, 80, and 100&#xa0;mM for 24&#xa0;h can downregulate the expressions of HK2, PDHK1, and LDHA by inhibiting the transcriptional activity of PI3K/AKT and the expression of HIF-1&#x3b1;, thus affecting the glucose uptake and lactic acid production of HCT116 cells under hypoxia (<xref ref-type="bibr" rid="B177">Wang et al., 2014</xref>). Meanwhile, an <italic>in vivo</italic> study showed that 30 and 60&#xa0;mg/kg wogonin could significantly reduce the tumor weight of male BALB/c nude mice, and decreased the expression of HIF-1&#x3b1;, glycolysis-related proteins, and PI3K/AKT (<xref ref-type="bibr" rid="B177">Wang et al., 2014</xref>). In another study, wogonin inhibited the survival of HCT116 cells and the glycolysis of HCT116 expressing wild type in a dose-dependent manner (<xref ref-type="bibr" rid="B225">Zhao et al., 2018</xref>). Wogonin increased the protein level as well as mRNA level of p53 and TIGAR in HCT116 cells, and decreased the protein and mRNA level of PGM, HK2, GLUT1, PDHK1, and LDHA, however, in p53-null and mt-p53 HCT-116 cells the expression and transcription of the glycolysis regulator barely changed. The experiment showed that the inhibitory effect of wogonin on cancer cell glycolysis was dependent on wt-p53. (<xref ref-type="bibr" rid="B225">Zhao et al., 2018</xref>).</p>
</sec>
<sec id="s5-2-5">
<title>5.2.5 Atractylenolide I</title>
<p>
<italic>Atractylodes macrocephala</italic> Koidz., which has been used for thousands of years in China, is mainly used to treat gastrointestinal diseases such as loss of appetite, abdominal distension and diarrhea, has the functions of invigorating the spleen for strengthening the stomach, and dispelling dampness for diuresis (<xref ref-type="bibr" rid="B103">Li et al., 2022b</xref>). Atractylenolide I (AT-I) is a sesquiterpenoid lactone derivative of <italic>Atractylodis macrocephalus</italic> (<xref ref-type="bibr" rid="B234">Zhu et al., 2018</xref>). AT-I downregulates the phosphorylation of proteins related to the AKT/mTOR pathway and the protein expression of GLUT1, LDH, HK2, and PKM2 in a dose-dependent manner in HCT116 and Colo205 cells, thus disrupting the glucose metabolism of colorectal tumors, followed by induction of apoptosis and reduced cell invasion (<xref ref-type="bibr" rid="B181">Wang K. et al., 2020</xref>). In Balb/c nude mice were xenografted with HCT116 cells treated with 25 and 75&#xa0;mg/kg AT-I, the tumor growth and the expression of glycolysis-related proteins were significantly inhibited, it is consistent with the <italic>in vitro</italic> experimental results (<xref ref-type="bibr" rid="B181">Wang K. et al., 2020</xref>). In addition, AT-I downregulates the expression of HK2 in HCT116 cells by inhibiting the JAK2/STAT3 pathway and reduces glucose consumption and lactate production in HCT116 cells, thus exerting anti-CRC effects (<xref ref-type="bibr" rid="B107">Li Y. et al., 2020</xref>). Similar results were also shown <italic>in vivo</italic> using an HCT116 transplanted mouse model treatment with AT-I at 50&#xa0;mg/kg/day for 3&#xa0;weeks. JAK2/STAT3, as a signaling network pathway, is responsible for transducing the signals conveyed by many cytokines from the cell membrane to the nucleus, and extensive studies have confirmed that JAK2/STAT3 plays an important role in the occurrence and development of tumors and drug resistance (<xref ref-type="bibr" rid="B124">Mengie Ayele et al., 2022</xref>).</p>
</sec>
<sec id="s5-2-6">
<title>5.2.6 Xanthatin</title>
<p>
<italic>Xanthium strumarium L</italic> (Asteraceae) is a commonly traditional Chinese herb have been applied for treating various diseases, including rhinitis, headache, arthritis, etc. (<xref ref-type="bibr" rid="B41">Fan et al., 2019</xref>). Xanthatin is a bioactive sesquiterpene lactone isolated from <italic>X. strumarium</italic> L. (<xref ref-type="bibr" rid="B41">Fan et al., 2019</xref>), which suppresses the growth of many tumors, such as lung cancer (<xref ref-type="bibr" rid="B163">Tao et al., 2016</xref>), glioma (<xref ref-type="bibr" rid="B116">Ma et al., 2020</xref>), and melanoma (<xref ref-type="bibr" rid="B102">Li et al., 2013</xref>). In addition, xanthatin downregulates ATP levels, lactic acid production, and glucose uptake in HCT116 and HT29 cells by inhibiting the mTOR pathway, and the mRNA and protein levels expression of GLUT1, MCT4 and the protein levels expression of HK1 is also inhibited (<xref ref-type="bibr" rid="B99">Li L. et al., 2022</xref>). Interestingly, elevated oxygen consumption rates (OCR) and downregulated succinic acid expression were observed in xanthatin-treated HT29 cells, which may be related to xanthatin-induced oxidative phosphorylation (<xref ref-type="bibr" rid="B99">Li L. et al., 2022</xref>). These results suggest that xanthatin may inhibit the glycolytic pathway of CRC cells by targeting the mTOR signaling pathway, in compensation for the activation of oxidative phosphorylation metabolism in cells, thereby causing mitochondrial dysfunction and ultimately inhibiting the growth and metastasis of CRC cells.</p>
</sec>
<sec id="s5-2-7">
<title>5.2.7 Halofuginone</title>
<p>Chang Shan (<italic>Dichroa febrifuga Lour</italic>) is a traditional Chinese medicine as a treatment for malaria, dating back about 2000 years of history (<xref ref-type="bibr" rid="B229">Zhou et al., 2013</xref>). Halofuginone is a natural quinazolinone alkaloid extracted from the plant <italic>Dichroa febrifuga</italic> (<xref ref-type="bibr" rid="B68">Jain et al., 2021</xref>). Halofuginone is less toxic to normal cells, but it significantly inhibits the growth of CRC and induces reactive oxygen species (ROS) production and cell apoptosis in a dose-dependent manner (<xref ref-type="bibr" rid="B19">Chen et al., 2015</xref>). Moreover, halofuginone downregulates the phosphorylation of AKT, mTORC1, and downstream p70S6K in SW480 and HCT116 cells, while the phosphorylation of 4EBP1 is increased in a dose-dependent manner. P70S6K is one of the effectors of mTORC1, which can activate the pentose phosphate pathway, and 4EBP1 inhibits glucose uptake and glycolysis. Halofuginone also significantly decreases the protein expression of HK2 and GLUT1 and the production of tricarboxylic acid cycle intermediates, indicating that halofuginone inhibits the glycolysis pathway of CRC, which may be mediated by the AKT/mTORC1 signaling pathway. A vivo experiment showed that halofuginone at 0.1&#xa0;mg/kg for 14 days downregulated the tumor weight and AKT/mTORC1 expression in female BALB/c nude mice xenotransplanted with HCT116 cells, which was consistent with the results of an <italic>in vitro</italic> experiment (<xref ref-type="bibr" rid="B19">Chen et al., 2015</xref>).</p>
</sec>
<sec id="s5-2-8">
<title>5.2.8 Beta-caryophyllene</title>
<p>Beta-caryophyllene (BCP) is a bicyclic sesquiterpene that is a common constituent of essential oils, such as clove oil obtained from the dried flower-buds of <italic>Syzygium aromaticum</italic> (<xref ref-type="bibr" rid="B117">Machado et al., 2018</xref>). Arginine-specific-mono-ADP-ribosyltransfer 1 (ART1) is highly expressed in CRC and inhibits CRC proliferation, invasion, and metastasis (<xref ref-type="bibr" rid="B202">Yang et al., 2016</xref>). The glycolytic pathway is upregulated in ART1-expressing CT26 cells, while BCP can inhibit the expression of ART1-influenced glycolysis-related expression, such that of p-AKT, p-mTOR, c-Myc, PDK1 and LDHA, and it reduces lactate concentrations and ATP levels in CT26 cells, as shown using <italic>in vivo</italic> and <italic>in vitro</italic> models (<xref ref-type="bibr" rid="B231">Zhou et al., 2018</xref>) This suggests that BCP may inhibit ART1-induced glycolysis through the AKT/mTOR pathway, and it may play a role in inhibiting CRC cell proliferation and inducing apoptosis.</p>
</sec>
<sec id="s5-2-9">
<title>5.2.9 Xanthohumol</title>
<p>Xanthohumol is a natural polyphenol chalcone from flowers of the common hop (<italic>Humulus lupulus</italic> L.) (<xref ref-type="bibr" rid="B173">Vicente de Andrade Silva et al., 2022</xref>). Xanthohumol has a variety of pharmacological activities, including antioxidant, anti-inflammatory, and anti-tumor effects (<xref ref-type="bibr" rid="B75">Jiang et al., 2018</xref>). The proliferation of HCT116, SW620, and HT29 cells is significantly inhibited and apoptosis is increased after treatment with xanthohumol (<xref ref-type="bibr" rid="B112">Liu et al., 2019</xref>); at the same time, glucose consumption, lactic acid production, and HK2 expression in cells are inhibited, and cell pH is decreased. In addition, xanthohumol inhibits the epidermal growth factor receptor (EGFR) and AKT signaling in a dose-dependent manner, and active Akt, Myr-Akt1 can rescued xanthohumol-induced HK2 suppression (<xref ref-type="bibr" rid="B112">Liu et al., 2019</xref>). Therefore, xanthohumol may downregulate HK2 expression by inhibiting the activation of the EGFR/AKT pathway, thus affecting the glycolytic pathway and inducing apoptosis in CRC cells. After xenotransplantation of HT29 and HCT116 cells into female athymic nude mice, the tumor weight of 10&#xa0;mg/kg every 2&#xa0;days in xanthohumol-treated mice was significantly reduced, and expression of Ki-67, p-AKT, and HK2 was downregulated, which was consistent with the results of <italic>in vitro</italic> experiment (<xref ref-type="bibr" rid="B112">Liu et al., 2019</xref>).</p>
</sec>
</sec>
<sec id="s5-3">
<title>5.3 Phytochemicals targeting AMPK to affect glycolysis in CRC</title>
<sec id="s5-3-1">
<title>5.3.1 Isoliquiritigenin</title>
<p>Isoliquiritigenin (ISL) is one of the bioactive ingredients isolated from the roots of plants including <italic>Glycyrrhiza uralensis</italic>, <italic>Mongolian glycyrrhiza</italic>, and <italic>Glycyrrhiza glabra</italic> (<xref ref-type="bibr" rid="B134">Peng et al., 2015</xref>). ISL has a variety of biological activities, such as anti-inflammatory, antioxidant, nerve protection, and anti-tumor growth effects (<xref ref-type="bibr" rid="B182">Wang et al., 2021</xref>). ISL and ISL-loaded nanoparticles (ISL-NLs) inhibit proliferation, increase apoptosis, inhibit glucose uptake and lactate production, downregulate OCR and ATP levels, and decrease basal ECAR and maximum ECAR in HCT116 cells (<xref ref-type="bibr" rid="B176">Wang G. et al., 2020</xref>). Further, the respective study showed that the cell membrane potential was decreased, ROS levels were significantly increased, and the mRNA and protein levels of molecules enolase 1 (ENO1), aldolase, fructose-bisphosphate A (ALDOA), LDHA, MCT4, c-myc, and HIF-1&#x3b1; were also significantly decreased. The authors found that ISL and ISL-NLS could though activate AMPK and downregulate the expression of AKT and mTOR in HCT116 cells, thereby affecting cellular glucose metabolism. Compared with ISL, ISL-NLs have a stronger inhibitory effect on CRC (<xref ref-type="bibr" rid="B176">Wang G. et al., 2020</xref>).</p>
</sec>
<sec id="s5-3-2">
<title>5.3.2 Caulerpin</title>
<p>Caulerpin is a bis-indole alkaloid, which has been isolated from <italic>Caulerpa racemosa</italic> and <italic>C. serrulata</italic> (<xref ref-type="bibr" rid="B14">Canch&#xe9; Chay et al., 2014</xref>). It has been proven to have anti-diabetic, anti-inflammatory, anti-tumor, anti-tuberculosis, and antibacterial effects (<xref ref-type="bibr" rid="B114">Lunagariya et al., 2019</xref>). A previous study found that caulerpin regulation of glucose metabolism in CRC cells depended on treatment time (<xref ref-type="bibr" rid="B211">Yu et al., 2017</xref>). After 8&#xa0;h of caulerpin treatment, glucose metabolism in CRC cells was upregulated; GLUT1 was downregulated in LoVo and SW480 cells after 48 h; and p-AMPK increased during the first 30&#xa0;min and decreased after 60&#xa0;min. The downstream targets of mTORC1 4E-BP1 and S6 were also found to be inhibited. The above results may be related to the inhibition of ROS by caulerpin, resulting in reduced intracellular ATP levels and activation of the energy sensor AMPK. Once activated, AMPK promotes glycolysis to compensate for the loss of ATP. However, long-term activation of AMPK by caulerpin disrupts glycolysis and glucose metabolism in colorectal cells, ultimately leading to cell death (<xref ref-type="bibr" rid="B211">Yu et al., 2017</xref>). In mice transplanted with SW480, caulerpin (30&#xa0;mg/kg) slowed tumor growth.</p>
</sec>
<sec id="s5-3-3">
<title>5.3.3 Resveratrol</title>
<p>Resveratrol is a natural polyphenol occurring in a wide variety of fruits and vegetables, including peanuts, pistachios, and grapes (<xref ref-type="bibr" rid="B140">Ren et al., 2021</xref>), and it has biological activities such as antioxidation and antiproliferation effects (<xref ref-type="bibr" rid="B70">Jang et al., 1997</xref>). Studies have shown that in Caco<sup>2</sup> and HCT116 cells, resveratrol by targeting the Ca<sup>2&#x2b;</sup>/CamKKB/AMPK pathway, activates PDH, increasing the oxidative capacity of colorectal cancer cells, reducing glycolysis, and changing the metabolic pattern of tumor cells (<xref ref-type="bibr" rid="B144">Saunier et al., 2017</xref>). Resveratrol-loaded polymeric nanoparticles suppress glucose metabolism and tumor growth of CT26 cells <italic>in vitro</italic> and <italic>in vivo</italic> (<xref ref-type="bibr" rid="B80">Jung et al., 2015</xref>). In addition, resveratrol can also reduce F-FDG uptake and glycolytic metabolism in HT29 cells by downregulating HIF-1&#x3b1; (<xref ref-type="bibr" rid="B81">Jung et al., 2013</xref>).</p>
</sec>
<sec id="s5-3-4">
<title>5.3.4 Oridonin</title>
<p>
<italic>Rabdosia rubescens</italic> is a Chinese medicine to treat sore throat, gingivitis, and rheumatoid arthritis and is widely distributed in China (<xref ref-type="bibr" rid="B1">Abdullah et al., 2021</xref>). Oridonin, which is purified from <italic>R. rubescens</italic>, is an active diterpenoid compound with significant anticancer activity (<xref ref-type="bibr" rid="B48">Fujita et al., 1976</xref>; <xref ref-type="bibr" rid="B201">Yang et al., 2017</xref>). The inhibition of cell growth and apoptosis induction refers to various cancers, including prostate cancer, non-small cell lung cancer, and glioblastoma (<xref ref-type="bibr" rid="B66">Ikezoe et al., 2003</xref>). Oridonin not only showed anti-CRC cell activity <italic>in vivo</italic> and <italic>in vitro</italic> but also related to p53. This study further confirmed that oridonin could reduce glucose consumption and extracellular lactate concentration, down-regulating the mRNA and protein expression of GLUT1 and MCT1 in SW480 cells, thereby affecting cancer cell metabolism, and similar results were observed in SW480 xenograft BALB/c nude mice (<xref ref-type="bibr" rid="B205">Yao et al., 2017</xref>). However, interestingly, the increased ATP level in the CRC cells treated with oridonin was found, which may be related to the deactivation of AMPK, downregulate the expression of GLUT1 caused by oridonin, metabolic disorder of CRC cells, and thus induced autophagy (<xref ref-type="bibr" rid="B205">Yao et al., 2017</xref>).</p>
</sec>
<sec id="s5-3-5">
<title>5.3.5 DT-13</title>
<p>Ophiopogonis Radix (Maidong in Chinese), the root of Ophiopogon japonicus, is widely used as a medicine in East Asia, with functions such as nourishing yin, promoting fluid production, and moistening the lungs (<xref ref-type="bibr" rid="B20">Chen et al., 2016</xref>). DT-13 is a saponin monomer of <italic>Liriope muscari</italic> (Decne.) Bailey has significant anti-tumor, anti-inflammatory, and heart protection effects (<xref ref-type="bibr" rid="B222">Zhang et al., 2015</xref>; <xref ref-type="bibr" rid="B85">Khan et al., 2018</xref>). DT-13 can inhibit the growth of HT29, HCT116, HCT15, and COLO205 cells (<xref ref-type="bibr" rid="B190">Wei et al., 2019</xref>). DT13 significantly inhibited glucose uptake, lactate production, and the expression of GLUT1 in HCT15 and HT29 cells, and also downregulated glycolysis-related mRNA and protein expressions such as HK2, PFK, and LDHA. Blocking GLUT1 attenuated the effects of DT13 on glucose uptake and cell proliferation in CRC cells (<xref ref-type="bibr" rid="B190">Wei et al., 2019</xref>). The <italic>in vivo</italic> study showed that DT-13 at dosages of 0.625, 1.25, and 2.5&#xa0;mg/kg not only reduced tumor size and weight but also downregulated GLUT1 expression in HCT-15 orthotopic nude mice. Meanwhile, this study also found that DT13 could inhibit the proliferation of CRC cells by activating AMPK and inhibiting mTOR and its downstream phosphorylation. Treatment with an AMPK inhibitor (Compound C) alleviated the proliferation inhibition of DT13 (<xref ref-type="bibr" rid="B190">Wei et al., 2019</xref>).</p>
</sec>
</sec>
<sec id="s5-4">
<title>5.4 Phytochemicals targeting HIF-1 to affect glycolysis in CRC</title>
<sec id="s5-4-1">
<title>5.4.1 Worenine</title>
<p>
<italic>Coptis Chinensis</italic> (Huanglian in Chinese), a famous traditional herbal medicine used for clearing heat and detoxification, is widely used to treat inflammatory and other diseases (<xref ref-type="bibr" rid="B180">Wang J. et al., 2019</xref>; <xref ref-type="bibr" rid="B204">Yang et al., 2021</xref>). Worenine is one of the bioactive components in the dried rhizomes of <italic>Coptis Chinensis</italic> (<xref ref-type="bibr" rid="B123">Meng et al., 2018</xref>), and it inhibits cell viability and induces cell cycle arrest of HCT116 and SW620 cells <italic>in vitro</italic> (<xref ref-type="bibr" rid="B72">Ji et al., 2021</xref>). Worenine-treated HCT116 and SW620 cells, the production of lactic acid and the uptake and consumption of glucose is significantly inhibited, the protein and mRNA levels of GLUT3, HK2, PFK-L, PKM2, and LDHA in HCT116 cells are reduced, and PKM activity is also knockdown. The above changes were achieved by reducing the level of HIF-1&#x3b1;, desferrioxamine (stabilize HIF-1&#x3b1;) treatment for HCT116 cells reversed worenine-induced effects on the Warburg effect (<xref ref-type="bibr" rid="B72">Ji et al., 2021</xref>).</p>
</sec>
<sec id="s5-4-2">
<title>5.4.2 Berberine</title>
<p>Berberine is a botanical alkaloid from the Ranunculaceae and Papaveraceae plant families (<xref ref-type="bibr" rid="B118">Mao et al., 2018</xref>). It is the active component of the Chinese medicine <italic>Rhizoma coptidis</italic> (<xref ref-type="bibr" rid="B199">Xiong et al., 2022</xref>), and it has shown anticancer activity in a variety of cancers, such as breast cancer (<xref ref-type="bibr" rid="B227">Zhong et al., 2022</xref>), lung cancer (<xref ref-type="bibr" rid="B2">Achi et al., 2022</xref>), gastric cancer (<xref ref-type="bibr" rid="B109">Liu et al., 2022</xref>), liver cancer (<xref ref-type="bibr" rid="B184">Wang et al., 2010</xref>), CRC (<xref ref-type="bibr" rid="B158">Sun Q. et al., 2022</xref>). Berberine significantly inhibits the growth and glucose uptake of HCT116 and KM12C cells in a dose-dependent manner and inhibited the mRNA levels of GLUT1, LDHA, and HK2. Further investigation of the underlying mechanism revealed that berberine inhibited glucose metabolism by suppressing mTOR-dependent HIF-1&#x3b1; protein synthesis in CRC cells (<xref ref-type="bibr" rid="B118">Mao et al., 2018</xref>).</p>
</sec>
<sec id="s5-4-3">
<title>5.4.3 Matrine</title>
<p>Sophora flavescens (Fabaceae), which has the effect of killing insects and dispelling dampness, has a long history of use for thousands of years (<xref ref-type="bibr" rid="B157">Sun P. et al., 2022</xref>). Matrine is a natural quinoline alkaloid that occurs in the traditional Chinese medicine <italic>Sophora flavescens</italic> (<xref ref-type="bibr" rid="B93">Lai et al., 2003</xref>; <xref ref-type="bibr" rid="B215">Zhang et al., 2020a</xref>). A study on the anti-tumor effects of matrine in CRC showed that glucose uptake and lactic acid production in HCT116 and SW620 after matrine treatment decreased, inhibiting the Warburg effect in CRC (<xref ref-type="bibr" rid="B63">Hong et al., 2019</xref>). Mechanistically, the transcription and expression of HIF-1&#x3b1; and its downstream related proteins GLUT1, HK2, and LDHA are significantly inhibited by matrine treatment, and knockdown of HIF-1&#x3b1; or overexpression of HIF-1&#x3b1; could reverse matrine&#x2019;s effect on glucose uptake and lactate production (<xref ref-type="bibr" rid="B63">Hong et al., 2019</xref>).</p>
</sec>
<sec id="s5-4-4">
<title>5.4.4 Quercetin</title>
<p>Quercetin is a flavonoid extract that is common in fruits and vegetables and which exerts anticancer effects by inhibiting cell proliferation, inducing cell apoptosis, and delaying the invasion and metastasis of cancer cells (<xref ref-type="bibr" rid="B183">Wang et al., 2022</xref>; <xref ref-type="bibr" rid="B196">Xia et al., 2022</xref>). Quercetin can induce apoptosis of HCT116 cells by inhibiting the activity of AMPK under hypoxia, down-regulating the expression of HIF-1&#x3b1; and its downstream vascular endothelial growth factor and GLUT1 (<xref ref-type="bibr" rid="B87">Kim et al., 2012</xref>). A previous study analyzed the effects of quercetin on the transcriptome and protein change in the discretion-rate colon mucosa of F344 rats and found that quercetin downregulated the expressions of glycolysis-related enzymes such as F-1,6-BP, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ENO1, PK, and upregulated the expression of genes related to mitochondrial fatty acid degradation, such as 3-hydroxy-3-methylglutaryl-CoA synthase 2, acetyl-CoA acyltransferase 1, and acyl-CoA dehydrogenase short-chain (<xref ref-type="bibr" rid="B33">Dihal et al., 2008</xref>). Quercetin may transform the glycolysis of CRC into the degradation of mitochondrial fatty acid in F334 rats, causing mitochondrial dysfunction and inhibiting the development of CRC (<xref ref-type="bibr" rid="B33">Dihal et al., 2008</xref>).</p>
</sec>
</sec>
<sec id="s5-5">
<title>5.5 Phytochemicals targeting c-myc to affect glycolysis in CRC</title>
<sec id="s5-5-1">
<title>5.5.1 Diosgenin and dioscin</title>
<p>Diosgenin (DSG) is a bioactive steroidal sapogenin, abundant in fenugreek seeds (<xref ref-type="bibr" rid="B138">Raju and Mehta, 2009</xref>). DSG not only showed inhibitory effects on the proliferation, invasion, and metastasis of CRC cells but also induced apoptosis (<xref ref-type="bibr" rid="B101">Li S. Y. et al., 2021</xref>). In SW1116 cells, DSG showed inhibitory effects on cancer cells glycolysis, including reduction of ECAR, OCR, lactate production, glucose uptake, and expression of GLUT2, GLUT3, and PC (<xref ref-type="bibr" rid="B101">Li S. Y. et al., 2021</xref>). Mechanistically, DSG regulated the expression of proteins involved in apoptosis, migration, invasion, and metabolic phenotypes of CRC cells by inhibiting the cAMP/PKA/CREB pathway in SW1116 and RKO cells. On xenograft tumor model of nude mice with SW1116 cells showed that 30&#xa0;mg/kg DSG can reduce the weight of tumors <italic>in vivo</italic>, and inhibit the expression of Ki67 and proliferating cell nuclear antigen, Consistent with previous results in cells, DSG also inhibited the cAMP/PKA/CREB signaling pathway in tumor of nude mice (<xref ref-type="bibr" rid="B101">Li S. Y. et al., 2021</xref>). The cAMP/PKA/CREB pathway has been confirmed to regulate the growth, migration, invasion, and metabolism of cancer cells, and it is closely related to CRC metastasis (<xref ref-type="bibr" rid="B216">Zhang et al., 2020b</xref>; <xref ref-type="bibr" rid="B47">Fujishita et al., 2022</xref>).</p>
<p>Dioscin, a structural analog of DSG, is also a steroid saponin isolated from <italic>Dioscoreae rhizome</italic> and <italic>Paridis rhizome,</italic> among others. Dioscin downregulates CRC cells (HT-29, HCT-116, and SW480) proliferation and colony formation by promoting FBW-7-mediated c-myc ubiquitination, leading to the downregulation of c-myc and HK2 expression, reduced lactate consumption and glucose absorption, and inhibition of glycolysis. In xenograft models of HCT116 and HT29, tumor growth was inhibited after 5&#xa0;mg/kg dioscin every 2&#xa0;days treatment, and expression of c-myc, Ki-67, and HK2 was significantly reduced, and apoptosis was upregulated (<xref ref-type="bibr" rid="B195">Wu et al., 2020</xref>). In addition, Dioscin was shown to downregulate S-phase kinase-associated protein 2 (Skp2) protein levels and inhibit the expression of HK2 and aerobic glycolysis in CRC cells <italic>in vitro</italic> and <italic>in vivo</italic> by inhibiting Skp2 S72 phosphorylation and enhancing Skp2 ubiquitination and degradation in a cadherin 1(Cdh1) dependent manner (<xref ref-type="bibr" rid="B230">Zhou L. et al., 2020</xref>). As an oncogene, the Skp2 gene is closely related to the pathogenesis of CRC and is essential for the growth of CRC cells.</p>
</sec>
<sec id="s5-5-2">
<title>5.5.2 Astragalus saponins</title>
<p>Astragalus membranaceus is a well-known Chinese tonic, that is used as an immune stimulant, antioxidant, diuretic, etc. (<xref ref-type="bibr" rid="B46">Fu et al., 2014</xref>). Astragalus saponins (AST), are extracted from the medicinal plant <italic>Astragalus membranaceus</italic>. Studies have shown that AST downregulates the mRNA expression and enzyme activities of LDHA and HK2 in SW620 cells, inhibits glucose uptake and lactate production, induces apoptosis, and inhibits cell growth and proliferation (<xref ref-type="bibr" rid="B53">Guo et al., 2019</xref>). The authors speculated that this may be related to the downregulation of c-myc expression in SW620 cells by AST. In DSS-induced colitis mice, AST attenuates DSS-induced body weight loss and inflammatory response and downregulated the mRNA expression of c-myc and glycolysis-related enzymes, such as LDHA, GLUT, and HK2, which was consistent with the <italic>in vitro</italic> results (<xref ref-type="bibr" rid="B53">Guo et al., 2019</xref>).</p>
</sec>
<sec id="s5-5-3">
<title>5.5.3 Morin and esculetin</title>
<p>Morin is a polyphenol compound originally isolated from members of the Moraceae family such as <italic>mulberry figs</italic> and <italic>fustic</italic> (<xref ref-type="bibr" rid="B25">Chung et al., 2016</xref>). Esculetin is the principal bioactive ingredient of <italic>Fraxinus rhynchophylla</italic> Hance (<xref ref-type="bibr" rid="B218">Zhang et al., 2022</xref>). In a rat colon cancer model induced by 1,2-dimethylhydrazine (DMH), Morin and esculetin at a dose of 50&#xa0;mg/kg were shown to reduce the incidence of DMH-induced tumors and down-regulating the expression of related proto-oncogenes. It also affects tumor metabolism through the &#x3b2;-cateinin/c-myc signaling pathway, including inhibiting the protein expression of GLUT, HK2, PKM2, LDHA and other glycolysis-related proteins, and promoting glutaminolysis (<xref ref-type="bibr" rid="B151">Sharma et al., 2017</xref>).</p>
<p>Morin also downregulated GLUT1 expression and glucose uptake, inhibited ATP production of SW480 cells, and induced ROS production, affecting mitochondrial function and promoting SW480 cells apoptosis (<xref ref-type="bibr" rid="B155">Sithara et al., 2017</xref>).</p>
</sec>
<sec id="s5-5-4">
<title>5.5.4 Apigenin</title>
<p>Apigenin is a natural flavonoid compound, which is common in vegetables and fruits (<xref ref-type="bibr" rid="B150">Sharma et al., 2019</xref>) and which significantly restrains cell survival and colony formation of HCT116, HT29, and DLD1 (<xref ref-type="bibr" rid="B148">Shan et al., 2017</xref>). Further studies showed that apigenin inhibited the mRNA and protein levels of PKM2 by specifically targeting the allosteric FBP binding site of PKM2 and blocking &#x3b2;-catenin/c-myc/PTBP1 signaling pathway to HCT116 cells, reducing the extracellular acidification rate, glucose consumption, and lactate production, blocking the glycolytic metabolism of HCT116 cells (<xref ref-type="bibr" rid="B148">Shan et al., 2017</xref>).</p>
</sec>
</sec>
<sec id="s5-6">
<title>5.6 Phytochemicals targeting other pathways that affect CRC glycolysis</title>
<sec id="s5-6-1">
<title>5.6.1 Oroxylin A</title>
<p>Oroxylin A (OA) is a flavonoid isolated from the root of <italic>S. baicalensis</italic> Georgi., which exerts various functions including cell growth inhibition and apoptosis induction in various cancer cells (<xref ref-type="bibr" rid="B189">Wei et al., 2013</xref>). A previous study showed that OA significantly inhibited glucose uptake and lactate production of HCT116 cells, and it significantly increased the protein level of p53 and the expression of TIGAR in cells and inhibited downstream the mRNA and protein levels of PGM and GLUT4; these inhibitory effects were confirmed to be mediated by p53 (<xref ref-type="bibr" rid="B224">Zhao et al., 2015</xref>). Mechanism studies showed that OA by promoting the deacetylation of sirtuin-3(SIRT3), increases the lipid phosphatase activity of PTEN and negatively regulates the transcription of MDM2, thus reducing the degradation of P53 (<xref ref-type="bibr" rid="B224">Zhao et al., 2015</xref>). An <italic>in vivo</italic> study showed that 100&#xa0;mg/kg OA inhibited the growth of nude mice xenograft tumor-inoculated HCT116 cells by down-regulating MDM2 level and glycolytic protein mediated by p53. As one of the widely studied tumor suppressor genes, the p53 gene plays an important role in inhibiting the growth of tumor cells, inducing apoptosis, and regulating metabolism (<xref ref-type="bibr" rid="B88">Komarova and Gudkov, 1998</xref>; <xref ref-type="bibr" rid="B175">Vogelstein et al., 2000</xref>). SIRT3 is a member of the SIRT family of proteins and has been considered to be related to genomic stability, tumorigenesis, and energy metabolism (<xref ref-type="bibr" rid="B44">Finkel et al., 2009</xref>). As a tumor suppressor gene, PTEN has been demonstrated in previous studies to inhibit p53 degradation by controlling MDM2 P1 promoter activity through its lipid phosphatase activity (<xref ref-type="bibr" rid="B45">Freeman et al., 2003</xref>).</p>
</sec>
<sec id="s5-6-2">
<title>5.6.2 Ganoderma acid D</title>
<p>
<italic>Ganoderma lucidum</italic> is a type of mushroom that grows on plum trees in Asia and is believed to protect body functions, regulate immunity, and promote health and longevity (<xref ref-type="bibr" rid="B78">Jin et al., 2016</xref>). Ganoderma acid D (GAD) is a kind of triterpene compound, which is the main active component of <italic>G. lucidum</italic> (<xref ref-type="bibr" rid="B212">Yuan et al., 2022</xref>). Studies have shown that GAD can reduce glucose uptake, lactic acid production, pyruvate production, and acetyl COA level of HT29 and SW620 cells by upregulating the expression of SIRT3 protein, inactivating acetylation cyclophilin D (CypD), thus playing a role in regulating CRC energy metabolism (<xref ref-type="bibr" rid="B113">Liu et al., 2018</xref>). SIRT3 is a mitochondrial deacetylase, and SIRT3 plays a key role in ROS and limiting cell oxidative damage (<xref ref-type="bibr" rid="B168">Torrens-Mas et al., 2017</xref>). SIRT3 can cause cell death under stress conditions, thus acting as a tumor suppressor (<xref ref-type="bibr" rid="B168">Torrens-Mas et al., 2017</xref>). CypD is one of the SIRT3-modified target proteins in mitochondria.</p>
</sec>
<sec id="s5-6-3">
<title>5.6.3 Rosmarinic acid</title>
<p>
<italic>Rosmarinus officinalis</italic> L. is a plant of the Lamiaceae family native to the Mediterranean region, which has anti-inflammatory, antioxidant, anti-proliferation and other pharmacological effects (<xref ref-type="bibr" rid="B31">de Oliveira et al., 2019</xref>). As a water-soluble polyphenol compound, rosmarinic acid (RA) was first isolated from <italic>R. officinalis</italic> L. (Lamiaceae) (<xref ref-type="bibr" rid="B86">Khojasteh et al., 2020</xref>). RA inhibits the inflammatory response to the tumor microenvironment by inhibiting the expression of miR-155-5p in HCT8 and HCT116 cells, down-regulating the levels of transcription factor STAT3 and inflammatory factor Interleukin 6(IL-6), resulting in the inhibition of glucose consumption and lactic acid production in CRC cells, and the down-regulating expression of LDH and HIF-1&#x3b1;, and play the role of anti-Warburg effect (<xref ref-type="bibr" rid="B200">Xu et al., 2016</xref>). After further intervention with a miR-155-5p agomir drug, it was found that the above inhibitory effects of RA were reversed (<xref ref-type="bibr" rid="B200">Xu et al., 2016</xref>). Recent studies have shown that miR-155 plays an important role in immunity, inflammation, cardiovascular disease, and tumors (<xref ref-type="bibr" rid="B38">Elton et al., 2013</xref>). IL-6 is an inflammatory molecule that is highly expressed in tumor tissues and closely related to tumor cell proliferation (<xref ref-type="bibr" rid="B92">Kumari et al., 2016</xref>).</p>
</sec>
<sec id="s5-6-4">
<title>5.6.4 6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid</title>
<p>The isoquinoline alkaloids 6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (M1) are isolated from the seeds of <italic>Mucuna pruriens(<xref ref-type="bibr" rid="B90">Kumar et al., 2016</xref>)</italic>. The cytotoxicity of M1 was determined by the cell growth inhibition (MTT) method, which showed its antiproliferative activity against Huh-7 (human hepatoma cell line) (<xref ref-type="bibr" rid="B90">Kumar et al., 2016</xref>). M1 also shows anticancer effects in CRC. A study showed that M1 at 10 and 25&#xa0;mg/kg doses for 15&#xa0;days inhibited the high expression of inflammatory cells such as IL-6 in DMH-induced CRC cells and inhibited the activation of the JAK2/STAT3 pathway mediated by IL-6 (<xref ref-type="bibr" rid="B126">Mishra et al., 2018</xref>); further, it downregulated the expression of enzymes such as LDH in CRC liver metastasis and inhibited the high uptake of lactic acid and glucose in CRC cells (<xref ref-type="bibr" rid="B126">Mishra et al., 2018</xref>).</p>
</sec>
</sec>
</sec>
<sec id="s6">
<title>6 Critical considerations</title>
<sec id="s6-1">
<title>6.1 Potential side-effects of phytochemicals</title>
<p>Although some phytochemicals show specific cytotoxicity to tumor cells, they may elicit adverse effects in humans, depending on the dosage and preparation. Studies have shown that the semi-lethal concentration (LC50) of quercetin is 448.45 &#xb1; 0.46&#xa0;mg/L, and low oral dosages of quercetin (128&#xa0;mg/kg) do not cause any significant changes in body appearance and general behavior in mice (<xref ref-type="bibr" rid="B132">Pal and Tripathi, 2020</xref>). However, higher dosages of quercetin (450&#xa0;mg/kg) showed mild toxic effects, including weight loss and liver function impairment (<xref ref-type="bibr" rid="B132">Pal and Tripathi, 2020</xref>). Oral dosages of quercetin-magnesium were recommended to be restricted to less than 130&#xa0;mg/kg to avoid possible toxic effects (<xref ref-type="bibr" rid="B51">Ghosh et al., 2017</xref>). Andrographolide show toxic side effects in a time-dependent manner, and they can significantly inhibit the proliferation of human renal tubular epithelium cells, induce cell apoptosis and inflammation, and increase nephrotoxicity (<xref ref-type="bibr" rid="B213">Zeng et al., 2022</xref>). Meanwhile, it has been reported that with andrographolide (PN355, Paracelsian, Inc.) in a phase-I clinical trial with HIV-positive patients, adverse effects such as anaphylaxis, fatigue, headache, rash, diarrhea, dry mouth, and decreased taste occurred with increasing dosage, and the adverse events disappeared 6&#xa0;weeks after trial interruption (<xref ref-type="bibr" rid="B13">Calabrese et al., 2000</xref>). Determining the safe dosage of phytochemicals <italic>in vivo</italic> and balancing the relationship between their therapeutic effects and toxic side effects is a prominent difficulty in the development of phytochemical drugs.</p>
</sec>
<sec id="s6-2">
<title>6.2 Bioavailability</title>
<p>Some phytochemicals have been demonstrated to inhibit the glycolytic pathway of CRC <italic>in vitro</italic> and <italic>in vivo</italic> studies, however, due to their poor water solubility, low bioavailability, low cell uptake, etc., their further application in clinical practice is limited (<xref ref-type="bibr" rid="B127">Mohapatra et al., 2022</xref>). How to prepare such drugs so that they can be effectively utilized by humans is one of the bottlenecks of drug development. Therefore, one main objective of drug development is to improve the absorption and pharmacokinetics of drugs <italic>in vivo</italic> (<xref ref-type="bibr" rid="B40">Estrela et al., 2017</xref>). Piperine, a component of black pepper (Piper spp.), can improve the bioavailability of curcumin, the tea polyphenol (-)-Epigallocatechin-3-gallate, and other phytochemicals by inhibiting their glucuronidation (<xref ref-type="bibr" rid="B94">Lambert et al., 2004</xref>; <xref ref-type="bibr" rid="B147">Shaikh et al., 2009</xref>).</p>
<p>A further prominent avenue to improve the bioavailability of phytochemical drugs is novel drug delivery systems such as nanocarriers, which can alter the pharmacokinetics and improve the stability and half-life of drugs (<xref ref-type="bibr" rid="B6">Aqil et al., 2013</xref>). Quercetin has shown promising anticancer activity in current studies, however, its applicability is limited due to its poor water solubility <italic>in vivo</italic>, poor deliverability, and unstable molecular structure. Nano-conjugated quercetin can overcome the limitations of quercetin and enhance its anticancer effect, thus offering development prospects (<xref ref-type="bibr" rid="B174">Vinayak and Maurya, 2019</xref>). Liposome nanocarriers of apigenin can improve its bioavailability, and dual-drug-loaded liposomes with apigenin and 5-FU show higher cytotoxicity, stronger inhibition of angiogenesis and cell proliferation, and increased apoptosis. This delivery mode also showed upregulation of AMPK and downregulation of downstream HIF-1 activity and stronger reversal of the Warburg effect in CRC cells, compared to the single agent (<xref ref-type="bibr" rid="B146">Sen et al., 2019</xref>).</p>
</sec>
<sec id="s6-3">
<title>6.3 Synergistic interactions of phytochemicals with other treatments</title>
<p>The combination of various phytochemicals can improve the blood concentrations and bioavailability of drugs. Therefore, identifying the synergistic effects of drugs is an important aspect of drug development. The synergistic effect of phytochemical drugs combined with chemoradiotherapy is thus a key direction of treatment research. HF and artemisinin (ATS) show synergistic effects in CRC, manifested as synergistic induction of apoptosis and autophagy by HF-ATS (<xref ref-type="bibr" rid="B52">Gong et al., 2022</xref>). Quercetin can be used in combination with 5-FU (<xref ref-type="bibr" rid="B11">Boersma et al., 1994</xref>), doxorubicin (<xref ref-type="bibr" rid="B7">Atashpour et al., 2015</xref>), and other chemotherapy drugs to enhance its anti-cancer effect and to reduce the cytotoxicity of chemotherapy drugs. Furthermore, quercetin also played a significant role in reducing the mechanism of CRC chemoresistance (<xref ref-type="bibr" rid="B233">Zhou Y. et al., 2020</xref>). Oroxylin A and wogonin can synergistically inhibit MCF-7 proliferation and induce cell apoptosis, and baicalein also shows increased gastric cancer AGS cells sensitivity to 5-FU by inhibiting glycolytic flux (<xref ref-type="bibr" rid="B24">Cheng et al., 2018</xref>). Currently used phytochemicals have shown great potential in the treatment of cancer, and synergistic effects of phytochemicals and other drugs are a key aspect of drug development.</p>
</sec>
<sec id="s6-4">
<title>6.4 Clinical transformation of phytochemicals</title>
<p>Numerous clinical trials have been conducted to develop phytochemical drugs. In a double-blind, randomized, placebo-controlled trial on berberine and patients who had undergone colorectal polypectomy within 6&#xa0;months before recruitment, the experimental group received berberine (0.3&#xa0;g, twice per day) and were followed for 2&#xa0;years; the results showed that the berberine treatment group had a lower incidence of recurrent adenomas (<xref ref-type="bibr" rid="B23">Chen et al., 2020</xref>). As a well-known proprietary Chinese medicine, Kangai injection consists of extracts of Astragalus, Ginseng, and Matrine. In a randomized trial, Kangai injection and platinum combination therapy have been shown to have a greater benefit than chemotherapy alone in patients with advanced non-small cell lung cancer, which can enhance the body&#x2019;s immunity and reduce the toxicity of chemotherapy drugs (<xref ref-type="bibr" rid="B24">Cheng et al., 2018</xref>). Aidi injection plays a role of advantages in the treatment of liver cancer (<xref ref-type="bibr" rid="B110">Liu et al., 2021</xref>). In CRC patients, the combined use of FOLFOX with Chinese herbal medicines such as Delisheng and Xiaoaiping shows higher safety and improved body functioning than treatment with FOLFOX alone (<xref ref-type="bibr" rid="B214">Zhang et al., 2019</xref>). Further evidence also suggests that the use of chemotherapeutic drugs combined with Chinese patent medicine may be more beneficial, and some studies have shown that phytochemicals have significant anticancer properties, however, further research is needed (<xref ref-type="bibr" rid="B164">Thomasset et al., 2007</xref>).</p>
</sec>
</sec>
<sec id="s7">
<title>7 Summary and prospect</title>
<p>In the past few decades, CRC screening has become increasingly common, and treatment methods have been developed, however, death and incidence rates of CRC are still increasing. At present, there is a lack of effective targeted therapy for CRC. Aerobic glycolysis, as one of the characteristics of tumors, is considered a therapeutic target. It has been found that many malignant tumors, including CRC, have higher glycolysis rates to maintain the proliferation, invasion, and metastasis of cancer cells. In CRC, glycolysis-related enzymes and transporters (e.g., GLUT1, HK2, LDHA, PKM2) are highly expressed, and the upregulation of HIF-1, AMPK, c-Myc, PI3K/Akt/mTOR and other related pathways and transporters also promote the glycolysis process of CRC. This review focuses on phytochemicals that target the glycolytic pathway in CRC. There is <italic>in vitro</italic> and <italic>in vivo</italic> evidence that some phytochemicals can affect the growth, invasion, and metastasis of CRC and induce CRC apoptosis by targeting the glycolytic pathway.</p>
<p>The results compiled for this review were classified according to different mechanism pathways targeted, including phytochemicals targeting PI3K/AKT/mTOR pathway (e.g., Thymoquinone and Daphnetin), AMPK pathway (e.g., Isoliquiritigenin and Resveratrol), HIF-1 (e.g., Worenine and Berberine), and c-myc (e.g., Astragalus saponins and Morin), and some phytochemicals directly affecting the glycolytic pathway of CRC without involving the above pathways. Examples include phytochemicals that directly target GLUT1 (e.g., Scutellarin and Kaempferol), PKM2 (e.g., Anthocyanin and Silybin), and MCT4 (e.g., Epigallocatechin-3-gallate). Although the phytochemicals mentioned above affect CRC cells through different pathways, they all suggest bright prospects for targeting CRC glycolytic pathways in the treatment of CRC.</p>
<p>Tumor metabolism is highly complex. Some phytochemicals have complex and diverse molecular targets, and further experiments are needed to verify their anticancer effects. We introduce several phytochemicals targeting CRC glycolysis metabolic pathways, which appears to be a promising direction; however, further research is required, including on how to maintain the stability of plant chemicals in the body, how to prepare plant chemicals that can be transmitted directly to the lesion site, and how to improve blood concentrations of phytochemicals. Therefore, exploiting synergistic effects of phytochemicals with other drugs may provide new ideas for further research and development of anticancer drugs. In addition to the regulation of glucose metabolism, some phytochemicals have shown the therapeutic action of multi-target and multi-pathway, and their anticancer mechanisms need further verification. Although some phytochemicals have shown potential therapeutic effects on colorectal cancer, but long-term evaluation for their possible toxic and side effects is required. In the future, more researches on phytochemicals targeting glycolysis can provide evidence for the drug development in CRC therapy.</p>
</sec>
</body>
<back>
<sec id="s8">
<title>Author contributions</title>
<p>LZ: Writing&#x2013;review and editing, Data curation, Formal Analysis, Writing&#x2013;original draft. FS: Writing&#x2013;original draft, Formal Analysis. QL: Writing&#x2013;original draft, Investigation. YW: Data curation, Methodology, Writing&#x2013;review and editing. FW: Data curation, Writing&#x2013;review and editing, Formal Analysis. ZH: Writing&#x2013;review and editing, Resources, Software. XC: Software, Resources, Writing&#x2013;review and editing. XY: Writing&#x2013;review and editing, Formal Analysis, Visualization. JW: Writing&#x2013;review and editing, Project administration, Resources. YiC: Writing&#x2013;review and editing, Data curation, Visualization. YG: Visualization, Writing&#x2013;review and editing. YuC: Writing&#x2013;review and editing, Funding acquisition, Supervision. XM: Funding acquisition, Supervision, Writing&#x2013;review and editing, Methodology. JZ: Funding acquisition, Supervision, Writing&#x2013;review and editing, Conceptualization.</p>
</sec>
<sec id="s9">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Program of Science and Technology Department of Sichuan Province (Grant Nos. 2023YFS0476, 2023YFQ0016, and 2023NSFSC0039), the Project of Traditional Chinese Medicine Administration of Sichuan Province (Grant Nos.MS461), &#x201c;Hundred Talents Program&#x201d; of the Hospital of the Chengdu University of Traditional Chinese Medicine (Grant Nos. 20-Q03 and 22-B09), Xinglin Scholar Research Promotion Project of Chengdu University of TCM (Grant Nos. QJJJ2022010 and QJRC2022028).</p>
</sec>
<sec sec-type="COI-statement" id="s10">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdullah</surname>
<given-names>N. A.</given-names>
</name>
<name>
<surname>Md Hashim</surname>
<given-names>N. F.</given-names>
</name>
<name>
<surname>Ammar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Muhamad Zakuan</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>An insight into the anti-angiogenic and anti-metastatic effects of oridonin: current knowledge and future potential</article-title>. <source>Molecules</source> <volume>26</volume> (<issue>4</issue>), <fpage>775</fpage>. <pub-id pub-id-type="doi">10.3390/molecules26040775</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Achi</surname>
<given-names>I. T.</given-names>
</name>
<name>
<surname>Sarbadhikary</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>George</surname>
<given-names>B. P.</given-names>
</name>
<name>
<surname>Abrahamse</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Multi-target potential of berberine as an antineoplastic and antimetastatic agent: a special focus on lung cancer treatment</article-title>. <source>Cells</source> <volume>11</volume> (<issue>21</issue>), <fpage>3433</fpage>. <pub-id pub-id-type="doi">10.3390/cells11213433</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akbarialiabad</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dahroud</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Khazaei</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Razmeh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zarshenas</surname>
<given-names>M. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Green tea, A medicinal food with promising neurological benefits</article-title>. <source>Curr. Neuropharmacol.</source> <volume>19</volume> (<issue>3</issue>), <fpage>349</fpage>&#x2013;<lpage>359</lpage>. <pub-id pub-id-type="doi">10.2174/1570159x18666200529152625</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>An</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>E. M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Extracellular vesicles derived from Lactobacillus plantarum restore chemosensitivity through the PDK2-mediated glucose metabolic pathway in 5-FU-resistant colorectal cancer cells</article-title>. <source>J. Microbiol.</source> <volume>60</volume> (<issue>7</issue>), <fpage>735</fpage>&#x2013;<lpage>745</lpage>. <pub-id pub-id-type="doi">10.1007/s12275-022-2201-1</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ancey</surname>
<given-names>P. B.</given-names>
</name>
<name>
<surname>Contat</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Meylan</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Glucose transporters in cancer - from tumor cells to the tumor microenvironment</article-title>. <source>Febs J.</source> <volume>285</volume> (<issue>16</issue>), <fpage>2926</fpage>&#x2013;<lpage>2943</lpage>. <pub-id pub-id-type="doi">10.1111/febs.14577</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aqil</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Munagala</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jeyabalan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vadhanam</surname>
<given-names>M. V.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Bioavailability of phytochemicals and its enhancement by drug delivery systems</article-title>. <source>Cancer Lett.</source> <volume>334</volume> (<issue>1</issue>), <fpage>133</fpage>&#x2013;<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2013.02.032</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atashpour</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fouladdel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Movahhed</surname>
<given-names>T. K.</given-names>
</name>
<name>
<surname>Barzegar</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ghahremani</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Ostad</surname>
<given-names>S. N.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Quercetin induces cell cycle arrest and apoptosis in CD133(&#x2b;) cancer stem cells of human colorectal HT29 cancer cell line and enhances anticancer effects of doxorubicin</article-title>. <source>Iran. J. Basic Med. Sci.</source> <volume>18</volume> (<issue>7</issue>), <fpage>635</fpage>&#x2013;<lpage>643</lpage>.</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baer</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Casaubon</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Younes</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia</article-title>. <source>J. Am. Acad. Dermatol</source> <volume>37</volume> (<issue>4</issue>), <fpage>575</fpage>&#x2013;<lpage>577</lpage>. <pub-id pub-id-type="doi">10.1016/s0190-9622(97)70174-9</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banik</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Khatoon</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Harsha</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rana</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Parama</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Thakur</surname>
<given-names>K. K.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Wogonin and its analogs for the prevention and treatment of cancer: a systematic review</article-title>. <source>Phytother. Res.</source> <volume>36</volume> (<issue>5</issue>), <fpage>1854</fpage>&#x2013;<lpage>1883</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.7386</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biller</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Schrag</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Diagnosis and treatment of metastatic colorectal cancer: a review</article-title>. <source>Jama</source> <volume>325</volume> (<issue>7</issue>), <fpage>669</fpage>&#x2013;<lpage>685</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2021.0106</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boersma</surname>
<given-names>H. H.</given-names>
</name>
<name>
<surname>Woerdenbag</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Scheithauer</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Kampinga</surname>
<given-names>H. H.</given-names>
</name>
<name>
<surname>Konings</surname>
<given-names>A. W.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Interaction between the cytostatic effects of quercetin and 5-fluorouracil in two human colorectal cancer cell lines</article-title>. <source>Phytomedicine</source> <volume>1</volume> (<issue>3</issue>), <fpage>239</fpage>&#x2013;<lpage>244</lpage>. <pub-id pub-id-type="doi">10.1016/s0944-7113(11)80071-1</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bui</surname>
<given-names>B. P.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>P. L.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Hypoxia-inducible factor-1: a novel therapeutic target for the management of cancer, drug resistance, and cancer-related pain</article-title>. <source>Cancers (Basel)</source> <volume>14</volume> (<issue>24</issue>), <fpage>6054</fpage>. <pub-id pub-id-type="doi">10.3390/cancers14246054</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calabrese</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Babish</surname>
<given-names>J. G.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shinto</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dorr</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>A phase I trial of andrographolide in HIV positive patients and normal volunteers</article-title>. <source>Phytother. Res.</source> <volume>14</volume> (<issue>5</issue>), <fpage>333</fpage>&#x2013;<lpage>338</lpage>. <pub-id pub-id-type="doi">10.1002/1099-1573(200008)14:5&#x3c;333::aid-ptr584&#x3e;3.0.co;2-d</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canch&#xe9; Chay</surname>
<given-names>C. I.</given-names>
</name>
<name>
<surname>G&#xf3;mez Cansino</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Espitia Pinz&#xf3;n</surname>
<given-names>C. I.</given-names>
</name>
<name>
<surname>Torres-Ochoa</surname>
<given-names>R. O.</given-names>
</name>
<name>
<surname>Mart&#xed;nez</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Synthesis and anti-tuberculosis activity of the marine natural product caulerpin and its analogues</article-title>. <source>Mar. Drugs</source> <volume>12</volume> (<issue>4</issue>), <fpage>1757</fpage>&#x2013;<lpage>1772</lpage>. <pub-id pub-id-type="doi">10.3390/md12041757</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Enhancing 5-fluorouracil efficacy through suppression of PKM2 in colorectal cancer cells</article-title>. <source>Cancer Chemother. Pharmacol.</source> <volume>82</volume> (<issue>6</issue>), <fpage>1081</fpage>&#x2013;<lpage>1086</lpage>. <pub-id pub-id-type="doi">10.1007/s00280-018-3676-7</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catanzaro</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gabbia</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cocetta</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Biagi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ragazzi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Montopoli</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Silybin counteracts doxorubicin resistance by inhibiting GLUT1 expression</article-title>. <source>Fitoterapia</source> <volume>124</volume>, <fpage>42</fpage>&#x2013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/j.fitote.2017.10.007</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chambers</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Hole&#x10d;kov&#xe1;</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Petr&#xe1;skov&#xe1;</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Biedermann</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Valentov&#xe1;</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Buchta</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>The silymarin composition and why does it matter???</article-title> <source>Food Res. Int.</source> <volume>100</volume>(<issue>3</issue>), <fpage>339</fpage>&#x2013;<lpage>353</lpage>. <pub-id pub-id-type="doi">10.1016/j.foodres.2017.07.017</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>High-fat diet-induced retinal dysfunction</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source> <volume>56</volume> (<issue>4</issue>), <fpage>2367</fpage>&#x2013;<lpage>2380</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.14-16143</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>G. Q.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>C. F.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X. K.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Fatima</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>X. H.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism</article-title>. <source>Oncotarget</source> <volume>6</volume> (<issue>27</issue>), <fpage>24148</fpage>&#x2013;<lpage>24162</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.4376</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X. J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>L. G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y. T.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Ophiopogon japonicus--A phytochemical, ethnomedicinal and pharmacological review</article-title>. <source>J. Ethnopharmacol.</source> <volume>181</volume>, <fpage>193</fpage>&#x2013;<lpage>213</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2016.01.037</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nishi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Morine</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tokunaga</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kashihara</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Epigallocatechin-3-gallate hinders metabolic coupling to suppress colorectal cancer malignancy through targeting aerobic glycolysis in cancer-associated fibroblasts</article-title>. <source>Int. J. Oncol.</source> <volume>60</volume> (<issue>2</issue>), <fpage>19</fpage>. <pub-id pub-id-type="doi">10.3892/ijo.2022.5309</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Pharmacokinetics and metabolism of the flavonoid scutellarin in humans after a single oral administration</article-title>. <source>Drug Metab. Dispos.</source> <volume>34</volume> (<issue>8</issue>), <fpage>1345</fpage>&#x2013;<lpage>1352</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.106.009779</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y. X.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Q. Y.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B. M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S. D.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>J. Q.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study</article-title>. <source>Lancet Gastroenterol. Hepatol.</source> <volume>5</volume> (<issue>3</issue>), <fpage>267</fpage>&#x2013;<lpage>275</lpage>. <pub-id pub-id-type="doi">10.1016/s2468-1253(19)30409-1</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Scutellaria baicalensis and cancer treatment: recent progress and perspectives in biomedical and clinical studies</article-title>. <source>Am. J. Chin. Med.</source> <volume>46</volume> (<issue>1</issue>), <fpage>25</fpage>&#x2013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1142/s0192415x18500027</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Oliva</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dwabe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vadgama</surname>
<given-names>J. V.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Combination treatment with flavonoid morin and telomerase inhibitor MST-312 reduces cancer stem cell traits by targeting STAT3 and telomerase</article-title>. <source>Int. J. Oncol.</source> <volume>49</volume> (<issue>2</issue>), <fpage>487</fpage>&#x2013;<lpage>498</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2016.3546</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciesielska-Figlon</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wojciechowicz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wardowska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lisowska</surname>
<given-names>K. A.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>The immunomodulatory effect of Nigella sativa</article-title>. <source>Antioxidants (Basel)</source> <volume>12</volume> (<issue>7</issue>), <fpage>1340</fpage>. <pub-id pub-id-type="doi">10.3390/antiox12071340</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coutte</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dreyer</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sablin</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Faivre</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Raymond</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2012</year>). [<article-title>PI3K-AKT-mTOR pathway and cancer</article-title>]. <source>Bull. Cancer</source> <volume>99</volume> (<issue>2</issue>), <fpage>173</fpage>&#x2013;<lpage>180</lpage>. <pub-id pub-id-type="doi">10.1684/bdc.2011.1384</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X. Y.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Expression of pyruvate kinase M2 in human colorectal cancer and its prognostic value</article-title>. <source>Int. J. Clin. Exp. Pathol.</source> <volume>8</volume> (<issue>9</issue>), <fpage>11393</fpage>&#x2013;<lpage>11399</lpage>.</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>X. G.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Z. T.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X. D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T. R.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>C. H.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>HIF1/2&#x3b1; mediates hypoxia-induced LDHA expression in human pancreatic cancer cells</article-title>. <source>Oncotarget</source> <volume>8</volume> (<issue>15</issue>), <fpage>24840</fpage>&#x2013;<lpage>24852</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.15266</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dang</surname>
<given-names>C. V.</given-names>
</name>
<name>
<surname>O&#x27;Donnell</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Zeller</surname>
<given-names>K. I.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Osthus</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>The c-Myc target gene network</article-title>. <source>Semin. Cancer Biol.</source> <volume>16</volume> (<issue>4</issue>), <fpage>253</fpage>&#x2013;<lpage>264</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2006.07.014</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Oliveira</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Camargo</surname>
<given-names>S. E. A.</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>L. D.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Rosmarinus officinalis L. (rosemary) as therapeutic and prophylactic agent</article-title>. <source>J. Biomed. Sci.</source> <volume>26</volume> (<issue>1</issue>), <fpage>5</fpage>. <pub-id pub-id-type="doi">10.1186/s12929-019-0499-8</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devi</surname>
<given-names>K. P.</given-names>
</name>
<name>
<surname>Malar</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Nabavi</surname>
<given-names>S. F.</given-names>
</name>
<name>
<surname>Sureda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nabavi</surname>
<given-names>S. M.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Kaempferol and inflammation: from chemistry to medicine</article-title>. <source>Pharmacol. Res.</source> <volume>99</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2015.05.002</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dihal</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>van der Woude</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hendriksen</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Charif</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dekker</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Ijsselstijn</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Transcriptome and proteome profiling of colon mucosa from quercetin fed F344 rats point to tumor preventive mechanisms, increased mitochondrial fatty acid degradation and decreased glycolysis</article-title>. <source>Proteomics</source> <volume>8</volume> (<issue>1</issue>), <fpage>45</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1002/pmic.200700364</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>ROS/PI3K/Akt and Wnt/&#x3b2;-catenin signalings activate HIF-1&#x3b1;-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>41</volume> (<issue>1</issue>), <fpage>15</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-021-02229-6</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Erigeron breviscapus (vant) hand-mazz: a promising natural neuroprotective agent for alzheimer&#x27;s disease</article-title>. <source>Front. Pharmacol.</source> <volume>13</volume>, <fpage>877872</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.877872</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donohoe</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>L. B.</given-names>
</name>
<name>
<surname>Wali</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bigler</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Bultman</surname>
<given-names>S. J.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation</article-title>. <source>Mol. Cell</source> <volume>48</volume> (<issue>4</issue>), <fpage>612</fpage>&#x2013;<lpage>626</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2012.08.033</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donovan</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Selmin</surname>
<given-names>O. I.</given-names>
</name>
<name>
<surname>Doetschman</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Romagnolo</surname>
<given-names>D. F.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Mediterranean diet: prevention of colorectal cancer</article-title>. <source>Front. Nutr.</source> <volume>4</volume>, <fpage>59</fpage>. <pub-id pub-id-type="doi">10.3389/fnut.2017.00059</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elton</surname>
<given-names>T. S.</given-names>
</name>
<name>
<surname>Selemon</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Elton</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Parinandi</surname>
<given-names>N. L.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Regulation of the MIR155 host gene in physiological and pathological processes</article-title>. <source>Gene</source> <volume>532</volume> (<issue>1</issue>), <fpage>1</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2012.12.009</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eslami</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sadrifar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Karbalaei</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Keikha</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kobyliak</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Yousefi</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Importance of the microbiota inhibitory mechanism on the Warburg effect in colorectal cancer cells</article-title>. <source>J. Gastrointest. Cancer</source> <volume>51</volume> (<issue>3</issue>), <fpage>738</fpage>&#x2013;<lpage>747</lpage>. <pub-id pub-id-type="doi">10.1007/s12029-019-00329-3</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Estrela</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Mena</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Obrador</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Benlloch</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Castellano</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Salvador</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Polyphenolic phytochemicals in cancer prevention and therapy: bioavailability versus bioefficacy</article-title>. <source>J. Med. Chem.</source> <volume>60</volume> (<issue>23</issue>), <fpage>9413</fpage>&#x2013;<lpage>9436</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01026</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Traditional uses, botany, phytochemistry, pharmacology, pharmacokinetics and toxicology of <italic>Xanthium strumarium</italic> L: a review</article-title>. <source>Molecules</source> <volume>24</volume> (<issue>2</issue>), <fpage>359</fpage>. <pub-id pub-id-type="doi">10.3390/molecules24020359</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faubert</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Boily</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Izreig</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Griss</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Samborska</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>AMPK is a negative regulator of the Warburg effect and suppresses tumor growth <italic>in vivo</italic>
</article-title>. <source>Cell Metab.</source> <volume>17</volume> (<issue>1</issue>), <fpage>113</fpage>&#x2013;<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2012.12.001</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y. Q.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Role of glucose metabolism related gene GLUT1 in the occurrence and prognosis of colorectal cancer</article-title>. <source>Oncotarget</source> <volume>8</volume> (<issue>34</issue>), <fpage>56850</fpage>&#x2013;<lpage>56857</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.18090</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finkel</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>C. X.</given-names>
</name>
<name>
<surname>Mostoslavsky</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Recent progress in the biology and physiology of sirtuins</article-title>. <source>Nature</source> <volume>460</volume> (<issue>7255</issue>), <fpage>587</fpage>&#x2013;<lpage>591</lpage>. <pub-id pub-id-type="doi">10.1038/nature08197</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freeman</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H. H.</given-names>
</name>
<name>
<surname>Kertesz</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lesche</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms</article-title>. <source>Cancer Cell</source> <volume>3</volume> (<issue>2</issue>), <fpage>117</fpage>&#x2013;<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1016/s1535-6108(03)00021-7</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi)</article-title>. <source>Phytother. Res.</source> <volume>28</volume> (<issue>9</issue>), <fpage>1275</fpage>&#x2013;<lpage>1283</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.5188</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujishita</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kojima</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kajino-Sakamoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mishiro-Sato</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hosoda</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>The cAMP/PKA/CREB and TGF-&#x3b2;/SMAD4 pathways regulate stemness and metastatic potential in colorectal cancer cells</article-title>. <source>Cancer Res.</source> <volume>82</volume>, <fpage>4179</fpage>&#x2013;<lpage>4190</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.Can-22-1369</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujita</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nagao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Node</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kaneko</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nakazawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kuroda</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>1976</year>). <article-title>Antitumor activity of the isodon diterpenoids: structural requirements for the activity</article-title>. <source>Experientia</source> <volume>32</volume> (<issue>2</issue>), <fpage>203</fpage>&#x2013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1007/bf01937766</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gatenby</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Gillies</surname>
<given-names>R. J.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Why do cancers have high aerobic glycolysis?</article-title> <source>Nat. Rev. Cancer</source> <volume>4</volume> (<issue>11</issue>), <fpage>891</fpage>&#x2013;<lpage>899</lpage>. <pub-id pub-id-type="doi">10.1038/nrc1478</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Georges</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Verset</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zlobec</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Demetter</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>De Wever</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Impact of the microenvironment on tumour budding in colorectal cancer</article-title>. <source>Adv. Exp. Med. Biol.</source> <volume>1110</volume>, <fpage>101</fpage>&#x2013;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-030-02771-1_7</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghosh</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sandur</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Janadri</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Acute, 28days sub acute and genotoxic profiling of Quercetin-Magnesium complex in Swiss albino mice</article-title>. <source>Biomed. Pharmacother.</source> <volume>86</volume>, <fpage>279</fpage>&#x2013;<lpage>291</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2016.12.015</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gong</surname>
<given-names>R. H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Kwan</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Lyu</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G. Q.</given-names>
</name>
<name>
<surname>Bian</surname>
<given-names>Z. X.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Cell death mechanisms induced by synergistic effects of halofuginone and artemisinin in colorectal cancer cells</article-title>. <source>Int. J. Med. Sci.</source> <volume>19</volume> (<issue>1</issue>), <fpage>175</fpage>&#x2013;<lpage>185</lpage>. <pub-id pub-id-type="doi">10.7150/ijms.66737</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Astragalus saponins inhibit cell growth, aerobic glycolysis and attenuate the inflammatory response in a DSS-induced colitis model</article-title>. <source>Int. J. Mol. Med.</source> <volume>43</volume> (<issue>2</issue>), <fpage>1041</fpage>&#x2013;<lpage>1048</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2018.4036</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haber</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Rathan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Weiser</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Pritsker</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Itzkowitz</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Bodian</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>1998</year>). <article-title>GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis</article-title>. <source>Cancer</source> <volume>83</volume> (<issue>1</issue>), <fpage>34</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1002/(sici)1097-0142(19980701)83:1&#x3c;34::aid-cncr5&#x3e;3.0.co;2-e</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamabe</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Konno</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Uemura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hata</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Combined evaluation of hexokinase 2 and phosphorylated pyruvate dehydrogenase-E1&#x3b1; in invasive front lesions of colorectal tumors predicts cancer metabolism and patient prognosis</article-title>. <source>Cancer Sci.</source> <volume>105</volume> (<issue>9</issue>), <fpage>1100</fpage>&#x2013;<lpage>1108</lpage>. <pub-id pub-id-type="doi">10.1111/cas.12487</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamer</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Jonkers</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Venema</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Vanhoutvin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Troost</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Brummer</surname>
<given-names>R. J.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Review article: the role of butyrate on colonic function</article-title>. <source>Aliment. Pharmacol. Ther.</source> <volume>27</volume> (<issue>2</issue>), <fpage>104</fpage>&#x2013;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2036.2007.03562.x</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer</article-title>. <source>Int. J. Oncol.</source> <volume>48</volume> (<issue>1</issue>), <fpage>215</fpage>&#x2013;<lpage>224</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2015.3225</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Daphnetin, a coumarin in genus stellera chamaejasme linn: chemistry, bioactivity and therapeutic potential</article-title>. <source>Chem. Biodivers.</source> <volume>19</volume> (<issue>9</issue>), <fpage>e202200261</fpage>. <pub-id pub-id-type="doi">10.1002/cbdv.202200261</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>ErbB2 promotes breast cancer metastatic potential via HSF1/LDHA axis-mediated glycolysis</article-title>. <source>Med. Oncol.</source> <volume>39</volume> (<issue>4</issue>), <fpage>45</fpage>. <pub-id pub-id-type="doi">10.1007/s12032-021-01641-4</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Retracted article: daphnetin inhibits proliferation and glycolysis in colorectal cancer cells by regulating the PI3K/Akt signaling pathway</article-title>. <source>RSC Adv.</source> <volume>8</volume> (<issue>60</issue>), <fpage>34483</fpage>&#x2013;<lpage>34490</lpage>. <pub-id pub-id-type="doi">10.1039/c8ra05583a</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Coomber</surname>
<given-names>B. L.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Pyruvate dehydrogenase kinase expression and metabolic changes following dichloroacetate exposure in anoxic human colorectal cancer cells</article-title>. <source>Exp. Cell Res.</source> <volume>331</volume> (<issue>1</issue>), <fpage>73</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2014.12.006</pub-id>
</citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollander</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Blumenthal</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Dennis</surname>
<given-names>P. A.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>PTEN loss in the continuum of common cancers, rare syndromes and mouse models</article-title>. <source>Nat. Rev. Cancer</source> <volume>11</volume> (<issue>4</issue>), <fpage>289</fpage>&#x2013;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1038/nrc3037</pub-id>
</citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Matrine reverses the Warburg effect and suppresses colon cancer cell growth via negatively regulating HIF-1&#x3b1;</article-title>. <source>Front. Pharmacol.</source> <volume>10</volume>, <fpage>1437</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2019.01437</pub-id>
</citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Houddane</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bultot</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Novellasdemunt</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Johanns</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gueuning</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Vertommen</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Role of Akt/PKB and PFKFB isoenzymes in the control of glycolysis, cell proliferation and protein synthesis in mitogen-stimulated thymocytes</article-title>. <source>Cell Signal</source> <volume>34</volume>, <fpage>23</fpage>&#x2013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2017.02.019</pub-id>
</citation>
</ref>
<ref id="B236">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Diabetic nephropathy: focusing on pathological signals, clinical treatment, and dietary regulation</article-title>. <source>Biomed. Pharmacother.</source> <volume>159</volume>, <fpage>114252</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2023.114252</pub-id>
</citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>Y. T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P. C.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>N. T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C. I.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H. S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Calcitriol suppresses Warburg effect and cell growth in human colorectal cancer cells</article-title>. <source>Life (Basel)</source> <volume>11</volume> (<issue>9</issue>), <fpage>963</fpage>. <pub-id pub-id-type="doi">10.3390/life11090963</pub-id>
</citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ikezoe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>X. J.</given-names>
</name>
<name>
<surname>Heber</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Taguchi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Koeffler</surname>
<given-names>H. P.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells</article-title>. <source>Int. J. Oncol.</source> <volume>23</volume> (<issue>4</issue>), <fpage>1187</fpage>&#x2013;<lpage>1193</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.23.4.1187</pub-id>
</citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imran</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Salehi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sharifi-Rad</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Aslam Gondal</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Saeed</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Imran</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Kaempferol: a key emphasis to its anticancer potential</article-title>. <source>Molecules</source> <volume>24</volume> (<issue>12</issue>), <fpage>2277</fpage>. <pub-id pub-id-type="doi">10.3390/molecules24122277</pub-id>
</citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jain</surname>
<given-names>P. P.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Halofuginone, a promising drug for treatment of pulmonary hypertension</article-title>. <source>Br. J. Pharmacol.</source> <volume>178</volume> (<issue>17</issue>), <fpage>3373</fpage>&#x2013;<lpage>3394</lpage>. <pub-id pub-id-type="doi">10.1111/bph.15442</pub-id>
</citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>K. H.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Hemistepsins with cytotoxic activity from Hemisteptia lyrata</article-title>. <source>Planta Med.</source> <volume>65</volume> (<issue>8</issue>), <fpage>765</fpage>&#x2013;<lpage>766</lpage>. <pub-id pub-id-type="doi">10.1055/s-2006-960863</pub-id>
</citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Udeani</surname>
<given-names>G. O.</given-names>
</name>
<name>
<surname>Slowing</surname>
<given-names>K. V.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>C. F.</given-names>
</name>
<name>
<surname>Beecher</surname>
<given-names>C. W.</given-names>
</name>
<etal/>
</person-group> (<year>1997</year>). <article-title>Cancer chemopreventive activity of resveratrol, a natural product derived from grapes</article-title>. <source>Science</source> <volume>275</volume> (<issue>5297</issue>), <fpage>218</fpage>&#x2013;<lpage>220</lpage>. <pub-id pub-id-type="doi">10.1126/science.275.5297.218</pub-id>
</citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Javed</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Saleem</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Xaveria</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Akhtar</surname>
<given-names>M. F.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Daphnetin: a bioactive natural coumarin with diverse therapeutic potentials</article-title>. <source>Front. Pharmacol.</source> <volume>13</volume>, <fpage>993562</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.993562</pub-id>
</citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Worenine reverses the Warburg effect and inhibits colon cancer cell growth by negatively regulating HIF-1&#x3b1;</article-title>. <source>Cell Mol. Biol. Lett.</source> <volume>26</volume> (<issue>1</issue>), <fpage>19</fpage>. <pub-id pub-id-type="doi">10.1186/s11658-021-00263-y</pub-id>
</citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jian</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Hsa_circ_001680 affects the proliferation and migration of CRC and mediates its chemoresistance by regulating BMI1 through miR-340</article-title>. <source>Mol. Cancer</source> <volume>19</volume> (<issue>1</issue>), <fpage>20</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-020-1134-8</pub-id>
</citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>B. H.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>J. Z.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hunter</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Vogt</surname>
<given-names>P. K.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1</article-title>. <source>Cell Growth Differ.</source> <volume>12</volume> (<issue>7</issue>), <fpage>363</fpage>&#x2013;<lpage>369</lpage>.</citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>T. L.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>D. X.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W. Q.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Anticancer activity and mechanism of xanthohumol: a prenylated flavonoid from hops (humulus lupulus L)</article-title>. <source>Front. Pharmacol.</source> <volume>9</volume>, <fpage>530</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2018.00530</pub-id>
</citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The role of microenvironment in tumor angiogenesis</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>39</volume> (<issue>1</issue>), <fpage>204</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-020-01709-5</pub-id>
</citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E. Y.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>T. W.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J. H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Hemistepsin A suppresses colorectal cancer growth through inhibiting pyruvate dehydrogenase kinase activity</article-title>. <source>Sci. Rep.</source> <volume>10</volume> (<issue>1</issue>), <fpage>21940</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-79019-1</pub-id>
</citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ruiz Beguerie</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sze</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>G. C.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Ganoderma lucidum (Reishi mushroom) for cancer treatment</article-title>. <source>Cochrane Database Syst. Rev.</source> <volume>4</volume> (<issue>4</issue>), <fpage>Cd007731</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD007731.pub3</pub-id>
</citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jing</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Glycosylation of anthocyanins enhances the apoptosis of colon cancer cells by handicapping energy metabolism</article-title>. <source>BMC Complement. Med. Ther.</source> <volume>20</volume> (<issue>1</issue>), <fpage>312</fpage>. <pub-id pub-id-type="doi">10.1186/s12906-020-03096-y</pub-id>
</citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Quach</surname>
<given-names>C. H. T.</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>Y. S.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Resveratrol-loaded polymeric nanoparticles suppress glucose metabolism and tumor growth <italic>in vitro</italic> and <italic>in vivo</italic>
</article-title>. <source>Int. J. Pharm.</source> <volume>478</volume> (<issue>1</issue>), <fpage>251</fpage>&#x2013;<lpage>257</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.11.049</pub-id>
</citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Thien Quach</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Paik</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J. W.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1&#x3b1; activation</article-title>. <source>J. Nucl. Med.</source> <volume>54</volume> (<issue>12</issue>), <fpage>2161</fpage>&#x2013;<lpage>2167</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.112.115436</pub-id>
</citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Burzangi</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>N. A.</given-names>
</name>
<name>
<surname>Ibrahim</surname>
<given-names>I. M.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>PI3K-AKT pathway modulation by thymoquinone limits tumor growth and glycolytic metabolism in colorectal cancer</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume> (<issue>4</issue>), <fpage>2305</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23042305</pub-id>
</citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katagiri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Karasawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takagi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yabuuchi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fujishima</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Hexokinase 2 in colorectal cancer: a potent prognostic factor associated with glycolysis, proliferation and migration</article-title>. <source>Histol. Histopathol.</source> <volume>32</volume> (<issue>4</issue>), <fpage>351</fpage>&#x2013;<lpage>360</lpage>. <pub-id pub-id-type="doi">10.14670/hh-11-799</pub-id>
</citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kazantseva</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Becerra</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Santos-Ruiz</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Traditional medicinal plants as a source of inspiration for osteosarcoma therapy</article-title>. <source>Molecules</source> <volume>27</volume> (<issue>15</issue>), <fpage>5008</fpage>. <pub-id pub-id-type="doi">10.3390/molecules27155008</pub-id>
</citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Rizwan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abbas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Naveed</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Boyang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Naeem</surname>
<given-names>M. A.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Pharmacological effects and potential therapeutic targets of DT-13</article-title>. <source>Biomed. Pharmacother.</source> <volume>97</volume>, <fpage>255</fpage>&#x2013;<lpage>263</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2017.10.101</pub-id>
</citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khojasteh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mirjalili</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Alcalde</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Cusido</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Eibl</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Palazon</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Powerful plant antioxidants: a new biosustainable approach to the production of rosmarinic acid</article-title>. <source>Antioxidants (Basel)</source> <volume>9</volume> (<issue>12</issue>), <fpage>1273</fpage>. <pub-id pub-id-type="doi">10.3390/antiox9121273</pub-id>
</citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Wannatung</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W. K.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>J. S.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Quercetin enhances hypoxia-mediated apoptosis via direct inhibition of AMPK activity in HCT116 colon cancer</article-title>. <source>Apoptosis</source> <volume>17</volume> (<issue>9</issue>), <fpage>938</fpage>&#x2013;<lpage>949</lpage>. <pub-id pub-id-type="doi">10.1007/s10495-012-0719-0</pub-id>
</citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Komarova</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Gudkov</surname>
<given-names>A. V.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Could p53 be a target for therapeutic suppression?</article-title> <source>Semin. Cancer Biol.</source> <volume>8</volume> (<issue>5</issue>), <fpage>389</fpage>&#x2013;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1006/scbi.1998.0101</pub-id>
</citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kopaskova</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hadjo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yankulova</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jovtchev</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Galova</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sevcovicova</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Extract of Lillium candidum L. can modulate the genotoxicity of the antibiotic zeocin</article-title>. <source>Molecules</source> <volume>17</volume> (<issue>1</issue>), <fpage>80</fpage>&#x2013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.3390/molecules17010080</pub-id>
</citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rawat</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Keshari</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Maity</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>De</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Antiproliferative effect of isolated isoquinoline alkaloid from Mucuna pruriens seeds in hepatic carcinoma cells</article-title>. <source>Nat. Prod. Res.</source> <volume>30</volume> (<issue>4</issue>), <fpage>460</fpage>&#x2013;<lpage>463</lpage>. <pub-id pub-id-type="doi">10.1080/14786419.2015.1020489</pub-id>
</citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gabrilovich</surname>
<given-names>D. I.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment</article-title>. <source>Immunology</source> <volume>143</volume> (<issue>4</issue>), <fpage>512</fpage>&#x2013;<lpage>519</lpage>. <pub-id pub-id-type="doi">10.1111/imm.12380</pub-id>
</citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumari</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dwarakanath</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bhatt</surname>
<given-names>A. N.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Role of interleukin-6 in cancer progression and therapeutic resistance</article-title>. <source>Tumour Biol.</source> <volume>37</volume> (<issue>9</issue>), <fpage>11553</fpage>&#x2013;<lpage>11572</lpage>. <pub-id pub-id-type="doi">10.1007/s13277-016-5098-7</pub-id>
</citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lai</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X. W.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Preparative separation and determination of matrine from the Chinese medicinal plant Sophora flavescens Ait by molecularly imprinted solid-phase extraction</article-title>. <source>Anal. Bioanal. Chem.</source> <volume>375</volume> (<issue>2</issue>), <fpage>264</fpage>&#x2013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1007/s00216-002-1675-2</pub-id>
</citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambert</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Mishin</surname>
<given-names>V. M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C. S.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Piperine enhances the bioavailability of the tea polyphenol (-)-epigallocatechin-3-gallate in mice</article-title>. <source>J. Nutr.</source> <volume>134</volume> (<issue>8</issue>), <fpage>1948</fpage>&#x2013;<lpage>1952</lpage>. <pub-id pub-id-type="doi">10.1093/jn/134.8.1948</pub-id>
</citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>D. Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E. H.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Role of oxidative stress and nrf2/KEAP1 signaling in colorectal cancer: mechanisms and therapeutic perspectives with phytochemicals</article-title>. <source>Antioxidants (Basel)</source> <volume>10</volume> (<issue>5</issue>), <fpage>743</fpage>. <pub-id pub-id-type="doi">10.3390/antiox10050743</pub-id>
</citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leung</surname>
<given-names>C. O.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>D. N.</given-names>
</name>
<name>
<surname>Kai</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>E. K.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>I. M.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma</article-title>. <source>Oncotarget</source> <volume>6</volume> (<issue>13</issue>), <fpage>10880</fpage>&#x2013;<lpage>10892</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.3534</pub-id>
</citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020a</year>). <article-title>S100A2 promotes glycolysis and proliferation via GLUT1 regulation in colorectal cancer</article-title>. <source>Faseb J.</source> <volume>34</volume> (<issue>10</issue>), <fpage>13333</fpage>&#x2013;<lpage>13344</lpage>. <pub-id pub-id-type="doi">10.1096/fj.202000555R</pub-id>
</citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2021a</year>). <article-title>LncRNA RAD51-AS1/miR-29b/c-3p/NDRG2 crosstalk repressed proliferation, invasion and glycolysis of colorectal cancer</article-title>. <source>IUBMB Life</source> <volume>73</volume> (<issue>1</issue>), <fpage>286</fpage>&#x2013;<lpage>298</lpage>. <pub-id pub-id-type="doi">10.1002/iub.2427</pub-id>
</citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022a</year>). <article-title>Xanthatin inhibits human colon cancer cells progression via mTOR signaling mediated energy metabolism alteration</article-title>. <source>Drug Dev. Res.</source> <volume>83</volume> (<issue>1</issue>), <fpage>119</fpage>&#x2013;<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1002/ddr.21850</pub-id>
</citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Silencing of FOXO6 inhibits the proliferation, invasion, and glycolysis in colorectal cancer cells</article-title>. <source>J. Cell Biochem.</source> <volume>120</volume> (<issue>3</issue>), <fpage>3853</fpage>&#x2013;<lpage>3860</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.27667</pub-id>
</citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>X. M.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H. Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R. H.</given-names>
</name>
<etal/>
</person-group> (<year>2021b</year>). <article-title>Diosgenin exerts anti-tumor effects through inactivation of cAMP/PKA/CREB signaling pathway in colorectal cancer</article-title>. <source>Eur. J. Pharmacol.</source> <volume>908</volume>, <fpage>174370</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2021.174370</pub-id>
</citation>
</ref>
<ref id="B102">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W. D.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>L. G.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>F. Z.</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>J. S.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Characterization of xanthatin: anticancer properties and mechanisms of inhibited murine melanoma <italic>in vitro</italic> and <italic>in vivo</italic>
</article-title>. <source>Phytomedicine</source> <volume>20</volume> (<issue>10</issue>), <fpage>865</fpage>&#x2013;<lpage>873</lpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2013.03.006</pub-id>
</citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2022b</year>). <article-title>Isolation, structure and bioactivity of polysaccharides from atractylodes macrocephala: a review</article-title>. <source>J. Ethnopharmacol.</source> <volume>296</volume>, <fpage>115506</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2022.115506</pub-id>
</citation>
</ref>
<ref id="B104">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020b</year>). <article-title>Oxymatrine inhibits colorectal cancer metastasis via attenuating PKM2-mediated aerobic glycolysis</article-title>. <source>Cancer Manag. Res.</source> <volume>12</volume>, <fpage>9503</fpage>&#x2013;<lpage>9513</lpage>. <pub-id pub-id-type="doi">10.2147/cmar.S267686</pub-id>
</citation>
</ref>
<ref id="B105">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2020c</year>). <article-title>Andrographolide enhanced radiosensitivity by downregulating glycolysis via the inhibition of the PI3K-Akt-mTOR signaling pathway in HCT116 colorectal cancer cells</article-title>. <source>J. Int. Med. Res.</source> <volume>48</volume> (<issue>8</issue>), <fpage>300060520946169</fpage>. <pub-id pub-id-type="doi">10.1177/0300060520946169</pub-id>
</citation>
</ref>
<ref id="B106">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2022c</year>). <article-title>Andrographolide, a natural anti-inflammatory agent: an Update</article-title>. <source>Front. Pharmacol.</source> <volume>13</volume>, <fpage>920435</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.920435</pub-id>
</citation>
</ref>
<ref id="B107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020d</year>). <article-title>Atractylenolide I induces apoptosis and suppresses glycolysis by blocking the JAK2/STAT3 signaling pathway in colorectal cancer cells</article-title>. <source>Front. Pharmacol.</source> <volume>11</volume>, <fpage>273</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.00273</pub-id>
</citation>
</ref>
<ref id="B108">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>MiR-141-3p inhibits cell proliferation, migration and invasion by targeting TRAF5 in colorectal cancer</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>514</volume> (<issue>3</issue>), <fpage>699</fpage>&#x2013;<lpage>705</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2019.05.002</pub-id>
</citation>
</ref>
<ref id="B109">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Berberine for gastric cancer prevention and treatment: multi-step actions on the Correa&#x27;s cascade underlie its therapeutic effects</article-title>. <source>Pharmacol. Res.</source> <volume>184</volume>, <fpage>106440</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2022.106440</pub-id>
</citation>
</ref>
<ref id="B110">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Shuai</surname>
<given-names>Y. P.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>K. S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Quantitative evaluation of the compatibility effects of aidi injection on the treatment of hepatocellular carcinoma using targeted metabolomics: a new strategy on the mechanism study of an anticancer compound in traditional Chinese medicine</article-title>. <source>World J. Tradit. Chin. Med.</source> <volume>7</volume> (<issue>1</issue>), <fpage>111</fpage>&#x2013;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.4103/wjtcm.wjtcm_86_20</pub-id>
</citation>
</ref>
<ref id="B111">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>SPRY4-IT1 promotes survival of colorectal cancer cells through regulating PDK1-mediated glycolysis</article-title>. <source>Anim. Cells Syst. Seoul.</source> <volume>24</volume> (<issue>4</issue>), <fpage>220</fpage>&#x2013;<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1080/19768354.2020.1784274</pub-id>
</citation>
</ref>
<ref id="B112">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Xanthohumol inhibits colorectal cancer cells via downregulation of Hexokinases II-mediated glycolysis</article-title>. <source>Int. J. Biol. Sci.</source> <volume>15</volume> (<issue>11</issue>), <fpage>2497</fpage>&#x2013;<lpage>2508</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.37481</pub-id>
</citation>
</ref>
<ref id="B113">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Effect of ganoderic acid D on colon cancer Warburg effect: role of SIRT3/cyclophilin D</article-title>. <source>Eur. J. Pharmacol.</source> <volume>824</volume>, <fpage>72</fpage>&#x2013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2018.01.026</pub-id>
</citation>
</ref>
<ref id="B114">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lunagariya</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bhadja</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vekariya</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Marine natural product bis-indole alkaloid caulerpin: chemistry and biology</article-title>. <source>Mini Rev. Med. Chem.</source> <volume>19</volume> (<issue>9</issue>), <fpage>751</fpage>&#x2013;<lpage>761</lpage>. <pub-id pub-id-type="doi">10.2174/1389557517666170927154231</pub-id>
</citation>
</ref>
<ref id="B115">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lunt</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Vander Heiden</surname>
<given-names>M. G.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Aerobic glycolysis: meeting the metabolic requirements of cell proliferation</article-title>. <source>Annu. Rev. Cell Dev. Biol.</source> <volume>27</volume>, <fpage>441</fpage>&#x2013;<lpage>464</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-cellbio-092910-154237</pub-id>
</citation>
</ref>
<ref id="B116">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Di</surname>
<given-names>Z. M.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>S. X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J. S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Xanthatin induces glioma cell apoptosis and inhibits tumor growth via activating endoplasmic reticulum stress-dependent CHOP pathway</article-title>. <source>Acta Pharmacol. Sin.</source> <volume>41</volume> (<issue>3</issue>), <fpage>404</fpage>&#x2013;<lpage>414</lpage>. <pub-id pub-id-type="doi">10.1038/s41401-019-0318-5</pub-id>
</citation>
</ref>
<ref id="B117">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Machado</surname>
<given-names>K. D. C.</given-names>
</name>
<name>
<surname>Islam</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Rouf</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Uddin</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Dev</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>A systematic review on the neuroprotective perspectives of beta-caryophyllene</article-title>. <source>Phytother. Res.</source> <volume>32</volume> (<issue>12</issue>), <fpage>2376</fpage>&#x2013;<lpage>2388</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.6199</pub-id>
</citation>
</ref>
<ref id="B118">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Berberine decelerates glucose metabolism via suppression of mTOR&#x2011;dependent HIF&#x2011;1&#x3b1; protein synthesis in colon cancer cells</article-title>. <source>Oncol. Rep.</source> <volume>39</volume> (<issue>5</issue>), <fpage>2436</fpage>&#x2013;<lpage>2442</lpage>. <pub-id pub-id-type="doi">10.3892/or.2018.6318</pub-id>
</citation>
</ref>
<ref id="B119">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>M. N.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>The expanding TOR signaling network</article-title>. <source>Curr. Opin. Cell Biol.</source> <volume>17</volume> (<issue>2</issue>), <fpage>158</fpage>&#x2013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1016/j.ceb.2005.02.008</pub-id>
</citation>
</ref>
<ref id="B120">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martins</surname>
<given-names>S. F.</given-names>
</name>
<name>
<surname>Amorim</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Viana-Pereira</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pinheiro</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>R. F.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis</article-title>. <source>BMC Cancer</source> <volume>16</volume>, <fpage>535</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-016-2566-9</pub-id>
</citation>
</ref>
<ref id="B121">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGhie</surname>
<given-names>T. K.</given-names>
</name>
<name>
<surname>Ainge</surname>
<given-names>G. D.</given-names>
</name>
<name>
<surname>Barnett</surname>
<given-names>L. E.</given-names>
</name>
<name>
<surname>Cooney</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Anthocyanin glycosides from berry fruit are absorbed and excreted unmetabolized by both humans and rats</article-title>. <source>J. Agric. Food Chem.</source> <volume>51</volume> (<issue>16</issue>), <fpage>4539</fpage>&#x2013;<lpage>4548</lpage>. <pub-id pub-id-type="doi">10.1021/jf026206w</pub-id>
</citation>
</ref>
<ref id="B122">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGhie</surname>
<given-names>T. K.</given-names>
</name>
<name>
<surname>Walton</surname>
<given-names>M. C.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>The bioavailability and absorption of anthocyanins: towards a better understanding</article-title>. <source>Mol. Nutr. Food Res.</source> <volume>51</volume> (<issue>6</issue>), <fpage>702</fpage>&#x2013;<lpage>713</lpage>. <pub-id pub-id-type="doi">10.1002/mnfr.200700092</pub-id>
</citation>
</ref>
<ref id="B123">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname>
<given-names>F. C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z. F.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Z. Q.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>L. G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q. W.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Coptidis rhizoma and its main bioactive components: recent advances in chemical investigation, quality evaluation and pharmacological activity</article-title>. <source>Chin. Med.</source> <volume>13</volume>, <fpage>13</fpage>. <pub-id pub-id-type="doi">10.1186/s13020-018-0171-3</pub-id>
</citation>
</ref>
<ref id="B124">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mengie Ayele</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tilahun Muche</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Behaile Teklemariam</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bogale Kassie</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chekol Abebe</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Role of JAK2/STAT3 signaling pathway in the tumorigenesis, chemotherapy resistance, and treatment of solid tumors: a systemic review</article-title>. <source>J. Inflamm. Res.</source> <volume>15</volume>, <fpage>1349</fpage>&#x2013;<lpage>1364</lpage>. <pub-id pub-id-type="doi">10.2147/jir.S353489</pub-id>
</citation>
</ref>
<ref id="B125">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>S. D.</given-names>
</name>
<name>
<surname>Islam</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Muench</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sedoris</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>c-Myc and cancer metabolism</article-title>. <source>Clin. Cancer Res.</source> <volume>18</volume> (<issue>20</issue>), <fpage>5546</fpage>&#x2013;<lpage>5553</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-12-0977</pub-id>
</citation>
</ref>
<ref id="B126">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mishra</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Raj</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bhadauria</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Rai</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid attenuates colon carcinogenesis via blockade of IL-6 mediated signals</article-title>. <source>Biomed. Pharmacother.</source> <volume>100</volume>, <fpage>282</fpage>&#x2013;<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.02.009</pub-id>
</citation>
</ref>
<ref id="B127">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohapatra</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sahoo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sahoo</surname>
<given-names>S. K.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Phytochemical based nanomedicine: a panacea for cancer treatment, present status and future prospective</article-title>. <source>OpenNano</source> <volume>7</volume>, <fpage>100055</fpage>. <pub-id pub-id-type="doi">10.1016/j.onano.2022.100055</pub-id>
</citation>
</ref>
<ref id="B128">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mori</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tsukinoki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yasuda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Miyazawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kaneko</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Glucose transporter type 1 expression are associated with poor prognosis in patients with salivary gland tumors</article-title>. <source>Oral Oncol.</source> <volume>43</volume> (<issue>6</issue>), <fpage>563</fpage>&#x2013;<lpage>569</lpage>. <pub-id pub-id-type="doi">10.1016/j.oraloncology.2006.06.006</pub-id>
</citation>
</ref>
<ref id="B129">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagle</surname>
<given-names>D. G.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y. D.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives</article-title>. <source>Phytochemistry</source> <volume>67</volume> (<issue>17</issue>), <fpage>1849</fpage>&#x2013;<lpage>1855</lpage>. <pub-id pub-id-type="doi">10.1016/j.phytochem.2006.06.020</pub-id>
</citation>
</ref>
<ref id="B130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narayanankutty</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>PI3K/Akt/mTOR pathway as a therapeutic target for colorectal cancer: a review of preclinical and clinical evidence</article-title>. <source>Curr. Drug Targets</source> <volume>20</volume> (<issue>12</issue>), <fpage>1217</fpage>&#x2013;<lpage>1226</lpage>. <pub-id pub-id-type="doi">10.2174/1389450120666190618123846</pub-id>
</citation>
</ref>
<ref id="B131">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nenkov</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ga&#xdf;ler</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Metabolic reprogramming of colorectal cancer cells and the microenvironment: implication for therapy</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume> (<issue>12</issue>), <fpage>6262</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22126262</pub-id>
</citation>
</ref>
<ref id="B132">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tripathi</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Toxicological and behavioral study of two potential antibacterial agents:4-chloromercuribenzoic acid and quercetin on Swiss-albino mice</article-title>. <source>Drug Chem. Toxicol.</source> <volume>43</volume> (<issue>6</issue>), <fpage>645</fpage>&#x2013;<lpage>655</lpage>. <pub-id pub-id-type="doi">10.1080/01480545.2018.1517774</pub-id>
</citation>
</ref>
<ref id="B133">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Noh</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>G. Y.</given-names>
</name>
<name>
<surname>Hyun</surname>
<given-names>J. W.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Hemistepsin A protects human keratinocytes against hydrogen peroxide-induced oxidative stress through activation of the Nrf2/HO-1 signaling pathway</article-title>. <source>Arch. Biochem. Biophys.</source> <volume>691</volume>, <fpage>108512</fpage>. <pub-id pub-id-type="doi">10.1016/j.abb.2020.108512</pub-id>
</citation>
</ref>
<ref id="B134">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>A review: the pharmacology of isoliquiritigenin</article-title>. <source>Phytother. Res.</source> <volume>29</volume> (<issue>7</issue>), <fpage>969</fpage>&#x2013;<lpage>977</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.5348</pub-id>
</citation>
</ref>
<ref id="B135">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phua</surname>
<given-names>C. Y. H.</given-names>
</name>
<name>
<surname>Teoh</surname>
<given-names>Z. L.</given-names>
</name>
<name>
<surname>Goh</surname>
<given-names>B. H.</given-names>
</name>
<name>
<surname>Yap</surname>
<given-names>W. H.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y. Q.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Triangulating the pharmacological properties of thymoquinone in regulating reactive oxygen species, inflammation, and cancer: therapeutic applications and mechanistic pathways</article-title>. <source>Life Sci.</source> <volume>287</volume>, <fpage>120120</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2021.120120</pub-id>
</citation>
</ref>
<ref id="B136">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prabakaran</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Karakkat</surname>
<given-names>J. V.</given-names>
</name>
<name>
<surname>Vijayan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chalissery</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ibrahim</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Kaimala</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Identification of early indicators of altered metabolism in normal development using a rodent model system</article-title>. <source>Dis. Model Mech.</source> <volume>11</volume> (<issue>3</issue>), <fpage>dmm031815</fpage>. <pub-id pub-id-type="doi">10.1242/dmm.031815</pub-id>
</citation>
</ref>
<ref id="B137">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>You</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Advances in ameliorating inflammatory diseases and cancers by andrographolide: pharmacokinetics, pharmacodynamics, and perspective</article-title>. <source>Med. Res. Rev.</source> <volume>42</volume> (<issue>3</issue>), <fpage>1147</fpage>&#x2013;<lpage>1178</lpage>. <pub-id pub-id-type="doi">10.1002/med.21873</pub-id>
</citation>
</ref>
<ref id="B138">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raju</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Cancer chemopreventive and therapeutic effects of diosgenin, a food saponin</article-title>. <source>Nutr. Cancer</source> <volume>61</volume> (<issue>1</issue>), <fpage>27</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1080/01635580802357352</pub-id>
</citation>
</ref>
<ref id="B139">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rankin</surname>
<given-names>E. B.</given-names>
</name>
<name>
<surname>Giaccia</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Hypoxic control of metastasis</article-title>. <source>Science</source> <volume>352</volume> (<issue>6282</issue>), <fpage>175</fpage>&#x2013;<lpage>180</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaf4405</pub-id>
</citation>
</ref>
<ref id="B140">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kwah</surname>
<given-names>M. X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Shanmugam</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Resveratrol for cancer therapy: challenges and future perspectives</article-title>. <source>Cancer Lett.</source> <volume>515</volume>, <fpage>63</fpage>&#x2013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2021.05.001</pub-id>
</citation>
</ref>
<ref id="B141">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robey</surname>
<given-names>R. B.</given-names>
</name>
<name>
<surname>Hay</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Is Akt the "Warburg kinase"?</article-title> <article-title>Akt-energy metabolism interactions and oncogenesis</article-title>. <source>Semin. Cancer Biol.</source> <volume>19</volume> (<issue>1</issue>), <fpage>25</fpage>&#x2013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2008.11.010</pub-id>
</citation>
</ref>
<ref id="B142">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rupaimoole</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Slack</surname>
<given-names>F. J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>MicroRNA therapeutics: towards a new era for the management of cancer and other diseases</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>16</volume> (<issue>3</issue>), <fpage>203</fpage>&#x2013;<lpage>222</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2016.246</pub-id>
</citation>
</ref>
<ref id="B143">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salimian Rizi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Caneba</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nowicka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nabiyar</surname>
<given-names>A. W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Nitric oxide mediates metabolic coupling of omentum-derived adipose stroma to ovarian and endometrial cancer cells</article-title>. <source>Cancer Res.</source> <volume>75</volume> (<issue>2</issue>), <fpage>456</fpage>&#x2013;<lpage>471</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.Can-14-1337</pub-id>
</citation>
</ref>
<ref id="B144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saunier</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Antonio</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Regazzetti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Auzeil</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lapr&#xe9;vote</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Shay</surname>
<given-names>J. W.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Resveratrol reverses the Warburg effect by targeting the pyruvate dehydrogenase complex in colon cancer cells</article-title>. <source>Sci. Rep.</source> <volume>7</volume> (<issue>1</issue>), <fpage>6945</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-07006-0</pub-id>
</citation>
</ref>
<ref id="B145">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saunier</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Benelli</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bortoli</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>The pyruvate dehydrogenase complex in cancer: an old metabolic gatekeeper regulated by new pathways and pharmacological agents</article-title>. <source>Int. J. Cancer</source> <volume>138</volume> (<issue>4</issue>), <fpage>809</fpage>&#x2013;<lpage>817</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.29564</pub-id>
</citation>
</ref>
<ref id="B146">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mandal</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer</article-title>. <source>Colloids Surf. B Biointerfaces</source> <volume>180</volume>, <fpage>9</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2019.04.035</pub-id>
</citation>
</ref>
<ref id="B147">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaikh</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ankola</surname>
<given-names>D. D.</given-names>
</name>
<name>
<surname>Beniwal</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>M. N.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer</article-title>. <source>Eur. J. Pharm. Sci.</source> <volume>37</volume> (<issue>3-4</issue>), <fpage>223</fpage>&#x2013;<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejps.2009.02.019</pub-id>
</citation>
</ref>
<ref id="B148">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Apigenin restrains colon cancer cell proliferation via targeted blocking of pyruvate kinase M2-dependent glycolysis</article-title>. <source>J. Agric. Food Chem.</source> <volume>65</volume> (<issue>37</issue>), <fpage>8136</fpage>&#x2013;<lpage>8144</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jafc.7b02757</pub-id>
</citation>
</ref>
<ref id="B149">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>Z. Y.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Q. N.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The protective effect of cyanidin-3-glucoside on myocardial ischemia-reperfusion injury through ferroptosis</article-title>. <source>Oxid. Med. Cell Longev.</source> <volume>2021</volume>, <fpage>8880141</fpage>. <pub-id pub-id-type="doi">10.1155/2021/8880141</pub-id>
</citation>
</ref>
<ref id="B150">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ghani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sak</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tuli</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Setzer</surname>
<given-names>W. N.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Probing into therapeutic anti-cancer potential of apigenin: recent trends and future directions</article-title>. <source>Recent Pat. Inflamm. Allergy Drug Discov.</source> <volume>13</volume> (<issue>2</issue>), <fpage>124</fpage>&#x2013;<lpage>133</lpage>. <pub-id pub-id-type="doi">10.2174/1872213x13666190816160240</pub-id>
</citation>
</ref>
<ref id="B151">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Thulasingam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chellappan</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Chinnaswamy</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nagarajan</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Morin and Esculetin supplementation modulates c-myc induced energy metabolism and attenuates neoplastic changes in rats challenged with the procarcinogen 1,2 - dimethylhydrazine</article-title>. <source>Eur. J. Pharmacol.</source> <volume>796</volume>, <fpage>20</fpage>&#x2013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2016.12.019</pub-id>
</citation>
</ref>
<ref id="B152">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheng</surname>
<given-names>Q. S.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>K. X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Z. F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F. X.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>L. L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Comparison of gut microbiome in human colorectal cancer in paired tumor and adjacent normal tissues</article-title>. <source>Onco Targets Ther.</source> <volume>13</volume>, <fpage>635</fpage>&#x2013;<lpage>646</lpage>. <pub-id pub-id-type="doi">10.2147/ott.S218004</pub-id>
</citation>
</ref>
<ref id="B153">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shinohara</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kogure</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ichihara</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Terada</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Steady state transcript levels of the type II hexokinase and type 1 glucose transporter in human tumor cell lines</article-title>. <source>Cancer Lett.</source> <volume>82</volume> (<issue>1</issue>), <fpage>27</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/0304-3835(94)90142-2</pub-id>
</citation>
</ref>
<ref id="B154">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simula</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Alifano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Icard</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>How phosphofructokinase-1 promotes PI3K and YAP/TAZ in cancer: therapeutic perspectives</article-title>. <source>Cancers (Basel)</source> <volume>14</volume> (<issue>10</issue>), <fpage>2478</fpage>. <pub-id pub-id-type="doi">10.3390/cancers14102478</pub-id>
</citation>
</ref>
<ref id="B155">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sithara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Arun</surname>
<given-names>K. B.</given-names>
</name>
<name>
<surname>Syama</surname>
<given-names>H. P.</given-names>
</name>
<name>
<surname>Reshmitha</surname>
<given-names>T. R.</given-names>
</name>
<name>
<surname>Nisha</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Morin inhibits proliferation of SW480 colorectal cancer cells by inducing apoptosis mediated by reactive oxygen species formation and uncoupling of Warburg effect</article-title>. <source>Front. Pharmacol.</source> <volume>8</volume>, <fpage>640</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2017.00640</pub-id>
</citation>
</ref>
<ref id="B156">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xuan</surname>
<given-names>L. I.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia</article-title>. <source>Oncol. Lett.</source> <volume>12</volume> (<issue>1</issue>), <fpage>334</fpage>&#x2013;<lpage>342</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2016.4600</pub-id>
</citation>
</ref>
<ref id="B157">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2022a</year>). <article-title>Chemical diversity, biological activities and Traditional uses of and important Chinese herb Sophora</article-title>. <source>Phytomedicine</source> <volume>100</volume>, <fpage>154054</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2022.154054</pub-id>
</citation>
</ref>
<ref id="B158">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ming</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2022b</year>). <article-title>Berberine suppresses colorectal cancer by regulation of Hedgehog signaling pathway activity and gut microbiota</article-title>. <source>Phytomedicine</source> <volume>103</volume>, <fpage>154227</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2022.154227</pub-id>
</citation>
</ref>
<ref id="B159">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2</article-title>. <source>Mol. Ther. Oncolytics</source> <volume>21</volume>, <fpage>87</fpage>&#x2013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.omto.2021.03.010</pub-id>
</citation>
</ref>
<ref id="B160">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>MiR-103a-3p promotes tumour glycolysis in colorectal cancer via hippo/YAP1/HIF1A axis</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>39</volume> (<issue>1</issue>), <fpage>250</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-020-01705-9</pub-id>
</citation>
</ref>
<ref id="B161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamene</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Endale</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Antibacterial activity of coumarins and carbazole alkaloid from roots of clausena anisata</article-title>. <source>Adv. Pharmacol. Sci.</source> <volume>2019</volume>, <fpage>5419854</fpage>. <pub-id pub-id-type="doi">10.1155/2019/5419854</pub-id>
</citation>
</ref>
<ref id="B162">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc</article-title>. <source>Nat. Commun.</source> <volume>10</volume> (<issue>1</issue>), <fpage>3499</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-11447-8</pub-id>
</citation>
</ref>
<ref id="B163">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Xanthatin anti-tumor cytotoxicity is mediated via glycogen synthase kinase-3&#x3b2; and &#x3b2;-catenin</article-title>. <source>Biochem. Pharmacol.</source> <volume>115</volume>, <fpage>18</fpage>&#x2013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2016.06.009</pub-id>
</citation>
</ref>
<ref id="B164">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomasset</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Berry</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>Garcea</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Marczylo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Steward</surname>
<given-names>W. P.</given-names>
</name>
<name>
<surname>Gescher</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Dietary polyphenolic phytochemicals--promising cancer chemopreventive agents in humans? A review of their clinical properties</article-title>. <source>Int. J. Cancer</source> <volume>120</volume> (<issue>3</issue>), <fpage>451</fpage>&#x2013;<lpage>458</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.22419</pub-id>
</citation>
</ref>
<ref id="B165">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thorens</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mueckler</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Glucose transporters in the 21st century</article-title>. <source>Am. J. Physiol. Endocrinol. Metab.</source> <volume>298</volume> (<issue>2</issue>), <fpage>E141</fpage>&#x2013;<lpage>E145</lpage>. <pub-id pub-id-type="doi">10.1152/ajpendo.00712.2009</pub-id>
</citation>
</ref>
<ref id="B166">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tokunaga</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Naseem</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Battaglin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: a meta-analysis using tribe, mavericc and FIRE3</article-title>. <source>Int. J. Cancer</source> <volume>145</volume> (<issue>8</issue>), <fpage>2082</fpage>&#x2013;<lpage>2090</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.32261</pub-id>
</citation>
</ref>
<ref id="B167">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Apigenin inhibits epithelial-mesenchymal transition of human colon cancer cells through NF-&#x3ba;B/Snail signaling pathway</article-title>. <source>Biosci. Rep.</source> <volume>39</volume> (<issue>5</issue>), <fpage>BSR20190452</fpage>. <pub-id pub-id-type="doi">10.1042/bsr20190452</pub-id>
</citation>
</ref>
<ref id="B168">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torrens-Mas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Oliver</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Roca</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sastre-Serra</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>SIRT3: oncogene and tumor suppressor in cancer</article-title>. <source>Cancers (Basel)</source> <volume>9</volume> (<issue>7</issue>), <fpage>90</fpage>. <pub-id pub-id-type="doi">10.3390/cancers9070090</pub-id>
</citation>
</ref>
<ref id="B169">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Towler</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Hardie</surname>
<given-names>D. G.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>AMP-activated protein kinase in metabolic control and insulin signaling</article-title>. <source>Circ. Res.</source> <volume>100</volume> (<issue>3</issue>), <fpage>328</fpage>&#x2013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1161/01.Res.0000256090.42690.05</pub-id>
</citation>
</ref>
<ref id="B170">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van der Jeught</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X. B.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Drug resistance and new therapies in colorectal cancer</article-title>. <source>World J. Gastroenterol.</source> <volume>24</volume> (<issue>34</issue>), <fpage>3834</fpage>&#x2013;<lpage>3848</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v24.i34.3834</pub-id>
</citation>
</ref>
<ref id="B171">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Stok</surname>
<given-names>E. P.</given-names>
</name>
<name>
<surname>Spaander</surname>
<given-names>M. C. W.</given-names>
</name>
<name>
<surname>Gr&#xfc;nhagen</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Verhoef</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kuipers</surname>
<given-names>E. J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Surveillance after curative treatment for colorectal cancer</article-title>. <source>Nat. Rev. Clin. Oncol.</source> <volume>14</volume> (<issue>5</issue>), <fpage>297</fpage>&#x2013;<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1038/nrclinonc.2016.199</pub-id>
</citation>
</ref>
<ref id="B172">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vasaikar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Petyuk</surname>
<given-names>V. A.</given-names>
</name>
<name>
<surname>Savage</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities</article-title>. <source>Cell</source> <volume>177</volume> (<issue>4</issue>), <fpage>1035</fpage>&#x2013;<lpage>1049.e19</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2019.03.030</pub-id>
</citation>
</ref>
<ref id="B173">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vicente de Andrade Silva</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Demaman Arend</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Antonio Ferreira Zielinski</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Di Luccio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ambrosi</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Xanthohumol properties and strategies for extraction from hops and brewery residues: a review</article-title>. <source>Food Chem.</source> <volume>404</volume>, <fpage>134629</fpage>. <pub-id pub-id-type="doi">10.1016/j.foodchem.2022.134629</pub-id>
</citation>
</ref>
<ref id="B174">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vinayak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Maurya</surname>
<given-names>A. K.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Quercetin loaded nanoparticles in targeting cancer: recent development</article-title>. <source>Anticancer Agents Med. Chem.</source> <volume>19</volume> (<issue>13</issue>), <fpage>1560</fpage>&#x2013;<lpage>1576</lpage>. <pub-id pub-id-type="doi">10.2174/1871520619666190705150214</pub-id>
</citation>
</ref>
<ref id="B175">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vogelstein</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Surfing the p53 network</article-title>. <source>Nature</source> <volume>408</volume> (<issue>6810</issue>), <fpage>307</fpage>&#x2013;<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1038/35042675</pub-id>
</citation>
</ref>
<ref id="B176">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y. Z.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>P. H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2020a</year>). <article-title>The effects and mechanisms of isoliquiritigenin loaded nanoliposomes regulated AMPK/mTOR mediated glycolysis in colorectal cancer</article-title>. <source>Artif. Cells Nanomed Biotechnol.</source> <volume>48</volume> (<issue>1</issue>), <fpage>1231</fpage>&#x2013;<lpage>1249</lpage>. <pub-id pub-id-type="doi">10.1080/21691401.2020.1825092</pub-id>
</citation>
</ref>
<ref id="B177">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L. T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-1&#x3b1; and glycolysis, by inhibiting PI3K/Akt signaling pathway</article-title>. <source>Mol. Carcinog.</source> <volume>53</volume> (<issue>1</issue>), <fpage>E107</fpage>&#x2013;<lpage>E118</lpage>. <pub-id pub-id-type="doi">10.1002/mc.22052</pub-id>
</citation>
</ref>
<ref id="B178">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2018a</year>). <article-title>Soft particles of gemini surfactant/conjugated polymer for enhanced anticancer activity of chemotherapeutics</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>10</volume> (<issue>1</issue>), <fpage>37</fpage>&#x2013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.7b16396</pub-id>
</citation>
</ref>
<ref id="B179">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer</article-title>. <source>Oncotarget</source> <volume>6</volume> (<issue>23</issue>), <fpage>19456</fpage>&#x2013;<lpage>19468</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.3318</pub-id>
</citation>
</ref>
<ref id="B180">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lou</surname>
<given-names>G. H.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>H. R.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Q. W.</given-names>
</name>
<etal/>
</person-group> (<year>2019a</year>). <article-title>Coptidis rhizoma: a comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology</article-title>. <source>Pharm. Biol.</source> <volume>57</volume> (<issue>1</issue>), <fpage>193</fpage>&#x2013;<lpage>225</lpage>. <pub-id pub-id-type="doi">10.1080/13880209.2019.1577466</pub-id>
</citation>
</ref>
<ref id="B181">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2020b</year>). <article-title>Atractylenolide I inhibits colorectal cancer cell proliferation by affecting metabolism and stemness via AKT/mTOR signaling</article-title>. <source>Phytomedicine</source> <volume>68</volume>, <fpage>153191</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2020.153191</pub-id>
</citation>
</ref>
<ref id="B182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Hsia</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Perspectives on the role of isoliquiritigenin in cancer</article-title>. <source>Cancers (Basel)</source> <volume>13</volume> (<issue>1</issue>), <fpage>115</fpage>. <pub-id pub-id-type="doi">10.3390/cancers13010115</pub-id>
</citation>
</ref>
<ref id="B183">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The targeting of noncoding RNAs by quercetin in cancer prevention and therapy</article-title>. <source>Oxid. Med. Cell Longev.</source> <volume>2022</volume>, <fpage>4330681</fpage>. <pub-id pub-id-type="doi">10.1155/2022/4330681</pub-id>
</citation>
</ref>
<ref id="B184">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tsang</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Man</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism</article-title>. <source>J. Cell Biochem.</source> <volume>111</volume> (<issue>6</issue>), <fpage>1426</fpage>&#x2013;<lpage>1436</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.22869</pub-id>
</citation>
</ref>
<ref id="B185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>L. F.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2018b</year>). <article-title>Glycolysis is essential for chemoresistance induced by transient receptor potential channel C5 in colorectal cancer</article-title>. <source>BMC Cancer</source> <volume>18</volume> (<issue>1</issue>), <fpage>207</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-018-4123-1</pub-id>
</citation>
</ref>
<ref id="B186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>K. L.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>AMP-activated protein kinase and cancer</article-title>. <source>Acta Physiol. (Oxf)</source> <volume>196</volume> (<issue>1</issue>), <fpage>55</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1111/j.1748-1716.2009.01980.x</pub-id>
</citation>
</ref>
<ref id="B187">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Q. N.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y. X.</given-names>
</name>
<etal/>
</person-group> (<year>2019b</year>). <article-title>LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer</article-title>. <source>Mol. Cancer</source> <volume>18</volume> (<issue>1</issue>), <fpage>174</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-019-1105-0</pub-id>
</citation>
</ref>
<ref id="B188">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Kallikrein-related peptidase (KLK10) cessation blunts colorectal cancer cell growth and glucose metabolism by regulating the PI3K/Akt/mTOR pathway</article-title>. <source>Neoplasma</source> <volume>67</volume> (<issue>4</issue>), <fpage>889</fpage>&#x2013;<lpage>897</lpage>. <pub-id pub-id-type="doi">10.4149/neo_2020_190814N758</pub-id>
</citation>
</ref>
<ref id="B189">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma</article-title>. <source>Cell Death Dis.</source> <volume>4</volume> (<issue>4</issue>), <fpage>e601</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2013.131</pub-id>
</citation>
</ref>
<ref id="B190">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>DT-13 inhibited the proliferation of colorectal cancer via glycolytic metabolism and AMPK/mTOR signaling pathway</article-title>. <source>Phytomedicine</source> <volume>54</volume>, <fpage>120</fpage>&#x2013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2018.09.003</pub-id>
</citation>
</ref>
<ref id="B191">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>J. E.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function</article-title>. <source>J. Exp. Biol.</source> <volume>206</volume> (<issue>12</issue>), <fpage>2049</fpage>&#x2013;<lpage>2057</lpage>. <pub-id pub-id-type="doi">10.1242/jeb.00241</pub-id>
</citation>
</ref>
<ref id="B192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ojo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>De Melo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cutz</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Changes in PKM2 associate with prostate cancer progression</article-title>. <source>Cancer Invest.</source> <volume>32</volume> (<issue>7</issue>), <fpage>330</fpage>&#x2013;<lpage>338</lpage>. <pub-id pub-id-type="doi">10.3109/07357907.2014.919306</pub-id>
</citation>
</ref>
<ref id="B193">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Kaempferol reverses aerobic glycolysis via miR-339-5p-mediated PKM alternative splicing in colon cancer cells</article-title>. <source>J. Agric. Food Chem.</source> <volume>69</volume> (<issue>10</issue>), <fpage>3060</fpage>&#x2013;<lpage>3068</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jafc.0c07640</pub-id>
</citation>
</ref>
<ref id="B194">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Kaempferol attenuates ROS-induced hemolysis and the molecular mechanism of its induction of apoptosis on bladder cancer</article-title>. <source>Molecules</source> <volume>23</volume> (<issue>10</issue>), <fpage>2592</fpage>. <pub-id pub-id-type="doi">10.3390/molecules23102592</pub-id>
</citation>
</ref>
<ref id="B195">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Dioscin inhibited glycolysis and induced cell apoptosis in colorectal cancer via promoting c-myc ubiquitination and subsequent hexokinase-2 suppression</article-title>. <source>Onco Targets Ther.</source> <volume>13</volume>, <fpage>31</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.2147/ott.S224062</pub-id>
</citation>
</ref>
<ref id="B196">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Quercetin-3-O-&#x3b2;-D-glucuronide inhibits mitochondria pathway-mediated platelet apoptosis via the phosphatidylinositol-3-kinase/AKT pathway in immunological bone marrow failure</article-title>. <source>World J. Tradit. Chin. Med.</source> <volume>8</volume> (<issue>1</issue>), <fpage>115</fpage>&#x2013;<lpage>122</lpage>. <pub-id pub-id-type="doi">10.4103/wjtcm.wjtcm_44_21</pub-id>
</citation>
</ref>
<ref id="B197">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xian</surname>
<given-names>Z. Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q. K.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H. Z.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Inhibition of LDHA suppresses tumor progression in prostate cancer</article-title>. <source>Tumour Biol.</source> <volume>36</volume> (<issue>10</issue>), <fpage>8093</fpage>&#x2013;<lpage>8100</lpage>. <pub-id pub-id-type="doi">10.1007/s13277-015-3540-x</pub-id>
</citation>
</ref>
<ref id="B198">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>MicroRNA-135b regulates the stability of PTEN and promotes glycolysis by targeting USP13 in human colorectal cancers</article-title>. <source>Oncol. Rep.</source> <volume>33</volume> (<issue>3</issue>), <fpage>1342</fpage>&#x2013;<lpage>1348</lpage>. <pub-id pub-id-type="doi">10.3892/or.2014.3694</pub-id>
</citation>
</ref>
<ref id="B199">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>R. G.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S. X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>D. D.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z. J.</given-names>
</name>
<name>
<surname>Saimaiti</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Anticancer effects and mechanisms of berberine from medicinal herbs: an update review</article-title>. <source>Molecules</source> <volume>27</volume> (<issue>14</issue>), <fpage>4523</fpage>. <pub-id pub-id-type="doi">10.3390/molecules27144523</pub-id>
</citation>
</ref>
<ref id="B200">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Anti-Warburg effect of rosmarinic acid via miR-155 in colorectal carcinoma cells</article-title>. <source>Eur. J. Cancer Prev.</source> <volume>25</volume> (<issue>6</issue>), <fpage>481</fpage>&#x2013;<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1097/cej.0000000000000205</pub-id>
</citation>
</ref>
<ref id="B201">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>I. H.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>N. P.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>S. D.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Oridonin induces apoptosis in human oral cancer cells via phosphorylation of histone H2AX</article-title>. <source>Eur. J. Oral Sci.</source> <volume>125</volume> (<issue>6</issue>), <fpage>438</fpage>&#x2013;<lpage>443</lpage>. <pub-id pub-id-type="doi">10.1111/eos.12387</pub-id>
</citation>
</ref>
<ref id="B202">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y. L.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Arginine ADP-ribosyltransferase 1 promotes angiogenesis in colorectal cancer via the PI3K/Akt pathway</article-title>. <source>Int. J. Mol. Med.</source> <volume>37</volume> (<issue>3</issue>), <fpage>734</fpage>&#x2013;<lpage>742</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2016.2473</pub-id>
</citation>
</ref>
<ref id="B203">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ali Shah</surname>
<given-names>S. B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Advances in pharmacology, biosynthesis, and metabolic engineering of Scutellaria-specialized metabolites</article-title>. <source>Crit. Rev. Biotechnol.</source> <volume>29</volume>, <fpage>1</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1080/07388551.2022.2149386</pub-id>
</citation>
</ref>
<ref id="B204">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Vong</surname>
<given-names>C. T.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Tracking evidences of Coptis chinensis for the treatment of inflammatory bowel disease from pharmacological, pharmacokinetic to clinical studies</article-title>. <source>J. Ethnopharmacol.</source> <volume>268</volume>, <fpage>113573</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2020.113573</pub-id>
</citation>
</ref>
<ref id="B205">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells</article-title>. <source>Cell Death Dis.</source> <volume>8</volume> (<issue>2</issue>), <fpage>e2633</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2017.35</pub-id>
</citation>
</ref>
<ref id="B206">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeh</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Hsiao</surname>
<given-names>H. F.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T. W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T. K.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Inflammatory interferon activates HIF-1&#x3b1;-mediated epithelial-to-mesenchymal transition via PI3K/AKT/mTOR pathway</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>37</volume> (<issue>1</issue>), <fpage>70</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-018-0730-6</pub-id>
</citation>
</ref>
<ref id="B207">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeung</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>M. H.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer</article-title>. <source>Cell Mol. Life Sci.</source> <volume>65</volume> (<issue>24</issue>), <fpage>3981</fpage>&#x2013;<lpage>3999</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-008-8224-x</pub-id>
</citation>
</ref>
<ref id="B208">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Younes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>R. W.</given-names>
</name>
<name>
<surname>Mody</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Laucirica</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>GLUT1 expression in human breast carcinoma: correlation with known prognostic markers</article-title>. <source>Anticancer Res.</source> <volume>15</volume> (<issue>6</issue>), <fpage>2895</fpage>&#x2013;<lpage>2898</lpage>.</citation>
</ref>
<ref id="B209">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Younes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lechago</surname>
<given-names>L. V.</given-names>
</name>
<name>
<surname>Lechago</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases</article-title>. <source>Clin. Cancer Res.</source> <volume>2</volume> (<issue>7</issue>), <fpage>1151</fpage>&#x2013;<lpage>1154</lpage>.</citation>
</ref>
<ref id="B210">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma</article-title>. <source>Mol. Cancer</source> <volume>14</volume>, <fpage>193</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-015-0462-6</pub-id>
</citation>
</ref>
<ref id="B211">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Metabolic reprogramming and AMPK&#x3b1;1 pathway activation by caulerpin in colorectal cancer cells</article-title>. <source>Int. J. Oncol.</source> <volume>50</volume> (<issue>1</issue>), <fpage>161</fpage>&#x2013;<lpage>172</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2016.3794</pub-id>
</citation>
</ref>
<ref id="B212">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X. X.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J. H.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Ganoderic acid D prevents oxidative stress-induced senescence by targeting 14-3-3&#x3b5; to activate CaM/CaMKII/NRF2 signaling pathway in mesenchymal stem cells</article-title>. <source>Aging Cell</source> <volume>21</volume> (<issue>9</issue>), <fpage>e13686</fpage>. <pub-id pub-id-type="doi">10.1111/acel.13686</pub-id>
</citation>
</ref>
<ref id="B213">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Andrographolide: a review of its pharmacology, pharmacokinetics, toxicity and clinical trials and pharmaceutical researches</article-title>. <source>Phytother. Res.</source> <volume>36</volume> (<issue>1</issue>), <fpage>336</fpage>&#x2013;<lpage>364</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.7324</pub-id>
</citation>
</ref>
<ref id="B214">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Network meta-analysis of Chinese herbal injections plus the FOLFOX regimen for the treatment of colorectal cancer in China</article-title>. <source>Integr. Cancer Ther.</source> <volume>18</volume>, <fpage>1534735419827098</fpage>. <pub-id pub-id-type="doi">10.1177/1534735419827098</pub-id>
</citation>
</ref>
<ref id="B215">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2020a</year>). <article-title>Matrine: a promising natural product with various pharmacological activities</article-title>. <source>Front. Pharmacol.</source> <volume>11</volume>, <fpage>588</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.00588</pub-id>
</citation>
</ref>
<ref id="B216">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2020b</year>). <article-title>Complex roles of cAMP-PKA-CREB signaling in cancer</article-title>. <source>Exp. Hematol. Oncol.</source> <volume>9</volume> (<issue>1</issue>), <fpage>32</fpage>. <pub-id pub-id-type="doi">10.1186/s40164-020-00191-1</pub-id>
</citation>
</ref>
<ref id="B217">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Si</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2021a</year>). <article-title>Andrographolide and its derivatives: current achievements and future perspectives</article-title>. <source>Eur. J. Med. Chem.</source> <volume>224</volume>, <fpage>113710</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2021.113710</pub-id>
</citation>
</ref>
<ref id="B218">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Esculetin: a review of its pharmacology and pharmacokinetics</article-title>. <source>Phytother. Res.</source> <volume>36</volume> (<issue>1</issue>), <fpage>279</fpage>&#x2013;<lpage>298</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.7311</pub-id>
</citation>
</ref>
<ref id="B219">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Pim1 supports human colorectal cancer growth during glucose deprivation by enhancing the Warburg effect</article-title>. <source>Cancer Sci.</source> <volume>109</volume> (<issue>5</issue>), <fpage>1468</fpage>&#x2013;<lpage>1479</lpage>. <pub-id pub-id-type="doi">10.1111/cas.13562</pub-id>
</citation>
</ref>
<ref id="B220">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>RPS7 inhibits colorectal cancer growth via decreasing HIF-1&#x3b1;-mediated glycolysis</article-title>. <source>Oncotarget</source> <volume>7</volume> (<issue>5</issue>), <fpage>5800</fpage>&#x2013;<lpage>5814</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.6807</pub-id>
</citation>
</ref>
<ref id="B221">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021b</year>). <article-title>Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers</article-title>. <source>J. Hematol. Oncol.</source> <volume>14</volume> (<issue>1</issue>), <fpage>169</fpage>. <pub-id pub-id-type="doi">10.1186/s13045-021-01179-y</pub-id>
</citation>
</ref>
<ref id="B222">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>The saponin DT-13 attenuates tumor necrosis factor-&#x3b1;-induced vascular inflammation associated with Src/NF-&#x43a;B/MAPK pathway modulation</article-title>. <source>Int. J. Biol. Sci.</source> <volume>11</volume> (<issue>8</issue>), <fpage>970</fpage>&#x2013;<lpage>981</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.11635</pub-id>
</citation>
</ref>
<ref id="B223">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>LDHA promotes tumor metastasis by facilitating epithelial-mesenchymal transition in renal cell carcinoma</article-title>. <source>Mol. Med. Rep.</source> <volume>16</volume> (<issue>6</issue>), <fpage>8335</fpage>&#x2013;<lpage>8344</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2017.7637</pub-id>
</citation>
</ref>
<ref id="B224">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells</article-title>. <source>J. Hematol. Oncol.</source> <volume>8</volume>, <fpage>41</fpage>. <pub-id pub-id-type="doi">10.1186/s13045-015-0137-1</pub-id>
</citation>
</ref>
<ref id="B225">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Selective anti-tumor activity of wogonin targeting the Warburg effect through stablizing p53</article-title>. <source>Pharmacol. Res.</source> <volume>135</volume>, <fpage>49</fpage>&#x2013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2018.07.011</pub-id>
</citation>
</ref>
<ref id="B226">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>N6-Methyladenosine modification of PTTG3P contributes to colorectal cancer proliferation via YAP1</article-title>. <source>Front. Oncol.</source> <volume>11</volume>, <fpage>669731</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2021.669731</pub-id>
</citation>
</ref>
<ref id="B227">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>X. D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>M. H.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Berberine as a potential agent for breast cancer therapy</article-title>. <source>Front. Oncol.</source> <volume>12</volume>, <fpage>993775</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2022.993775</pub-id>
</citation>
</ref>
<ref id="B228">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lyu</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>H. K.</given-names>
</name>
<name>
<surname>Bahr</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q. Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2020a</year>). <article-title>Redox regulation by SOD2 modulates colorectal cancer tumorigenesis through AMPK-mediated energy metabolism</article-title>. <source>Mol. Carcinog.</source> <volume>59</volume> (<issue>5</issue>), <fpage>545</fpage>&#x2013;<lpage>556</lpage>. <pub-id pub-id-type="doi">10.1002/mc.23178</pub-id>
</citation>
</ref>
<ref id="B229">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Schimmel</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase</article-title>. <source>Nature</source> <volume>494</volume> (<issue>7435</issue>), <fpage>121</fpage>&#x2013;<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1038/nature11774</pub-id>
</citation>
</ref>
<ref id="B230">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2020b</year>). <article-title>Cdh1-mediated Skp2 degradation by dioscin reprogrammes aerobic glycolysis and inhibits colorectal cancer cells growth</article-title>. <source>EBioMedicine</source> <volume>51</volume>, <fpage>102570</fpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2019.11.031</pub-id>
</citation>
</ref>
<ref id="B231">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q. S.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Effects of &#x3b2;-caryophyllene on arginine ADP-ribosyltransferase 1-mediated regulation of glycolysis in colorectal cancer under high-glucose conditions</article-title>. <source>Int. J. Oncol.</source> <volume>53</volume> (<issue>4</issue>), <fpage>1613</fpage>&#x2013;<lpage>1624</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2018.4506</pub-id>
</citation>
</ref>
<ref id="B232">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tozzi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells</article-title>. <source>Cancer Res.</source> <volume>72</volume> (<issue>1</issue>), <fpage>304</fpage>&#x2013;<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.Can-11-1674</pub-id>
</citation>
</ref>
<ref id="B233">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020c</year>). <article-title>Quercetin overcomes colon cancer cells resistance to chemotherapy by inhibiting solute carrier family 1, member 5 transporter</article-title>. <source>Eur. J. Pharmacol.</source> <volume>881</volume>, <fpage>173185</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173185</pub-id>
</citation>
</ref>
<ref id="B234">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q. L.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>L. P.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The traditional uses, phytochemistry, and pharmacology of atractylodes macrocephala Koidz.: a review</article-title>. <source>J. Ethnopharmacol.</source> <volume>226</volume>, <fpage>143</fpage>&#x2013;<lpage>167</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2018.08.023</pub-id>
</citation>
</ref>
<ref id="B235">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zuo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Long non-coding RNA MEG3 activated by vitamin D suppresses glycolysis in colorectal cancer via promoting c-myc degradation</article-title>. <source>Front. Oncol.</source> <volume>10</volume>, <fpage>274</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2020.00274</pub-id>
</citation>
</ref>
</ref-list>
<sec id="s12">
<title>Glossary </title>
<table-wrap id="udT1" position="float">
<table>
<tbody valign="top">
<tr>
<td align="left">
<bold>AMPK</bold>
</td>
<td align="left">Adenosine 5&#x2032;-monophosphate (AMP)-activated protein kinase</td>
</tr>
<tr>
<td align="left">
<bold>ALDOA</bold>
</td>
<td align="left">Aldolase, fructose-bisphosphate A</td>
</tr>
<tr>
<td align="left">
<bold>Cdh1</bold>
</td>
<td align="left">Cadherin 1</td>
</tr>
<tr>
<td align="left">
<bold>CamKKB</bold>
</td>
<td align="left">Calmodulin-dependent protein kinase beta</td>
</tr>
<tr>
<td align="left">
<bold>CAFs</bold>
</td>
<td align="left">Cancer-associated fibroblasts</td>
</tr>
<tr>
<td align="left">
<bold>CoA</bold>
</td>
<td align="left">Coenzyme A</td>
</tr>
<tr>
<td align="left">
<bold>CRC</bold>
</td>
<td align="left">Colorectal cancer</td>
</tr>
<tr>
<td align="left">
<bold>cAMP</bold>
</td>
<td align="left">cyclic adenosine monophosphate</td>
</tr>
<tr>
<td align="left">
<bold>CREB</bold>
</td>
<td align="left">Cyclic-AMP response binding protein</td>
</tr>
<tr>
<td align="left">
<bold>CypD</bold>
</td>
<td align="left">Cyclophilin D</td>
</tr>
<tr>
<td align="left">
<bold>DMH</bold>
</td>
<td align="left">1,2-dimethylhydrazine</td>
</tr>
<tr>
<td align="left">
<bold>ENO1</bold>
</td>
<td align="left">Enolase 1</td>
</tr>
<tr>
<td align="left">
<bold>EGFR</bold>
</td>
<td align="left">Epidermal growth factor receptor</td>
</tr>
<tr>
<td align="left">
<bold>ECAR</bold>
</td>
<td align="left">Extracellular acidification rate</td>
</tr>
<tr>
<td align="left">
<bold>ERK (1/2)</bold>
</td>
<td align="left">Extracellular regulated protein kinases (1/2)</td>
</tr>
<tr>
<td align="left">
<bold>5-FU</bold>
</td>
<td align="left">5-Fluorouracil</td>
</tr>
<tr>
<td align="left">
<bold>GLUTs</bold>
</td>
<td align="left">Glucose transporters</td>
</tr>
<tr>
<td align="left">
<bold>GAPDH</bold>
</td>
<td align="left">Glyceraldehyde-3-phosphate dehydrogenase</td>
</tr>
<tr>
<td align="left">
<bold>hnRNPA1</bold>
</td>
<td align="left">heterogeneous nuclear ribonucleoprotein A1</td>
</tr>
<tr>
<td align="left">
<bold>HK(2)</bold>
</td>
<td align="left">Hexokinase (2)</td>
</tr>
<tr>
<td align="left">
<bold>HIF-1(&#x3b1;)</bold>
</td>
<td align="left">Hypoxia-inducible factor-1(&#x3b1;)</td>
</tr>
<tr>
<td align="left">
<bold>IL-6</bold>
</td>
<td align="left">Interleukin 6</td>
</tr>
<tr>
<td align="left">
<bold>JAK2/STAT3</bold>
</td>
<td align="left">Janus kinase 2/signal transducer and activator of transcription 3</td>
</tr>
<tr>
<td align="left">
<bold>LDH (A/B)</bold>
</td>
<td align="left">Lactate dehydrogenase (A/B);</td>
</tr>
<tr>
<td align="left">
<bold>LncRNA GLCC1</bold>
</td>
<td align="left">glycolysis-associated lncRNA of colorectal cancer</td>
</tr>
<tr>
<td align="left">
<bold>LncRNAs</bold>
</td>
<td align="left">Long non-coding RNAs</td>
</tr>
<tr>
<td align="left">
<bold>mTOR</bold>
</td>
<td align="left">mammalian target of rapamycin</td>
</tr>
<tr>
<td align="left">
<bold>MCTs</bold>
</td>
<td align="left">Monocarboxylic acid transporters</td>
</tr>
<tr>
<td align="left">
<bold>OCR</bold>
</td>
<td align="left">Oxygen consumption rates</td>
</tr>
<tr>
<td align="left">
<bold>PTEN</bold>
</td>
<td align="left">Phosphatase and tensin homolog</td>
</tr>
<tr>
<td align="left">
<bold>PI3K/AKT</bold>
</td>
<td align="left">Phosphatidylinositol 3-kinases/protein kinase B</td>
</tr>
<tr>
<td align="left">
<bold>PGM</bold>
</td>
<td align="left">Phosphoglucomutase</td>
</tr>
<tr>
<td align="left">
<bold>PTBP1</bold>
</td>
<td align="left">Polypyrimidine tract-binding protein 1</td>
</tr>
<tr>
<td align="left">
<bold>PKA</bold>
</td>
<td align="left">Protein kinase A</td>
</tr>
<tr>
<td align="left">
<bold>PDK1</bold>
</td>
<td align="left">Pyruvate dehydrogenase kinase 1</td>
</tr>
<tr>
<td align="left">
<bold>PK(M2)</bold>
</td>
<td align="left">Pyruvate kinase (M2)</td>
</tr>
<tr>
<td align="left">
<bold>ROS</bold>
</td>
<td align="left">Reactive oxygen species</td>
</tr>
<tr>
<td align="left">
<bold>SIRT3</bold>
</td>
<td align="left">Sirtuin-3</td>
</tr>
<tr>
<td align="left">
<bold>Skp2</bold>
</td>
<td align="left">S-phase kinase associated protein 2</td>
</tr>
<tr>
<td align="left">
<bold>SOD2</bold>
</td>
<td align="left">Superoxide dismutase 2</td>
</tr>
<tr>
<td align="left">
<bold>TIGAR</bold>
</td>
<td align="left">TP53-induced glycolysis and apoptosis regulator</td>
</tr>
<tr>
<td align="left">
<bold>YAP1</bold>
</td>
<td align="left">Yes-associated protein 1</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</back>
</article>